Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33500.0 | 2017-09-22 00:00:00 UTC | Here's Why You Should Add Abbott (ABT) to Your Portfolio Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-add-abbott-abt-to-your-portfolio-now-2017-09-22 | nan | nan | AbbottABT is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500's 2.5% gain and the broader industry 's 1.5% decline.
The stock has a market cap of $89.9 billion. The company's current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry. With solid prospects, this Zacks Rank #2 (Buy) stock emerges an attractive pick.
The Illinois-based medical device major's estimate revision trend for the current year has also been positive. In the past coup | AbbottABT is on a healthy growth trajectory of late. The company's current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry. With solid prospects, this Zacks Rank #2 (Buy) stock emerges an attractive pick. | AbbottABT is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500's 2.5% gain and the broader industry 's 1.5% decline. The company's current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry. | AbbottABT is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500's 2.5% gain and the broader industry 's 1.5% decline. The company's current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry. | AbbottABT is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500's 2.5% gain and the broader industry 's 1.5% decline. The stock has a market cap of $89.9 billion. |
33501.0 | 2017-09-19 00:00:00 UTC | Here's Why Quidel Corporation Stock Is Popping Today | ABT | https://www.nasdaq.com/articles/heres-why-quidel-corporation-stock-popping-today-2017-09-19 | nan | nan | What happened
Shares of Quidel Corporation (NASDAQ: QDEL) , a molecular diagnostics specialist with a focus on quick turnarounds, ticked up 9.3% as of 11:26 a.m. EDT on Tuesday in response to a positive development concerning a recent agreement with Alere Inc. (NYSE: ALR) . Investors are pleased with a revision that will tack on global rights to sales of a test and the equipment that runs it.
So what
To satisfy antitrust regulators scrutinizing Abbott 's acquisition of Alere, the latter must divest some assets. Earlier this summer, Quidel agreed to scoop up Alere's Triage MeterPro cardiovascular and toxicology assets, along with its business developing B-type Naturietic Peptide (BNP) assays, which are run on Beckman Coulter analyzers and test for heart failure, for $400 million up front and $40 million in contingent consideration.
After the bell yesterday, Quidel announced it would also acquire global commercialization rights to the BNP business for an additional $240 million in deferred consideration. Investors are pleased with the revision because it looks like Quidel picked up the rights at a fire-sale price. During the 12-month period ended this June, the BNP business generated an estimated $107 million in revenue.
Now what
The sale to Quidel is contingent on Abbott completing its acquisition of Alere. The diagnostics giant expects to close by the end of the month, and Quidel expects its deal with Alere to close within 30 days of the larger acquisition.
Quidel stock has risen more than 60% since the original deal with Alere was announced, but investors might want to remain cautious. The company might be getting Alere's assets at a fair price, but it will take on more debt to finance a portion of the deal. The company finished the second quarter with $151 million in long-term debt, which is already an awful lot for a company with operations that have dipped in and out of profitability a few times over the past several years.
10 stocks we like better than Quidel
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Quidel wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Quidel Corporation (NASDAQ: QDEL) , a molecular diagnostics specialist with a focus on quick turnarounds, ticked up 9.3% as of 11:26 a.m. EDT on Tuesday in response to a positive development concerning a recent agreement with Alere Inc. (NYSE: ALR) . Earlier this summer, Quidel agreed to scoop up Alere's Triage MeterPro cardiovascular and toxicology assets, along with its business developing B-type Naturietic Peptide (BNP) assays, which are run on Beckman Coulter analyzers and test for heart failure, for $400 million up front and $40 million in contingent consideration. After the bell yesterday, Quidel announced it would also acquire global commercialization rights to the BNP business for an additional $240 million in deferred consideration. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market. | Earlier this summer, Quidel agreed to scoop up Alere's Triage MeterPro cardiovascular and toxicology assets, along with its business developing B-type Naturietic Peptide (BNP) assays, which are run on Beckman Coulter analyzers and test for heart failure, for $400 million up front and $40 million in contingent consideration. Quidel stock has risen more than 60% since the original deal with Alere was announced, but investors might want to remain cautious. 10 stocks we like better than Quidel When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Investors are pleased with the revision because it looks like Quidel picked up the rights at a fire-sale price. Now what The sale to Quidel is contingent on Abbott completing its acquisition of Alere. The company might be getting Alere's assets at a fair price, but it will take on more debt to finance a portion of the deal. |
33502.0 | 2017-09-19 00:00:00 UTC | 3 Value Stocks at 52-Week Highs Still Worth Buying | ABT | https://www.nasdaq.com/articles/3-value-stocks-52-week-highs-still-worth-buying-2017-09-19 | nan | nan | The whole idea behind being a value investor is that you find over-looked, un-loved, usually boring businesses, and buy them on the cheap. The very idea of buying a "value" stock at or near it 52-week high seems illogical.
Yet there are times when a company's prospects are still not fully reflected in its stock price -- even if that price is sitting higher than it has at any other point in the past year.
Today, three of our Foolish investors give you their take on value stocks that might appear expensive but are actually still attractive. Read on to see why Apple (NASDAQ: AAPL) , Toronto-Dominion Bank (NYSE: TD) , and AbbVie (NYSE: ABBV) all fit the bill.
Don't overthink this one
Brian Stoffel(Apple): In picking out a value stock trading near 52-week highs, it can be tempting to go for a company with an incredibly low P/E, or a sustainable dividend hovering over 3%. But I'm not going to fall into that trap. In Apple, we've got a stock trading at all time highs that's still a solid value play.
What makes it a value stock? Consider the following:
It has $261 billion in cash and investments versus "just" $90 billion in long-term debt.
If we back out all that cash (net debt) from the market cap, the company is trading for just 13 times free cash flow.
In addition, Apple has undeniable pricing power -- which could soon be demonstrated once again with the release of the iPhone X. Forbes rates the Apple brand as the world's most valuable, coming in at $170 billion.
And even though the company's dividend currently yields just 1.6%, there's tons of room for growth there: Apple needed to use only 24% of free cash flow over the past 12 months to pay for it.
This bank stock has paid dividends since the 1800s
Matt Frankel (Toronto-Dominion Bank): The banking sector has been one of the hottest areas of the market over the past year, but many banks could have much more room to climb. Canadian banks look especially attractive right now, as they haven't skyrocketed quite as much as most of their U.S. counterparts.
One great example, which recently reached a new 52-week high, is Toronto-Dominion Bank, better known to most consumers simply as TD Bank.
There are several reasons to like TD. The bank is Canada's largest credit card issuer, and it has been expanding its presence in the U.S. recently with valuable co-branding partnerships such as Target and Nordstrom . With an abundance of low- or no-interest deposits, TD stands to benefit tremendously from the expected rising interest rates in coming years. And finally, with a presence in less than one-third of U.S. states, TD has lots of room to grow.
For income-seeking investors, it's also important to mention that TD Bank has steadily paid dividends for 160 years , and also has a strong history of increasing its payout. Since 1995, the bank has increased its dividend at a 11% annualized rate, and its 3.6% yield is well above its peer-group average. And since it's not a U.S. bank, TD has more freedom to set its own dividend policy.
A biotech without a lot of risk
Rich Duprey(AbbVie): Even though shares of biotech giant AbbVie hit a new 52-week high and are up 42% so far in 2017, the stock trades at less than 22 times earnings and under 14 times next year's estimates. That compares favorably with the S&P 500, which goes for around 25 times earnings and 19 times estimates.
Although AbbVie depends on its rheumatoid arthritis therapy Humira for around two-thirds of its revenue, its next leading treatment, Imbruvica, could become one of the top five cancer drugs on the market, while the biotech has one of the best drug pipeline s in the industry, including two cancer drugs (Rova-T and Veliparib) and an autoimmune-disease drug (ABT-494).
AbbVie also pays a dividend of $2.56 per share that currently yields around 2.9%, and if you include the time before it was spun off from Abbott Labs in 2013, it has a history of raising its payout to shareholders for over 25 years, making it a Dividend Aristocrat.
Also, AbbVie's payout ratio -- the percentage of its net profits the biopharmaceutical pays out in dividends -- was a reasonable 60% over the past year, indicating that the company's generous reward to shareholders will continue.
With analysts expecting AbbVie to expand earnings at a 14% clip annually over the next five years, its stock still makes sense to buy despite the heights it's already obtained.
10 stocks we like better than Apple
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Apple wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Brian Stoffel owns shares of Apple. Matthew Frankel owns shares of Apple and The Toronto-Dominion Bank. Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although AbbVie depends on its rheumatoid arthritis therapy Humira for around two-thirds of its revenue, its next leading treatment, Imbruvica, could become one of the top five cancer drugs on the market, while the biotech has one of the best drug pipeline s in the industry, including two cancer drugs (Rova-T and Veliparib) and an autoimmune-disease drug (ABT-494). Don't overthink this one Brian Stoffel(Apple): In picking out a value stock trading near 52-week highs, it can be tempting to go for a company with an incredibly low P/E, or a sustainable dividend hovering over 3%. Also, AbbVie's payout ratio -- the percentage of its net profits the biopharmaceutical pays out in dividends -- was a reasonable 60% over the past year, indicating that the company's generous reward to shareholders will continue. | Although AbbVie depends on its rheumatoid arthritis therapy Humira for around two-thirds of its revenue, its next leading treatment, Imbruvica, could become one of the top five cancer drugs on the market, while the biotech has one of the best drug pipeline s in the industry, including two cancer drugs (Rova-T and Veliparib) and an autoimmune-disease drug (ABT-494). Read on to see why Apple (NASDAQ: AAPL) , Toronto-Dominion Bank (NYSE: TD) , and AbbVie (NYSE: ABBV) all fit the bill. If we back out all that cash (net debt) from the market cap, the company is trading for just 13 times free cash flow. | Although AbbVie depends on its rheumatoid arthritis therapy Humira for around two-thirds of its revenue, its next leading treatment, Imbruvica, could become one of the top five cancer drugs on the market, while the biotech has one of the best drug pipeline s in the industry, including two cancer drugs (Rova-T and Veliparib) and an autoimmune-disease drug (ABT-494). Don't overthink this one Brian Stoffel(Apple): In picking out a value stock trading near 52-week highs, it can be tempting to go for a company with an incredibly low P/E, or a sustainable dividend hovering over 3%. This bank stock has paid dividends since the 1800s Matt Frankel (Toronto-Dominion Bank): The banking sector has been one of the hottest areas of the market over the past year, but many banks could have much more room to climb. | Although AbbVie depends on its rheumatoid arthritis therapy Humira for around two-thirds of its revenue, its next leading treatment, Imbruvica, could become one of the top five cancer drugs on the market, while the biotech has one of the best drug pipeline s in the industry, including two cancer drugs (Rova-T and Veliparib) and an autoimmune-disease drug (ABT-494). This bank stock has paid dividends since the 1800s Matt Frankel (Toronto-Dominion Bank): The banking sector has been one of the hottest areas of the market over the past year, but many banks could have much more room to climb. One great example, which recently reached a new 52-week high, is Toronto-Dominion Bank, better known to most consumers simply as TD Bank. |
33503.0 | 2017-09-19 00:00:00 UTC | Health Care Sector Update for 09/19/2017: QDEL,ALR,MDGS,ALDX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-09192017-qdelalrmdgsaldx-2017-09-19 | nan | nan | Top Health Care Stocks
JNJ -0.11%
PFE -0.34%
ABT -1.35%
MRK -0.21%
AMGN -0.17%
Health care stocks fell today, with the NYSE Health Care Index declining over 0.5% while shares of health care companies in the S&P 500 were down nearly 0.9% as a group.
In company news, Quidel Corp ( QDEL ) jumped to a new record high on Tuesday, with shares of the diagnostics equipment manufacturer topping out at a best-ever $45.55 a share after the company today unveiled its revised agreement to acquire certain assets from rival diagnostics company Alere ( ALR ) for up to $680 million.
The deal to buy Alere's BNP assay business running on Beckman Coulter analyzers was revised to provide Quidel with direct commercial responsibility for the unit following the upcoming purchase while a separate agreement to acquire Triage MeterPro cardiovascular and toxicology assets stayed "substantially unchanged.
The overall price tag for the deal consists of $400 million for the Triage business along with $40 million in contingent payments for the EEA BNP business and $240 million in deferred consideration for the rest-of-world BNP business.
The acquisitions are subject to completion of Abbott Laboratories' ( ABT ) purchase of Alere in addition to other regulatory approvals and other customary closing conditions. The deal is slated to close by Sept. 30.
In other sector news,
(+) MDGS, Narrows Q2 operating loss to $1.3 mln from $2.7 mln during the same quarter last year. Net sales decline 16% to $82,000. No analyst estimates were available for comparison.
(-) ALDX, Tuesday prices $25 mln public offering of 3.45 mln shares at $7.25 apiece, a 20.3% discount to yesterday's closing price for the stock. Net proceeds will be used to fund ongoing development of its ADX-102 product candidate as well as debt maintenance and working capital.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The acquisitions are subject to completion of Abbott Laboratories' ( ABT ) purchase of Alere in addition to other regulatory approvals and other customary closing conditions. The deal to buy Alere's BNP assay business running on Beckman Coulter analyzers was revised to provide Quidel with direct commercial responsibility for the unit following the upcoming purchase while a separate agreement to acquire Triage MeterPro cardiovascular and toxicology assets stayed "substantially unchanged. Net proceeds will be used to fund ongoing development of its ADX-102 product candidate as well as debt maintenance and working capital. | The acquisitions are subject to completion of Abbott Laboratories' ( ABT ) purchase of Alere in addition to other regulatory approvals and other customary closing conditions. Top Health Care Stocks Health care stocks fell today, with the NYSE Health Care Index declining over 0.5% while shares of health care companies in the S&P 500 were down nearly 0.9% as a group. | The acquisitions are subject to completion of Abbott Laboratories' ( ABT ) purchase of Alere in addition to other regulatory approvals and other customary closing conditions. Health care stocks fell today, with the NYSE Health Care Index declining over 0.5% while shares of health care companies in the S&P 500 were down nearly 0.9% as a group. In company news, Quidel Corp ( QDEL ) jumped to a new record high on Tuesday, with shares of the diagnostics equipment manufacturer topping out at a best-ever $45.55 a share after the company today unveiled its revised agreement to acquire certain assets from rival diagnostics company Alere ( ALR ) for up to $680 million. | The acquisitions are subject to completion of Abbott Laboratories' ( ABT ) purchase of Alere in addition to other regulatory approvals and other customary closing conditions. Health care stocks fell today, with the NYSE Health Care Index declining over 0.5% while shares of health care companies in the S&P 500 were down nearly 0.9% as a group. In company news, Quidel Corp ( QDEL ) jumped to a new record high on Tuesday, with shares of the diagnostics equipment manufacturer topping out at a best-ever $45.55 a share after the company today unveiled its revised agreement to acquire certain assets from rival diagnostics company Alere ( ALR ) for up to $680 million. |
33504.0 | 2017-09-18 00:00:00 UTC | IWB, SLB, ABT, UNP: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iwb-slb-abt-unp-large-outflows-detected-etf-2017-09-18 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $55.7 million dollar outflow -- that's a 0.3% decrease week over week (from 138,500,000 to 138,100,000). Among the largest underlying components of IWB, in trading today Schlumberger Ltd (Symbol: SLB) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Union Pacific Corp (Symbol: UNP) is lower by about 0.7%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $115.81 per share, with $139.85 as the 52 week high point - that compares with a last trade of $139.76. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Schlumberger Ltd (Symbol: SLB) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Union Pacific Corp (Symbol: UNP) is lower by about 0.7%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $115.81 per share, with $139.85 as the 52 week high point - that compares with a last trade of $139.76. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Schlumberger Ltd (Symbol: SLB) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Union Pacific Corp (Symbol: UNP) is lower by about 0.7%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $115.81 per share, with $139.85 as the 52 week high point - that compares with a last trade of $139.76. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Schlumberger Ltd (Symbol: SLB) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Union Pacific Corp (Symbol: UNP) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $55.7 million dollar outflow -- that's a 0.3% decrease week over week (from 138,500,000 to 138,100,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $115.81 per share, with $139.85 as the 52 week high point - that compares with a last trade of $139.76. | Among the largest underlying components of IWB, in trading today Schlumberger Ltd (Symbol: SLB) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Union Pacific Corp (Symbol: UNP) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $55.7 million dollar outflow -- that's a 0.3% decrease week over week (from 138,500,000 to 138,100,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $115.81 per share, with $139.85 as the 52 week high point - that compares with a last trade of $139.76. |
33505.0 | 2017-09-14 00:00:00 UTC | Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod | ABT | https://www.nasdaq.com/articles/abbotts-abt-freestyle-libre-gets-uk-reimbursement-nod-2017-09-14 | nan | nan | AbbottABT recently announced the receipt of national reimbursement for the FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. Notably, this was a major breakthrough in its diabetics business.
The development has widened this Illinois-based medical device major's customer base in diabetes management. Beginning Nov 1, Abbott's flagship glucose monitoring system will be available for reimbursement through the NHS across England and Wales, NHS Scotland, and the Health and Social Care in Northern Ireland.
Per Abbott, the grant of reimbursement will also make FreeStyleLibre system widely available to around 3.5 million people in the U.K.who are diagnosed with diabetes. Also, management expects that there may be roughly 549,000 people in the U.K.who have diabetes but are yet to be diagnosed.
This reimbursement approval in U.K. marks another milestone where Abbott's FreeStyle Libre system stands partially or fully covered in 17 countries, including France, Germany and Japan. Notably, FreeStyle Libre system is presently under review by the FDA and awaits approval in the United States.
Meanwhile, Abbott has been moving steadily toward development in its diabetics segment. Recently, the company announced the receipt of national reimbursement for FreeStyle Libre in Japan.
Moreover, the company recently announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. This will further stimulate growth in the Diabetes Care sales segment, which was up 18.7% in second-quarter 2017 on continued consumer acceptance of FreeStyle Libre internationally.
We expect Freestyle Libre to further contribute to Abbott's top line as along with the U.K., Japanese and Canadian developments, the French Health Ministry recently approved national reimbursement for the device.
This apart, in July, the company partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.
Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%.
Considering the market potential and Abbott's slew of latest developments in the diabetes care segment, the recent national reimbursement grant in U.K. will accelerate the top line.
However, the diabetes market is dominated by many well established players, Johnson & Johnson JNJ being the most prominent one. In this space, Johnson & Johnson also has a tie-up with U.S.-based Animas Corporation to successfully develop and innovate insulin delivery systems.
Share Price Performance
Abbott has been gaining investor confidence on consistently positive results. Over the last three months, Abbott's share price has outperformed the broader industry . The stock has gained 8.1%, in comparison with the broader industry's 1.5% gain. The company has also outperformed the 2.7% gain of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks in the medical sector are Edwards Lifesciences Corporation EW and Lantheus Holdings, Inc. LNTH . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 39.4% over the last six months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT recently announced the receipt of national reimbursement for the FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. This reimbursement approval in U.K. marks another milestone where Abbott's FreeStyle Libre system stands partially or fully covered in 17 countries, including France, Germany and Japan. | AbbottABT recently announced the receipt of national reimbursement for the FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently announced the receipt of national reimbursement for the FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. We expect Freestyle Libre to further contribute to Abbott's top line as along with the U.K., Japanese and Canadian developments, the French Health Ministry recently approved national reimbursement for the device. | AbbottABT recently announced the receipt of national reimbursement for the FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). |
33506.0 | 2017-09-14 00:00:00 UTC | How Safe Is Abbott Labs' Dividend? | ABT | https://www.nasdaq.com/articles/how-safe-abbott-labs-dividend-2017-09-14 | nan | nan | Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. For much of its history, Abbott was a true healthcare conglomerate, producing both pharmaceuticals and medical devices to serve a large patient population. With the company's spinoff of its proprietary pharmaceutical business into AbbVie (NYSE: ABBV) , the continuing Abbott Labs now focuses on medical devices and generic pharmaceuticals. That focus hasn't prevented the stock from hitting new all-time record highs, but it has raised questions from time to time about whether the dividend growth that Abbott enjoyed in the past is sustainable for the more-focused company going forward. Let's take a closer look at Abbott Labs to see whether investors can be confident in its ability to keep its dividend moving higher.
Dividend stats on Abbott Labs
Data source: Yahoo! Finance. Last increase refers to ex-dividend date. * After accounting for AbbVie spinoff.
Dividend yield
Abbott Labs has a yield of 2%, which matches up well with the S&P 500 's current average dividend yield. However, it does mark a decline from the stock's typical yield before it spun off AbbVie. Immediately before the split, Abbott's yield was consistently between 3% and 4%. Since the spinoff, yields have ranged from roughly 1.5% to 2.5%, putting the current dividend right in the middle of Abbott's typical post-spinoff level.
Payout ratio
Abbott Labs has seen its payout ratio skyrocket recently, dramatically exceeding its more typical range of around 30% to 60%. However, the rise has been generally attributable to one-off negative impacts on its earnings, and investors fully expect the company to recover and see its earnings get back to more typical levels in the next year or two. If those expectations come to pass, then they imply a future payout ratio of 35% to 45%, and that would put Abbott back in a comfortable zone for dividend investors.
Dividend growth
Abbott Labs has put together an impressive track record of dividend growth, with 45 straight years of rising payouts after allowing for the spinoff of AbbVie. Throughout most of that history, the growth rate in Abbott's dividend has been impressive. You can see below that Abbott has changed that trend in its most recent boost, which amounted to just half a cent or less than 2%. Again, the temporary hit to earnings likely motivated the less aggressive increase, but profit recovery should help Abbott to restore healthier growth rates in 2018 and beyond.
ABT Dividend data by YCharts .
What's happened with Abbott Labs lately?
Abbott Labs has worked hard to maintain its growth in recent years, and despite headwinds in the medical device space, the company's efforts have shown substantial success. In its most recent quarter, Abbott reported a 2.9% rise in worldwide sales, with sizable gains in the diabetes, electrophysiology, neuromodulation, and structural heart focus areas. Abbott raised its full-year adjusted earnings guidance, and it believes that it has tapped into some promising opportunities that could push growth in the future.
In particular, Abbott's acquisition of St. Jude Medical has been a big advance for the company. The combination produced considerable complementary impacts on key market areas, with the combined company holding No. 1 or No. 2 positions in nearly every key cardiovascular device market. Expense savings have also been a key driver of better results. Although costs related to the merger were primarily responsible for depressed earnings -- and likely played a role in Abbott's decision to keep its dividend growth modest this year -- the promise of better gains in the future warrant the investment.
What to expect from Abbott Labs
Abbott Labs has done a good job of finding new avenues for growth in its post-spinoff business, and shareholders have reaped the rewards. Even with some warning signs in its dividend that have raised concerns, Abbott Labs appears to be doing everything it needs to in order to ensure that it will be able to keep its dividend payments safe far into the future.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. ABT Dividend data by YCharts . Abbott Labs has worked hard to maintain its growth in recent years, and despite headwinds in the medical device space, the company's efforts have shown substantial success. | Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. ABT Dividend data by YCharts . With the company's spinoff of its proprietary pharmaceutical business into AbbVie (NYSE: ABBV) , the continuing Abbott Labs now focuses on medical devices and generic pharmaceuticals. | Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. ABT Dividend data by YCharts . Dividend yield Abbott Labs has a yield of 2%, which matches up well with the S&P 500 's current average dividend yield. | Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. ABT Dividend data by YCharts . Since the spinoff, yields have ranged from roughly 1.5% to 2.5%, putting the current dividend right in the middle of Abbott's typical post-spinoff level. |
33507.0 | 2017-09-14 00:00:00 UTC | Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA | ABT | https://www.nasdaq.com/articles/daily-dividend-report-intc-csco-bmy-abt-kr-krc-nfg-mfa-2017-09-14 | nan | nan | Intel has declared a quarterly dividend of $0.2725 per share ($1.09 per share on an annual basis) on the company's common stock. The dividend will be payable on Dec. 1, 2017, to stockholders of record on Nov. 7, 2017.
Cisco ( CSCO ) declared a quarterly dividend of $0.29 per common share to be paid on October 25, 2017 to all shareholders of record as of the close of business on October 5, 2017.
Bristol-Myers Squibb Company ( BMY ) declared a quarterly dividend of thirty-nine cents per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.
Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. The cash dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.
The Kroger Co.'s ( KR ) declared a quarterly dividend of 12.5 per share to be paid on December 1, 2017, to shareholders of record as of the close of business on November 15, 2017.
Kilroy Realty ( KRC ) declared a regular quarterly cash dividend of $0.425 per common share payable on October 18, 2017 to stockholders of record on September 29, 2017.
National Fuel Gas Company (NFG) approved a regular quarterly dividend of 41.5 cents per share on the Company's common stock. The dividend is payable Oct. 13, 2017, to shareholders of record at the close of business on Sept. 29, 2017.
MFA Financial (MFA) declared a regular quarterly cash dividend of $0.20 per share of common stock for the third quarter of 2017. The dividend will be paid on October 31, 2017, to stockholders of record on September 28, 2017.
VIDEO: Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bristol-Myers Squibb Company ( BMY ) declared a quarterly dividend of thirty-nine cents per share on the $.10 par value Common Stock of the corporation. | VIDEO: Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. Kilroy Realty ( KRC ) declared a regular quarterly cash dividend of $0.425 per common share payable on October 18, 2017 to stockholders of record on September 29, 2017. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Cisco ( CSCO ) declared a quarterly dividend of $0.29 per common share to be paid on October 25, 2017 to all shareholders of record as of the close of business on October 5, 2017. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017. |
33508.0 | 2017-09-14 00:00:00 UTC | Health Care Sector Update for 09/14/2017: JNJ, PFE, ABT, MRK, AMGN, EKSO, RARE, CRIS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-09142017-jnj-pfe-abt-mrk-amgn-ekso-rare-cris-2017-09-14 | nan | nan | Top Health Care Stocks:
JNJ: +1.2%
PFE: +1.7%
ABT: -0.8%
MRK: +1.4%
AMGN: -0.1%
Health care shares were mostly higher as Thursday's session closed.
In sector news, Ekso Bionics Holdings ( EKSO ), which is in the field of medical and industrial exoskeletons, and Genesis Rehab Services, a provider of physical, occupational and respiratory therapy, disclosed Thursday a collaboration to study opportunities for incorporating EksoGT in skilled nursing facilities. With guidance from Genesis, the company said in a statement it will learn more about post-acute rehabilitation settings to support better patient outcomes in skilled nursing facilities.
In other sector news,
(+) RARE (+6.8%) Wedbush upgrades shares to outperform
(-) CRIS (-5.9%) Prices 20 million shares of common stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Ekso Bionics Holdings ( EKSO ), which is in the field of medical and industrial exoskeletons, and Genesis Rehab Services, a provider of physical, occupational and respiratory therapy, disclosed Thursday a collaboration to study opportunities for incorporating EksoGT in skilled nursing facilities. With guidance from Genesis, the company said in a statement it will learn more about post-acute rehabilitation settings to support better patient outcomes in skilled nursing facilities. In other sector news, (+) RARE (+6.8%) Wedbush upgrades shares to outperform (-) CRIS (-5.9%) Prices 20 million shares of common stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: In other sector news, (+) RARE (+6.8%) Wedbush upgrades shares to outperform (-) CRIS (-5.9%) Prices 20 million shares of common stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Ekso Bionics Holdings ( EKSO ), which is in the field of medical and industrial exoskeletons, and Genesis Rehab Services, a provider of physical, occupational and respiratory therapy, disclosed Thursday a collaboration to study opportunities for incorporating EksoGT in skilled nursing facilities. In other sector news, (+) RARE (+6.8%) Wedbush upgrades shares to outperform (-) CRIS (-5.9%) Prices 20 million shares of common stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited. | Health care shares were mostly higher as Thursday's session closed. In sector news, Ekso Bionics Holdings ( EKSO ), which is in the field of medical and industrial exoskeletons, and Genesis Rehab Services, a provider of physical, occupational and respiratory therapy, disclosed Thursday a collaboration to study opportunities for incorporating EksoGT in skilled nursing facilities. In other sector news, (+) RARE (+6.8%) Wedbush upgrades shares to outperform (-) CRIS (-5.9%) Prices 20 million shares of common stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33509.0 | 2017-09-12 00:00:00 UTC | 3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-abbott-laboratories-abt-aetna-inc-aet-and-boston | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Another rally sits ready to move stocks higher on Tuesday as the S&P 500 Index is starting to make a rush at making new highs. Looking at the sector level, the biotech stocks continue to press higher as investors are migrating from the technology sector into other, more relatively valued stocks.
This morning, our scans have been awash with healthcare-related stocks as we're seeing an increasing number of the stocks within this seemingly hated sector make new highs ahead of the S&P 500 making a similar move. Today's three big stock charts look at Abbott Laboratories (NYSE: ABT ), Aetna Inc (NYSE: AET ) and Boston Scientific Corporation (NYSE: BSX ), three stocks leading the group that's pressing to make new 52-week highs. Should you jump on these stocks now?
Abbott Laboratories (ABT)
Abbott Labs shares have been trading in a bull market trend since crossing above their 20-month moving average in January 2017. This, for the most part, has gone unnoticed as the stock has been lost among the mediocrity that has been the healthcare sector. ABT shares are now making another press higher and they look to have legs to run higher.
Abbott shares are breaking into a new volatility rally as the stock is moving above its top Bollinger Band. ABT stock saw a similar break in June 2017, which resulted in a rally that sparked an 8% rally in the shares.
Abbott stock is overbought as indicated by the high reading of its RSI indicator. This is a similar situation to what we saw in May when the stock went parabolic as the RSI readings were already elevated. In this case, these volatility rallies tend to push overbought stocks higher regardless as the crowd moves in to buy.
Volume on the recent rally has been on the rise, indicating that this move should be strong and have some breadth behind it. Currently, our technical model is targeting a move to $57 for ABT shares.
Aetna Inc (AET)
The 10 Best Tech Stocks from Top-Ranked Analysts
Volume and higher prices are pushing Aetna shares into a volatility rally of their own as the stock just moved to new highs while breaking above their top Bollinger Band. We saw a similar break and move in April when AET shares of the insurer rallied from $130 to $145.
Despite a low short interest ratio, the short interest activity on Aetna is indicating that the shorts are covering positions as bets against the stock dropped by 18% in the last report. This additional volume is helping push Aetna to new highs.
In the event that AET shares do see some selling pressure from their overbought RSI, the stock should find chart support for a consolidation at $160 as represents the price that launched the volatility rally and the previous spike higher in August.
Boston Scientific Corporation (BSX)
Why Rite Aid Corporation (RAD) Stock Has More Room to Run
After spending much of the summer consolidating at $27.50, shares of Boston Scientific have now gone into a rapid ascent as the result of a volatility rally triggered by a strong move above the top Bollinger Band.
In addition to the bullish signal from the Bollinger Band break, shares of BSX moved above their 50-day moving average at the same time that the bullish break occurred. This adds to the magnitude of the intermediate-term signal.
The rally has the 50-day moving average trend shifting into an intermediate-term bullish outlook. The last time that we saw a similar signal from this consistently successful indicator was in April 2017 as BSX stock initiated a move from $24.50 to $28 before this indicator went back to bearish. We're targeting a move to $32 on the most recent signal.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
More From InvestorPlace
7 Stocks to Sell Before They Crash
7 F-Rated Stocks to Sell Before They Get Even Uglier
10 Stocks That Every 20-Year-Old Should Buy
The post 3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Today's three big stock charts look at Abbott Laboratories (NYSE: ABT ), Aetna Inc (NYSE: AET ) and Boston Scientific Corporation (NYSE: BSX ), three stocks leading the group that's pressing to make new 52-week highs. Abbott Laboratories (ABT) Abbott Labs shares have been trading in a bull market trend since crossing above their 20-month moving average in January 2017. ABT shares are now making another press higher and they look to have legs to run higher. | Today's three big stock charts look at Abbott Laboratories (NYSE: ABT ), Aetna Inc (NYSE: AET ) and Boston Scientific Corporation (NYSE: BSX ), three stocks leading the group that's pressing to make new 52-week highs. More From InvestorPlace 7 Stocks to Sell Before They Crash 7 F-Rated Stocks to Sell Before They Get Even Uglier 10 Stocks That Every 20-Year-Old Should Buy The post 3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) appeared first on InvestorPlace . Abbott Laboratories (ABT) Abbott Labs shares have been trading in a bull market trend since crossing above their 20-month moving average in January 2017. | More From InvestorPlace 7 Stocks to Sell Before They Crash 7 F-Rated Stocks to Sell Before They Get Even Uglier 10 Stocks That Every 20-Year-Old Should Buy The post 3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) appeared first on InvestorPlace . Today's three big stock charts look at Abbott Laboratories (NYSE: ABT ), Aetna Inc (NYSE: AET ) and Boston Scientific Corporation (NYSE: BSX ), three stocks leading the group that's pressing to make new 52-week highs. Abbott Laboratories (ABT) Abbott Labs shares have been trading in a bull market trend since crossing above their 20-month moving average in January 2017. | Today's three big stock charts look at Abbott Laboratories (NYSE: ABT ), Aetna Inc (NYSE: AET ) and Boston Scientific Corporation (NYSE: BSX ), three stocks leading the group that's pressing to make new 52-week highs. Abbott Laboratories (ABT) Abbott Labs shares have been trading in a bull market trend since crossing above their 20-month moving average in January 2017. ABT shares are now making another press higher and they look to have legs to run higher. |
33510.0 | 2017-09-08 00:00:00 UTC | 4 Top MedTech Stocks for Dividend Investors in 2017 | ABT | https://www.nasdaq.com/articles/4-top-medtech-stocks-for-dividend-investors-in-2017-2017-09-08 | nan | nan | The buzz about Obamacare or the Affordable Care Act (ACA) remains persistent in Capitol Hill. The lukewarm response to its replacement, The American Health Care Act (AHCA), has forced Republicans to continue to seek new avenues. In a bid to save its face, the Trump administration attempted a "skinny" repeal bill which failed to make any headway in the senate.
Going ahead, we believe the impasse is slated to continue as President Trump has always been an outspoken critic of the ACA. Our apprehension comes from the uncertainty regarding the outcome of a slew of events including the possibility of a rate hike by the Fed, a stronger dollar, debate over the fate of Cadillac tax (40% excise tax on high-cost healthcare plans) and the stance of healthcare insurance companies over ACA. These are expected to spark bouts of volatility. Added to these factors are the effects of Hurricane Harvey over the bourses and the reasons which are worrying investors.
Amid this uncertainty, finding investment options that are not perturbed by market gyrations is a tough decision.
Dividend Investing to the Rescue
As evident from the MedTech story, stocks can be volatile and are risky at times.. With uncertainty ruling the markets, it is not surprising that dividend investing has emerged as one of the most popular investing themes.
Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks. These stocks are generally less volatile in nature and hence, are dependable when it comes to long-term investment planning. They not only offer higher income in the current environment - where rates remain low despite expected hikes - but also provide relief in adverse market conditions.
Dividend stocks are a safe bet to create wealth, as the payouts generally act as a hedge against economic uncertainty and simultaneously provide downside protection by offering sizable yields on a regular basis.
How to Pick the Best Stocks?
Although the benefits of dividend investing cannot be stressed enough, one should keep in mind that not every company can keep up with its dividend paying momentum. Hence, investors need to be cautious in order to select the best stocks with the potential for steady returns.
We have used the Zacks Stock Screener to narrow down to four stocks that offer decent dividend yield and have a market cap of $1 billion or more. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Our Choices
Abbott LaboratoriesABT
Abbott Park, IL-based Abbott Laboratories discovers, develops, manufactures and sells a diversified line of health care products. The company also has a large pharmaceuticals business and is a major player in the nutritionals and diagnostics markets. In 2016, Abbott generated revenues of $20.8 billion. The company's dividend currently yields 2.32% and its five-year historical dividend growth rate is 2.29%.
Cardinal Health Inc.CAH
Headquartered in Dublin, OH, Cardinal Health Inc. is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. The company has two reporting segments - Pharmaceutical and Medical. The company generated revenues in excess of $130 billion in the last reported fiscal. Cardinal Health's dividend currently yields 2.70% and its five-year historical dividend growth rate is 13.71%.
Patterson Companies Inc.PDCO
Headquartered in St. Paul, MN, Patterson Companies is one of the leading distributors of dental and animal health products. The company distributes its products mainly through two subsidiaries - Patterson Dental and Patterson Animal Health. It reported revenues of $5.9 billion in fiscal 2017. The company's dividend currently yields 2.67% and its five-year historical dividend growth rate is 14.35%.
Owens & Minor Inc.OMI
Based in Mechanicsville, VA, Owens & Minor is a global healthcare services company focused on providing supply chain services to healthcare providers and manufacturers of healthcare products. The company provides logistics services across the spectrum of medical products from disposable medical supplies to devices and implants. The company generated revenues in excess of $9 billion in the last reported fiscal. The company's dividend currently yields 3.62% and its five-year historical dividend growth rate is 2.90%.
Bottom Line
Amid the unpredictable MedTech setting, investing in these high-yielding dividend stocks might fetch you promising returns.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Owens & Minor, Inc. (OMI): Free Stock Analysis Report
Patterson Companies, Inc. (PDCO): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Our Choices Abbott LaboratoriesABT Abbott Park, IL-based Abbott Laboratories discovers, develops, manufactures and sells a diversified line of health care products. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. The lukewarm response to its replacement, The American Health Care Act (AHCA), has forced Republicans to continue to seek new avenues. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Our Choices Abbott LaboratoriesABT Abbott Park, IL-based Abbott Laboratories discovers, develops, manufactures and sells a diversified line of health care products. Cardinal Health's dividend currently yields 2.70% and its five-year historical dividend growth rate is 13.71%. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Our Choices Abbott LaboratoriesABT Abbott Park, IL-based Abbott Laboratories discovers, develops, manufactures and sells a diversified line of health care products. Dividend Investing to the Rescue As evident from the MedTech story, stocks can be volatile and are risky at times.. With uncertainty ruling the markets, it is not surprising that dividend investing has emerged as one of the most popular investing themes. | Our Choices Abbott LaboratoriesABT Abbott Park, IL-based Abbott Laboratories discovers, develops, manufactures and sells a diversified line of health care products. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Dividend Investing to the Rescue As evident from the MedTech story, stocks can be volatile and are risky at times.. With uncertainty ruling the markets, it is not surprising that dividend investing has emerged as one of the most popular investing themes. |
33511.0 | 2017-09-07 00:00:00 UTC | Abbott (ABT) Hits a 52-Week High: What's Driving the Stock? | ABT | https://www.nasdaq.com/articles/abbott-abt-hits-a-52-week-high%3A-whats-driving-the-stock-2017-09-07 | nan | nan | Share price of AbbottABT scaled a new 52-week high of $51.42 on Sep 6, eventually closing nominally lower at $51.19. The company has gained 9.6% over the past three months, much higher than the S&P 500's gain of 0.7% over the same frame. Abbott has also outperformed the broader industry 's decline of 0.1% with respect to share price movement over the past three months. The stock has a market cap of $88.94 billion.
Further, Abbott's estimate revision trend for the current year has been favorable. In the past 60 days, seven estimates moved up while one moved down. The estimates were up from $2.46 per share to $2.49 over the same time frame.
The company also has a trailing four-quarter average positive earnings surprise of 4.6%. Its positive long-term growth of 10.7% holds promise.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
Abbott carries a Zacks Rank #3 (Hold). The company has an impressive Growth Style Score of B. Our Growth Style Score highlights all the vital metrics of a company's financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 offer the best investment opportunities.
Growth Drivers
The market is upbeat about Abbott's recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device (LVAD).
The company also announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan. The development has widened this Illinois-based medical device major's customer base in diabetes management.
Further, the company recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Abbott expects this alliance to solidify its footprint in the rapidly growing diagnostics market.
Meanwhile, Abbott's second-quarter performance has been promising with sales and adjusted earnings from continuing operations increasing year over year.
All these factors are expected to boost the company's share price.
Key Picks
A few better-ranked medical stocks are Edwards Lifesciences Corporation EW , Lantheus Holdings, Inc. LNTH and Chemed Corporation CHE . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Chemed carry a Zacks Rank #2 (Buy). You cansee the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 25.4% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 25.7% over the last six months.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained around 8.9% over the last six months.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report
Chemed Corp. (CHE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Share price of AbbottABT scaled a new 52-week high of $51.42 on Sep 6, eventually closing nominally lower at $51.19. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott has also outperformed the broader industry 's decline of 0.1% with respect to share price movement over the past three months. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of AbbottABT scaled a new 52-week high of $51.42 on Sep 6, eventually closing nominally lower at $51.19. Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote Abbott carries a Zacks Rank #3 (Hold). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of AbbottABT scaled a new 52-week high of $51.42 on Sep 6, eventually closing nominally lower at $51.19. Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote Abbott carries a Zacks Rank #3 (Hold). | Share price of AbbottABT scaled a new 52-week high of $51.42 on Sep 6, eventually closing nominally lower at $51.19. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 offer the best investment opportunities. |
33512.0 | 2017-09-04 00:00:00 UTC | Revealed: The Secret to Safe 12% Yearly Gains … for Life | ABT | https://www.nasdaq.com/articles/revealed-secret-safe-12-yearly-gains-life-2017-09-04 | nan | nan | By Brett Owens
Don't let the pundits deceive you. Despite their endless bleating about an overheated market and an imminent crash, now is a great time to buy.
But you need to look beyond the breathless reporting about the S&P 500's daily push higher--or its ratchet-tight P/E ratio.
Because the real winning stocks are cloaked behind something most folks don't pay nearly enough attention to: dividends--particularly dividend growth !
Let me explain.
Dividends Are Great Again
A quietly released report from investment manager Janus Henderson Group ( JHG ) tells the tale--and it's a happy one for American investors.
According to Janus, global dividends jumped 5.4% year-over-year in the second quarter. Buried under that headline was a 9.8% surge from US companies, to $111.6 billion, as fatter corporate bottom lines started flowing to investors in the form of fatter dividend checks.
It gets better: the suits at Janus now expect a record $1.208 trillion in global dividends this year, up 3.9% from 2016 and $50 billion more than the last estimate.
A Shortcut to a Safe Double-Digit Yield
In a moment, I'll reveal 3 all-American stocks that are leading the pack on the dividend-growth front. All 3 are ripe for buying now.
I'll also show you a simple strategy for uncovering the dividend growers that can put you on the path to grinding out a steady 12% yearly total return from your portfoliofor life.
That's enough to double your portfolio's value every 6 years! And it's nearly twice the 7% or so the market's doled out, on average, over the long term.
Plus you'll build an ever-growing income stream, too.
In fact, what I'm about to show you will have you raking in 10% dividends in short order! So even if you have a relatively modest nest egg and a few years to go till retirement, you're looking at a real chance of living on dividends alone when you do clock out.
So let's get going, starting with how a relentlessly rising dividend can ignite your income and your gains in one fell swoop.
The Curious Case of the "Hidden" Yield
For most folks, dividends always take a backseat to capital gains.
It's easy to see why: when you own a stock that could explode for gains of 5%, 10% or more practically overnight, it's tough to get worked up about a sub-2% dividend--particularly when the dividend yield on your average S&P 500 stock is shrinking :
The S&P 500: Thin Gruel for Dividend Fans
But the herd has it backwards. Because when you look past the current yield and focus a completely ignored number--the yield on your initial investment-- the picture changes dramatically.
This is where dividend growth comes in.
Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . (It's up more than 12% since then and still has room to run).
If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield.
Not bad! That's way ahead of both inflation and the S&P 500 average.
But fast-forward to today--not even four years later--and the income stream on your original buy would have surged to 5.1% thanks to a 60% increase in AbbVie's quarterly payout, including a monster 12% hike announced last October!
That's only half the story, though.
Because we haven't talked about capital gains--and big dividend hikes like these have a huge (and underappreciated) impact here. Check out how AbbVie's stock marched higher in lockstep with its dividend increases:
AbbVie Investors Win Twice
The company owns rheumatoid-arthritis treatment Humira, the world's top-selling drug, and spends a massive 18% of revenue on R&D. Management has translated that cash into a pipeline that's the envy of the biotech world, with 17 treatments in Phase 3 trials.
AbbVie also pays out 59% of earnings per share as dividends--easily manageable in light of rising adjusted earnings per share (up 12.7% year-over-year in Q2). That, plus its low valuation of 13.6 times expected earnings, makes this stock ripe for buying now.
Now let's move on to…
Another Overlooked Dividend-Growth Play
Alexandria Real Estate Equities ( ARE ) is a real estate investment trust (REIT) with a current yield you might also be tempted to ignore: 2.8%.
But Alexandria--which owns 202 labs and other tech centers in innovation hotbeds like Boston and San Francisco--has an ace up its sleeve: one of the tightest correlations between share price and dividend growth I've ever seen!
Check out how its surging payout has driven an almost identical rise in the share price over the last five years:
60% Dividend Increase ... 60% Gain
12 times!
A fast look at second-quarter financials shows why: per-share funds from operations (FFO, the REIT equivalent of EPS) jumped 10.3% and occupancy clocked in at a healthy 95.7% (set to rise as high as 97.7% for the full year). The dividend is also well covered at a low (for a REIT) 56% of trailing-twelve-month FFO.
Alexandria's tenant list is a who's-who of the tech and pharma elite. For extra ballast, it includes mainstays like the US government, MIT and New York University:
The time to buy is now--before that growth drives the share price, and the dividend, higher.
The King of the Airwaves
Much as I love Alexandria, American Tower ( AMT ) beats it in two crucial ways: it hikes its dividend even more frequently: every quarter. It also trumps its REIT cousin in dividend growth, with a payout that's surged 178% in five years.
Here's the best part: due to overdone interest-rate fears that have weighed on all REITs, AMT's share price hasn't kept pace with those dividend hikes.
The opportunity here is obvious.
AMT's Wide-Open Buy Window
The company also boasts a growing portfolio and top-flight tenants, including nearly 150,000 communications sites leased to the likes of AT&T (T) and Verizon (VZ) .
More payout growth is dialed in: AMT's adjusted per-share FFO surged 18.8% in the second quarter, and it sends just 35.8% of its adjusted FFO out the door as dividends--ridiculously low for a REIT.
So don't be thrown off by AMT's 1.7% current yield. It's a smokescreen for a company whose dividend--and share price--have lots of jump left.
7 Quick Buys to DOUBLE Your Money in 6 Years or Less
I've just uncovered 7 more stealth dividend growers poised to keep rising while handing you solid income right away.
Together, these 7 low-key income plays can easily grow your money 12% a year FOREVER--doubling your portfolio every 6 years!
You could even throw them together in their own "mini-portfolio" and lean on them for immediate payments, growing retirement income and solid capital gains year in and year out!
If that's not the holy grail of investing, I don't know what is.
I'm ready to share my complete research in a special investor report I've just published here .
Here's a quick look at just 3 of these all-star dividend stocks :
The Dividend Doubler: This company starts out with a gaudy dividend yield--4.7%--but it's already hiked its payout TWICE in the past year! If it keeps up that pace, you'll be in line fora 9.4% yield on your initial buy in short order. But you need to make your move now.
The 800% Income Machine: This company's dividend has exploded eightfold since a dynamic new management team took over four years ago, PLUS they're expertly buying back stocks to goose the share price even more. This one is a complete no-brainer for anyone looking to pocket bigger and bigger dividend checks from here on out!
The 250% Gainer: This one trades for a ridiculous 6 TIMES cash flow --and the last time that number fell below 10, the stock exploded on a monster 252% run! The stars are aligning for a repeat, but the dividend and management's smart buybacks alone could push your investment up 12% or more.
I'm ready to share full details on these stocks and 4 more red-hot dividend-growth plays. All you have to do is CLICK HERE go get my complete research, including each stock's name, ticker and buy-under price .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. But Alexandria--which owns 202 labs and other tech centers in innovation hotbeds like Boston and San Francisco--has an ace up its sleeve: one of the tightest correlations between share price and dividend growth I've ever seen! A fast look at second-quarter financials shows why: per-share funds from operations (FFO, the REIT equivalent of EPS) jumped 10.3% and occupancy clocked in at a healthy 95.7% (set to rise as high as 97.7% for the full year). | If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. AbbVie also pays out 59% of earnings per share as dividends--easily manageable in light of rising adjusted earnings per share (up 12.7% year-over-year in Q2). You could even throw them together in their own "mini-portfolio" and lean on them for immediate payments, growing retirement income and solid capital gains year in and year out! | If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. It's easy to see why: when you own a stock that could explode for gains of 5%, 10% or more practically overnight, it's tough to get worked up about a sub-2% dividend--particularly when the dividend yield on your average S&P 500 stock is shrinking : The S&P 500: Thin Gruel for Dividend Fans But the herd has it backwards. Here's a quick look at just 3 of these all-star dividend stocks : The Dividend Doubler: This company starts out with a gaudy dividend yield--4.7%--but it's already hiked its payout TWICE in the past year! | If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. That, plus its low valuation of 13.6 times expected earnings, makes this stock ripe for buying now. Check out how its surging payout has driven an almost identical rise in the share price over the last five years: 60% Dividend Increase ... 60% Gain 12 times! |
33513.0 | 2017-09-01 00:00:00 UTC | Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm | ABT | https://www.nasdaq.com/articles/abbotts-amplatzer-pivotal-study-to-strengthen-vascular-arm-2017-09-01 | nan | nan | AbbottABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. This device is designed to correct a common congenital heart defect in pre-term infants. The device is same as the larger sized AMPLATZER Duct Occluder II product. The clinical study will be conducted on 50 patients at up to 10 centers across the United States.
According to Abbott, Patent ductus arteriosus (PDA) is a life-threatening vascular pathway or duct in the heart that remains open due to the failure of the fetal duct to close after birth. In some cases, the PDA fails to close spontaneously in premature babies leading to difficulty in breathing and feeding.
Pharmaceuticals can be used at times to close the duct but are less effective in pre-term infants. Current treatment options for pre-term infants who are not responsive to pharmaceuticals are limited to surgery. However, surgery is not always possible and leaving the duct open can lead to fatal outcomes for infants. Breaking the conventional treatment, Abbott is developing the AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) device to provide physicians with a nonsurgical treatment option for addressing the PDA defect in newborns and pre-term infants. ADO II AS is already approved for use in Europe.
We note that Abbott has been consistently trying to expand its vascular business under the Medical Device segment that is on solid growth trajectory of late. In the last reported second quarter, the Medical Devices business sales spiked 89.2% on a reported basis.
Also, the recent developments include the receipt of FDA approval for Full MagLev HeartMate 3Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system enables physicians managing advanced heart failure patients in need of short-term hemodynamic support.
Abbott also announced CE Mark and first use of the new Confirm Rx Insertable Cardiac Monitor (ICM). This is the world's first smartphone-compatible ICM which helps physicians identify difficult-to-detect cardiac arrhythmias, including atrial fibrillation (AF).
According to a report by Markets and Markets, the global pediatric interventional cardiology market is estimated to see a CAGR of 9% from 2013 to 2018. Looking at the bountiful opportunities in this niche space, we believe the company's latest development by is a strategical fit.
Over the last three months, Abbott has been trading above the broader industry . The stock has till now gained 7.9% as against the industry's decline of 1.2%.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation EW , Lantheus Holdings, Inc. LNTH and IDEXX Laboratories, Inc. IDXX . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You cansee the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 21.6% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.9% over the last six months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Abbott has been consistently trying to expand its vascular business under the Medical Device segment that is on solid growth trajectory of late. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. Breaking the conventional treatment, Abbott is developing the AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) device to provide physicians with a nonsurgical treatment option for addressing the PDA defect in newborns and pre-term infants. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. Breaking the conventional treatment, Abbott is developing the AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) device to provide physicians with a nonsurgical treatment option for addressing the PDA defect in newborns and pre-term infants. | AbbottABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmaceuticals can be used at times to close the duct but are less effective in pre-term infants. |
33514.0 | 2017-09-01 00:00:00 UTC | Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod | ABT | https://www.nasdaq.com/articles/abbotts-abt-freestyle-libre-gets-japan-reimbursement-nod-2017-09-01 | nan | nan | As a major breakthrough in its diabetics business, AbbottABT recently announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan.
The development has widened this Illinois-based medical device major's customer base in diabetes management. Per management, with around 9.5 million population diagnosed with diabetes, Japan is considered a nation with the highest rate of people suffering with the condition.
The company states that the grant of reimbursement will also make FreeStyle Libre system widely available to more than one million Japanese people diagnosed with both Type 1 and Type 2 diabetes and on insulin therapy varying from ages six and above.
Also, the reimbursement approval in Japan marks another milestone where Abbott's FreeStyle Libre system stands partially or fully covered in 16 countries, including France and Germany. Notably, FreeStyle Libre system is presently under review by the FDA and awaits approval in the United States.
Abbott has been moving steadily toward development in its diabetics segment. In July, the company partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.
Moreover, the company recently announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. This will further stimulate growth in the Diabetes Care sales segment, which was up 18.7% in second-quarter 2017 on continued consumer acceptance of FreeStyle Libre internationally.
We expect Freestyle Libre to further contribute to Abbott's top line as along with the Canadian development, the French Health Ministry recently approved national reimbursement for the device.
Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%.
Considering the market potential and Abbott's current developments in the diabetes care segment, the recent national reimbursement grant in Japan will accelerate the top line.
We believe an ageing population, unhealthy lifestyle and rising awareness and expenditure in healthcare will continue to drive growth in the diabetes market. However, this market is dominated by many well established players, Johnson & Johnson (JNJ) being the most prominent one. In this space, Johnson & Johnson also has a tie-up with U.S.-based Animas Corporation to successfully develop and innovate insulin delivery systems.
Moreover, Abbott has been gaining investor confidence on consistently positive results. Over the last three months, the company's share price has outperformed the broader industry . The stock has gained 7.9%, in contrast to the broader industry's decline of 1.2%. The company has also outperformed the 0.8% fall of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation EW , Lantheus Holdings, Inc. LNTH and IDEXX Laboratories, Inc. IDXX . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 21.6% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.9% over the last six months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a major breakthrough in its diabetics business, AbbottABT recently announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. Also, the reimbursement approval in Japan marks another milestone where Abbott's FreeStyle Libre system stands partially or fully covered in 16 countries, including France and Germany. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. As a major breakthrough in its diabetics business, AbbottABT recently announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan. A few better-ranked medical stocks are Edwards Lifesciences Corporation EW , Lantheus Holdings, Inc. LNTH and IDEXX Laboratories, Inc. IDXX . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. As a major breakthrough in its diabetics business, AbbottABT recently announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan. Considering the market potential and Abbott's current developments in the diabetes care segment, the recent national reimbursement grant in Japan will accelerate the top line. | As a major breakthrough in its diabetics business, AbbottABT recently announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). |
33515.0 | 2017-09-01 00:00:00 UTC | Health Care Sector Update for 09/01/2017: JNJ, PFE, ABT, MRK, AMGN, IOVA, APVO, PGNX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-09012017-jnj-pfe-abt-mrk-amgn-iova-apvo-pgnx-2017-09-01 | nan | nan | Top Health Care Stocks:
JNJ: +0.02%
PFE: +0.03%
ABT: flat
MRK: flat
AMGN: +0.3%
Health care shares were mainly firmer in pre-market trade Friday.
In sector news, Iovance Biotherapeutics ( IOVA ) rose more than 11% after it said late Thursday that the U.S. Food and Drug Administration has granted Fast Track designation for LN-144, the company's adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma. C-144-01 is a Phase 2 study evaluating LN-144, Iovance's lead product, for treatment of patients with metastatic melanoma. The study is currently enrolling and is expected to enroll up to 60 patients in two cohorts. The company reported data from the first cohort of the study, which showed clinically-meaningful outcomes in the evaluable patients, with a 29% Objective Response Rate including one complete response continuing beyond 15 months post-administration of a single TIL treatment, and 77% of patients had reduction in target tumor size.
In other sector news,
(+) APVO (+80.5%) Regains worldwide rights to the treatment for metastatic castration resistant prostate cancer
(-) PGNX (-1.9%) Suspends development of vertigo drug after trial misses endpoints
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat In sector news, Iovance Biotherapeutics ( IOVA ) rose more than 11% after it said late Thursday that the U.S. Food and Drug Administration has granted Fast Track designation for LN-144, the company's adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma. The company reported data from the first cohort of the study, which showed clinically-meaningful outcomes in the evaluable patients, with a 29% Objective Response Rate including one complete response continuing beyond 15 months post-administration of a single TIL treatment, and 77% of patients had reduction in target tumor size. | ABT: flat MRK: flat C-144-01 is a Phase 2 study evaluating LN-144, Iovance's lead product, for treatment of patients with metastatic melanoma. In other sector news, (+) APVO (+80.5%) Regains worldwide rights to the treatment for metastatic castration resistant prostate cancer (-) PGNX (-1.9%) Suspends development of vertigo drug after trial misses endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Health care shares were mainly firmer in pre-market trade Friday. The company reported data from the first cohort of the study, which showed clinically-meaningful outcomes in the evaluable patients, with a 29% Objective Response Rate including one complete response continuing beyond 15 months post-administration of a single TIL treatment, and 77% of patients had reduction in target tumor size. | ABT: flat MRK: flat Top Health Care Stocks: C-144-01 is a Phase 2 study evaluating LN-144, Iovance's lead product, for treatment of patients with metastatic melanoma. |
33516.0 | 2017-08-31 00:00:00 UTC | Health Care Sector Update for 08/31/2017: JNJ, PFE, ABT, MRK, AMGN, IPXL, INSY | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08312017-jnj-pfe-abt-mrk-amgn-ipxl-insy-2017-08-31 | nan | nan | Top Health Care Stocks
JNJ, +1%
PFE, +1.6%
ABT, +1.7%
MRK, +1.1%
AMGN, +2.2%
Health care stocks were firmer as Thursday's regular session drew to a close.
In company news, Impax Laboratories ( IPXL ). rose 23.1% after Shanghai Fosun Pharmaceutical Group disclosed in a regulatory filing Thursday it has acquired 3.9 million shares of common stock of the company. The acquisition represents a 5.19% passive stake in Impax.
In other sector news,
(+) MRK (+1.1%) FDA issues alert on safety concerns on Keytruda for multiple myeloma after two halted trials
(-) INSY (-4.2%) Sued by Arizona's attorney general for fraudelent marketing scheme
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care stocks were firmer as Thursday's regular session drew to a close. rose 23.1% after Shanghai Fosun Pharmaceutical Group disclosed in a regulatory filing Thursday it has acquired 3.9 million shares of common stock of the company. In other sector news, (+) MRK (+1.1%) FDA issues alert on safety concerns on Keytruda for multiple myeloma after two halted trials (-) INSY (-4.2%) Sued by Arizona's attorney general for fraudelent marketing scheme The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks In other sector news, (+) MRK (+1.1%) FDA issues alert on safety concerns on Keytruda for multiple myeloma after two halted trials (-) INSY (-4.2%) Sued by Arizona's attorney general for fraudelent marketing scheme The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care stocks were firmer as Thursday's regular session drew to a close. rose 23.1% after Shanghai Fosun Pharmaceutical Group disclosed in a regulatory filing Thursday it has acquired 3.9 million shares of common stock of the company. In other sector news, (+) MRK (+1.1%) FDA issues alert on safety concerns on Keytruda for multiple myeloma after two halted trials (-) INSY (-4.2%) Sued by Arizona's attorney general for fraudelent marketing scheme The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks Health care stocks were firmer as Thursday's regular session drew to a close. In company news, Impax Laboratories ( IPXL ). |
33517.0 | 2017-08-30 00:00:00 UTC | 5 Greatest Health-Care Stocks of All Time | ABT | https://www.nasdaq.com/articles/5-greatest-health-care-stocks-all-time-2017-08-30 | nan | nan | Health-care stocks have always benefited from the powerful demographic forces of steady population growth and longer life expectancy. Indeed, the population of the U.S. has more than tripled over the past 100 years. And the average American can expect to live to the age of 79, up from 51 a century ago. Those trends have given the health-care sector a steady influx of new customers for decades. At the same time, technological breakthroughs let health-care companies develop everything from better drugs to more effective medical devices.
The bottom line is that the relentless growth and aging of the U.S. population has helped a number of health-care stocks deliver some of the best returns in the stock market. This came to light when Hendrik Bessembinder of Arizona State University's W. P. Carey School of Business analyzed the lifetime returns of 25,782 common stocks over a 90-year span. The finance professor found that 96% of all stocks collectively performed no better than risk-free 1-month Treasury bills. The remaining 4% - just 1,000 stocks - generated all of the nearly $32 trillion in wealth created by the stock market between July 1926 and December 2015. Even more striking, the top 30 stocks accounted for one-third of that amount. Five of the 30 top-performing stocks can be found in the health-care sector. You're sure to recognize these names, which are among the titans of the health and drug industry.
SEE ALSO: The 30 Greatest Stocks of All Time
Ticker symbol: PFE
Lifetime wealth creation: $171.6 billion
Lifetime cumulative return: 2,588,650%
Current share price: $33.50
Current dividend yield: 3.8%
Current analyst ratings: 7 strong buy, 0 buy, 7 hold, 0 sell, 1 strong sell
It should come as no surprise that many of the top-performing stocks since 1926 are components of the Dow, which dates back to 1896. The popular benchmark is made up of 30 of the bluest blue-chip stocks available to investors, and components change infrequently. Pfizer, founded in 1849 and public since 1942, had to wait until 2004 before it was finally added to the industrial average. The pharmaceutical giant earned the honor in large part thanks to its history of developing blockbuster drugs. Among the best known are Lipitor (for cholesterol) and Viagra (for erectile dysfunction). Pfizer also owes its growth to its many successful acquisitions. Since 2000, it has purchased Warner-Lambert, Pharmacia and Wyeth. Despite the stock's remarkable lifetime performance, it's been ordinary in recent years. Including dividends, returns come to 107% over the past 10 years. The broader Standard & Poor's 500-stock index is up 110% over the same span, including dividends. Over the last 52 weeks, the stock is down nearly 4% on a price basis.
SEE ALSO: Best Stock in Every State to Buy Now
Ticker symbol: BMY
Lifetime wealth creation: $177.2 billion
Lifetime cumulative return: 3,484,840%
Current share price: $58.86
Current dividend yield: 2.7%
Current analyst ratings: 5 strong buy, 1 buy, 5 hold, 0 sell, 1 strong sell
Add another pharmaceutical maker to the list of the greatest creators of stock market wealth for investors over the 90-year span. The modern-day Bristol-Myers Squibb resulted from the 1989 merger of Bristol-Myers and Squibb, but even before joining forces the two separate companies boasted distinguished business lineages that stretch back into the 19th century. A long track record of successful acquisitions has kept the pipeline primed with big-name drugs over the years. Among the better-known names today are Coumadin, a blood thinner, and Glucophage, for Type 2 diabetes. Despite a phenomenal lifetime return for the stock through 2015, shares cratered a year ago after one of the company's key cancer drugs failed a clinical study. Bristol-Myers Squibb stock is still in recovery mode. Excluding dividends, it's up 2.8% over the last 52 weeks. The S&P 500 has gained 12% over the same time frame, dividends not included.
SEE ALSO: Quiz: Test Your Bull Market IQ
Ticker symbol: ABT
Lifetime wealth creation: $189.6 billion
Lifetime cumulative return: 2,820,670%
Current share price: $50.15
Current dividend yield: 2.1%
Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell
Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. The company has a long and eventful history that dates to its founding in 1888. Abbott first paid a dividend in 1924, and it has raised its payout annual for the last 46 years in a row. The company went public in 1929 on the eve of the Great Depression. Its many decades as a dividend-paying public company have certainly attributed to the extraordinary lifetime returns of its stock. A new era began for Abbott in 2013, when it spun off AbbVie as a standalone maker of branded drugs and therapies. Abbott now focuses on generic drugs, medical devices, nutrition and diagnostic products. Since the spinoff, however, Abbott's share-price performance has trailed that of both AbbVie and the broader S&P 500 index.
SEE ALSO: 25 Surprising Stocks Paying Dividends for 25 Years or More
Ticker symbol: MRK
Lifetime wealth creation: $265.7 billion
Lifetime cumulative return: 791,780%
Current share price: $63.12
Current dividend yield: 3%
Current analyst ratings: 6 strong buy, 1 buy, 3 hold, 1 sell, 0 strong sell
Merck is the top-performing drug maker on this list with lifetime wealth creation between 1926 and 2015 totaling more than a quarter-trillion dollars. This shouldn't come as a surprise considering Merck's corporate pedigree. The company was established in 1891, and the stock has been a component of the Dow since 1979. The Merck family's involvement in the pharmaceutical business dates back to 17th century Germany. The 21st century has been less kind, however. The stock price, adjusted for splits and dividends, remains well below its 2000 peak near $95 a share. In the past 17 years, Merck has experience plenty of ups and downs, from the Vioxx recall in 2004 to its megamerger with Schering-Plough in 2009. With nearly $40 billion in annual sales, Merck remains a formidable player in the global drug business. Whether the stock can regain its former glory remains to be seen.
SEE ALSO: 10 Small Towns With Big Millionaire Populations
Ticker symbol: JNJ
Lifetime wealth creation: $383.7 billion
Lifetime cumulative return: 2,930,670%
Current share price: $132.21
Current dividend yield: 2.6%
Current analyst ratings: 5 strong buy, 1 buy, 7 hold, 0 sell, 2 strong sell
Johnson & Johnson operates in several different areas of health care including pharmaceutical products and medical devices. The company is best known, however, for its over-the-counter consumer brands including Listerine mouthwash and Tylenol pain reliever. J&J has been at the health-care game for a very long time. Founded in 1886 by three brothers, the company created the first commercial first aid kits and it was the first to mass-produce dental floss - all before 1900. Its iconic Band-Aid bandages hit the market in 1921. Somewhat surprisingly, J&J wasn't added to the Dow until 1997, even though shares had been publicly traded since 1944. The ever-rising dividend, along with the popularity of its products, eventually made the stock too conspicuous to ignore. J&J has increased the amount of its annual payout to shareholders every year since 1963.
SEE ALSO: 25 Dividend Stocks You Can Buy and Hold Forever
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SEE ALSO: Quiz: Test Your Bull Market IQ Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $50.15 Current dividend yield: 2.1% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. Health-care stocks have always benefited from the powerful demographic forces of steady population growth and longer life expectancy. This came to light when Hendrik Bessembinder of Arizona State University's W. P. Carey School of Business analyzed the lifetime returns of 25,782 common stocks over a 90-year span. | SEE ALSO: Quiz: Test Your Bull Market IQ Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $50.15 Current dividend yield: 2.1% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. SEE ALSO: 25 Surprising Stocks Paying Dividends for 25 Years or More Ticker symbol: MRK Lifetime wealth creation: $265.7 billion Lifetime cumulative return: 791,780% Current share price: $63.12 Current dividend yield: 3% Current analyst ratings: 6 strong buy, 1 buy, 3 hold, 1 sell, 0 strong sell Merck is the top-performing drug maker on this list with lifetime wealth creation between 1926 and 2015 totaling more than a quarter-trillion dollars. SEE ALSO: 10 Small Towns With Big Millionaire Populations Ticker symbol: JNJ Lifetime wealth creation: $383.7 billion Lifetime cumulative return: 2,930,670% Current share price: $132.21 Current dividend yield: 2.6% Current analyst ratings: 5 strong buy, 1 buy, 7 hold, 0 sell, 2 strong sell Johnson & Johnson operates in several different areas of health care including pharmaceutical products and medical devices. | SEE ALSO: Quiz: Test Your Bull Market IQ Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $50.15 Current dividend yield: 2.1% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. SEE ALSO: The 30 Greatest Stocks of All Time Ticker symbol: PFE Lifetime wealth creation: $171.6 billion Lifetime cumulative return: 2,588,650% Current share price: $33.50 Current dividend yield: 3.8% Current analyst ratings: 7 strong buy, 0 buy, 7 hold, 0 sell, 1 strong sell It should come as no surprise that many of the top-performing stocks since 1926 are components of the Dow, which dates back to 1896. SEE ALSO: Best Stock in Every State to Buy Now Ticker symbol: BMY Lifetime wealth creation: $177.2 billion Lifetime cumulative return: 3,484,840% Current share price: $58.86 Current dividend yield: 2.7% Current analyst ratings: 5 strong buy, 1 buy, 5 hold, 0 sell, 1 strong sell Add another pharmaceutical maker to the list of the greatest creators of stock market wealth for investors over the 90-year span. | SEE ALSO: Quiz: Test Your Bull Market IQ Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $50.15 Current dividend yield: 2.1% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. Five of the 30 top-performing stocks can be found in the health-care sector. Including dividends, returns come to 107% over the past 10 years. |
33518.0 | 2017-08-30 00:00:00 UTC | Health Care Sector Update for 08/30/2017: JNJ, PFE, ABT, MRK, AMGN, MDCO, OTIC | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08302017-jnj-pfe-abt-mrk-amgn-mdco-otic-2017-08-30 | nan | nan | Top Health Care Stocks:
JNJ: -0.2%
PFE: flat
ABT: flat
MRK: flat
AMGN: +0.3%
Health care shares were mainly inactive in pre-market trade Wednesday.
In sector news, The Medicines Company's ( MDCO ) subsidiary, Rempex Pharmaceuticals, has received approval from the U.S. Food and Drug Administration for Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria. MDCO shares were up 6.5%.
In other sector news,
(+) AMGN (+0.3%) Study results show new cholesterol drug lowers stroke risk in certain patients
(-) OTIC (-81%) Suspends development of vertigo drug after trial misses endpoints
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat MRK: flat In sector news, The Medicines Company's ( MDCO ) subsidiary, Rempex Pharmaceuticals, has received approval from the U.S. Food and Drug Administration for Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria. | PFE: flat ABT: flat MRK: flat Health care shares were mainly inactive in pre-market trade Wednesday. In other sector news, (+) AMGN (+0.3%) Study results show new cholesterol drug lowers stroke risk in certain patients (-) OTIC (-81%) Suspends development of vertigo drug after trial misses endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat MRK: flat Health care shares were mainly inactive in pre-market trade Wednesday. In sector news, The Medicines Company's ( MDCO ) subsidiary, Rempex Pharmaceuticals, has received approval from the U.S. Food and Drug Administration for Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. | PFE: flat ABT: flat MRK: flat Health care shares were mainly inactive in pre-market trade Wednesday. In sector news, The Medicines Company's ( MDCO ) subsidiary, Rempex Pharmaceuticals, has received approval from the U.S. Food and Drug Administration for Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. |
33519.0 | 2017-08-23 00:00:00 UTC | 30 Great Stocks of All Time | ABT | https://www.nasdaq.com/articles/30-great-stocks-all-time-2017-08-23 | nan | nan | A finance professor made a startling discovery about the stock market: Over a 90-year span, 96% of all stocks collectively performed no better than risk-free 1-month Treasury bills. After analyzing the lifetime returns of 25,782 common stocks, Hendrik Bessembinder determined that just 1,000 of those stocks - or about 4% of the total - generated all of the nearly $32 trillion in wealth created by the stock market between July 1926 and December 2015. Even more striking, a mere 30 stocks accounted for one-third of that amount.
But before we get to our profiles of the 30 best-performing stocks, most of which are (or were) components of the Dow Jones industrial average, a word of caution. Accurately identifying the precious few "home run" stocks amid the many thousands of underachieving names is extremely difficult. It might be impossible. Your portfolio is more likely to suffer because you guessed wrong and failed to invest in the top long-term winners, says Bessembinder of Arizona State University's W. P. Carey School of Business.
A better alternative to trying to find a needle in a haystack? To paraphrase Jack Bogle, the Vanguard founder and pioneer of index investing: Just buy the haystack. "The results reinforce the importance of diversification," says Bessembinder, "and low-cost index funds are an excellent way to diversify broadly."
Take a look at the 30 top-performing stocks since 1926.
Ticker symbol: PFE
Lifetime wealth creation: $171.6 billion
Lifetime cumulative return: 2,588,650%
Current share price: $32.67
Current dividend yield: 3.9%
Current analyst ratings: 7 strong buy, 0 buy, 7 hold, 0 sell, 1 strong sell
It should come as no surprise that many of the top-performing stocks since 1926 are components of the Dow, which dates back to 1896. The popular benchmark is made up of 30 of the bluest blue-chip stocks available to investors, and components change infrequently. Pfizer, founded in 1849 and public since 1942, had to wait until 2004 before it was finally added to the industrial average. The pharmaceutical giant earned the honor in large part thanks to its history of developing blockbuster drugs. Among the best known are Lipitor (for cholesterol) and Viagra (for erectile dysfunction). Pfizer also owes its growth to its many successful acquisitions. Since 2000, it has purchased Warner-Lambert, Pharmacia and Wyeth. Despite the stock's remarkable lifetime performance, it hasn't been as remarkable in recent years. Returns lag the broader Standard & Poor's 500-stock index by 30 percentage points over the past decade. Over the last 52 weeks, the stock is down 6%.
SEE ALSO: Best Stock in Every State to Buy Now
Ticker symbol: MCD
Lifetime wealth creation: $172.2 billion
Lifetime cumulative return: 370,930%
Current share price: $157.76
Current dividend yield: 2.4%
Current analyst ratings: 17 strong buy, 1 buy, 6 hold, 0 sell, 0 strong sell
McDonald's needs no introduction. The world's biggest burger chain has been a stock market and dietary staple for decades. That's partly because management has a knack for changing with the times. Shares performed poorly in the early 2000s, for example, around the time the low-carb Atkins diet surged in popularity. McDonald's responded by adding more healthy fare to its menu and the stock recovered. To this day, McDonald's continues to focus on healthier items to compete with new chains boasting fresher offerings, but it was the launch of all-day breakfast in 2015 that has given the Golden Arches its latest jolt of life. Over the last two years, shares are up 58%. History suggests it's never wise to count out McDonald's, a public company since 1965 and a Dow component since 1985. Its dividend dates back to 1976 and has gone up every year since.
Ticker symbol: BMY
Lifetime wealth creation: $177.2 billion
Lifetime cumulative return: 3,484,840%
Current share price: $56.42
Current dividend yield: 2.8%
Current analyst ratings: 5 strong buy, 1 buy, 5 hold, 0 sell, 1 strong sell
Add another pharmaceutical maker to the list of the greatest creators of stock market wealth for investors over the 90-year span. The modern-day Bristol-Myers Squibb resulted from the 1989 merger of Bristol-Myers and Squibb, but even before joining forces the two separate companies boasted distinguished business lineages that stretch back into the 19th century. A long track record of successful acquisitions has kept the pipeline primed with big-name drugs over the years. Among the better-known names today are Coumadin, a blood thinner, and Glucophage, for Type 2 diabetes. Despite a phenomenal lifetime return for the stock through 2015, shares cratered a year ago after one of the company's key cancer drugs failed a clinical study. Bristol-Myers Squibb stock has yet to recover, with the price down 5% over the last 52 weeks.
Ticker symbol: MMM
Lifetime wealth creation: $180.7 billion
Lifetime cumulative return: 749,260%
Current share price: $203.53
Current dividend yield: 2.3%
Current analyst ratings: 4 strong buy, 0 buy, 6 hold, 0 sell, 2 strong sell
Perhaps best known for Scotch tape and Post-It notes, it's easy to forget that one of the three M's in 3M stands for mining. (The other two M's stand for Minnesota and manufacturing, as in Minnesota Mining and Manufacturing Co.) The company began in 1902 as a small-time outfit in search of corundum, an abrasive mineral used in manufacturing. The mining venture didn't pan out, but the failure did force the company to innovate and branch out. It hasn't stopped since. Today, 3M makes 60,000 products, with one-third of sales coming from products invented in the last five years. The company's legacy of success earned it a spot in the Dow in 1976. Shareholders have happily gone along for the ride. 3M's dividend dates back a century and has increased annually for 58 consecutive years. Shares hit an all-time high in June.
Ticker symbol: ABT
Lifetime wealth creation: $189.6 billion
Lifetime cumulative return: 2,820,670%
Current share price: $48.74
Current dividend yield: 2.2%
Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell
Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. The company has a long and eventful history that dates to its founding in 1888. Abbott first paid a dividend in 1924, and it has raised its payout annual for the last 46 years in a row. The company went public in 1929 on the eve of the Great Depression. Its many decades as a dividend-paying public company have certainly attributed to the extraordinary lifetime returns of its stock. A new era began for Abbott in 2013, when it spun off AbbVie as a standalone maker of branded drugs and therapies. Abbott now focuses on generic drugs, medical devices, nutrition and diagnostic products. Since the spinoff, however, Abbott's stock has trailed the performance of both AbbVie and the broader S&P 500 index.
Ticker symbol: DIS
Lifetime wealth creation: $192.8 billion
Lifetime cumulative return: 811,520%
Current share price: $100.70
Current dividend yield: 1.6%
Current analyst ratings: 9 strong buy, 2 buy, 8 hold, 0 sell, 1 strong sell
Disney began as a cartoon studio in 1923, and Mickey Mouse appeared in his first starring role five years later. The company issued stock for the first time in 1940. In the decades since, Walt Disney expanded into live-action films, theme parks, toys and television. In the last 20 years alone Disney has gobbled up ABC, Pixar Animation Studios, Marvel Entertainment and Lucasfilm (of "Star Wars" fame). The stock has tripled in value over the last 10 years, but shares face increasing pressure as viewers cut the cable cord and turn to other forms of entertainment. Disney owns cable properties including ESPN and the Disney Channel. But Disney has survived the challenges of a changing media landscape throughout its history, so don't be too quick to write off this longtime great stock.
SEE ALSO: Quiz: Test Your Bull Market IQ
Ticker symbol: N/A
Lifetime wealth creation: $202.6 billion
Lifetime cumulative return: 279,550%
Current share price: N/A
Current dividend yield: N/A
Current analyst ratings: N/A
For the purposes of Bessembinder's study, returns for the original Mobil Corp. stopped in 1999, when Mobil merged with Exxon to form today's energy powerhouse ExxonMobil. That fact makes the lifetime performance of Mobil stock (original ticker symbol "MOB") all the more impressive considering it missed out on the current bull market, one of the longest in U.S. history. Even prior to the merger, Mobil was among the largest oil companies in the nation, tracing its lineage back to Standard Oil Company of New York. As for the wisdom of its deal with Exxon almost two decade ago, keep reading to learn where ExxonMobil lands among the 30 greatest stocks since 1926.
Ticker symbol: ORCL
Lifetime wealth creation: $203.7 billion
Lifetime cumulative return: 60,750%
Current share price: $48.62
Current dividend yield: 1.6%
Current analyst ratings: 17 strong buy, 2 buy, 8 hold, 0 sell, 0 strong sell
Oracle is one of several technology stocks to crack the top 30, a notable feat considering most Big Tech companies are relatively young compared to the rest of the names on this list. Founded in 1977 and publicly traded since 1986, Oracle got its start as a provider of database management software. As much as any high-tech company of the era, it rode the late-1990s tech bubble to lofty heights -- and then crashed. It's been a long, slow recovery ever since, driven by a wide portfolio of software aimed at corporate customers. Where Oracle goes from here is less clear. Larry Ellison is still with the company after 40 years, though now in the role of chief technology officer. Management, led by co-CEOs Mark Hurd and Safra Catz, is in the midst of a major transformation, trying to reinvent the company and embrace the rush to cloud-based services.
Ticker symbol: BRK.B
Lifetime wealth creation: $209.8 billion
Lifetime cumulative return: 290,880%
Current share price: $177.56
Current dividend yield: N/A
Current analyst ratings: 2 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell
It should come as no surprise that the greatest value investor of all time would be behind one of the best stocks of all time. Warren Buffett took control of Berkshire Hathaway, a struggling textile manufacturer, in the early 1960s. As it quickly became clear that U.S. textile manufacturing was in decline, Buffett decided to shift gears. By the late 1960s Buffett had already diversified into banking, insurance and newspaper publishing. He never looked back. Berkshire is now a holding company comprised of dozens of diverse businesses selling everything from underwear (Fruit of the Loom) to insurance policies (Geico). Berkshire has also been a vehicle for Buffett to invest in stocks, which he has done shrewdly and successfully. At 86 years old, Buffett has given no indication when he will retire. Berkshire shareholders aren't complaining.
Ticker symbol: PEP
Lifetime wealth creation: $213.9 billion
Lifetime cumulative return: 4,228,440%
Current share price: $117.60
Current dividend yield: 2.7%
Current analyst ratings: 8 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell
Despite being no more than a middle-aged company, PepsiCo has delivered whopping returns over the past five decades. It helps that so much cash is paid out to shareholders. Founded in 1965 by the merger of Pepsi-Cola and Frito-Lay, PepsiCo has increased its dividend every year for 46 straight years. The next five decades might not go down as easily. PepsiCo is working against a long-term slide in soda sales. Like the rest of the industry, it has responded by expanding its offerings of non-carbonated beverages. It sells Gatorade sports drinks, Tropicana juices and Aquafina water, among other brands. That might not be enough to restore it to the growth rates of old, however. One advantage Pepsi has is the Frito-Lay side of the business. Demand for salty snacks remains solid.
Ticker symbol: HD
Lifetime wealth creation: $225.2 billion
Lifetime cumulative return: 523,990%
Current share price: $147.49
Current dividend yield: 2.4%
Current analyst ratings: 10 strong buy, 3 buy, 6 hold, 0 sell, 0 strong sell
Home Depot has been a publicly traded company since 1981. It was included in the S&P 500 index in 1988 and added to the Dow in 1999. Yet, shares in the nation's largest home-improvement chain have generated a big chunk of their gains just in the last six years. The collapse of the housing market that precipitated the Great Recession of the late 2000s was a painful period for Home Depot. It's resurgence since on the back of low mortgage rates - coupled with a shortage of new housing - has remade its fortunes of late. Shares of Home Depot have gained 162% in the last five years alone. After notching an all-time high this year, it remains to be seen how much upside is left, at least in the short term.
SEE ALSO: 25 Surprising Stocks Paying Dividends for 25 Years or More
Ticker symbol: INTC
Lifetime wealth creation: $246.0 billion
Lifetime cumulative return: 119,590%
Current share price: $35.01
Current dividend yield: 3.1%
Current analyst ratings: 12 strong buy, 2 buy, 7 hold, 1 sell, 2 strong sell
Intel is an old-timer among publicly traded technology companies. The semiconductor manufacturer held its initial stock offering way back in 1971. Intel ran away with the market for the chips that are a computer's brain in the early years of PC sales. The company had close to 100% market share in central processing units for personal computers at one point. It still has 80% today. But PC sales are like a slowly melting iceberg. Softening the blow, Intel remains the biggest player in making CPUs for back-end servers, which are very much in demand in order to power the rapid shift to cloud-based computing. What's troubling is that Intel missed opportunities to make chips for mobile devices, which is where much of future growth lies. Intel was added to the Dow in 1999, near the height of the dot-com boom.
Ticker symbol: WFC
Lifetime wealth creation: $250.8 billion
Lifetime cumulative return: 79,700%
Current share price: $51.68
Current dividend yield: 3%
Current analyst ratings: 6 strong buy, 1 buy, 10 hold, 0 sell, 5 strong sell
Wells Fargo has been in the banking business for a long time - make that a very long time. The company was founded in 1852, and even today its name is synonymous with the iconic six-horse stagecoach of the 19th century American West. Warren Buffett's history with Wells Fargo goes way back, too. His holding company, Berkshire Hathaway, first started buying shares of the bank in 1989. Today, Berkshire is Wells Fargo's largest shareholder with a nearly 10% stake worth more than $25 billion. Like most of Buffett's moves, this investment has worked out pretty well over the long haul. Wells Fargo's stock crashed hard during last decade's financial crisis but has since gone on to rise six-fold despite a fake-accounts scandal that cost the CEO his job last year.
Ticker symbol: MRK
Lifetime wealth creation: $265.7 billion
Lifetime cumulative return: 791,780%
Current share price: $61.49
Current dividend yield: 3.1%
Current analyst ratings: 7 strong buy, 1 buy, 3 hold, 1 sell, 0 strong sell
Merck is the top-performing drug maker on this list with lifetime wealth creation between 1926 and 2015 totaling more than a quarter-trillion dollars. This shouldn't come as a surprise considering Merck's corporate pedigree. The company was established in 1891, and the stock has been a component of the Dow since 1979. The Merck family's involvement in the pharmaceutical business dates back to 17th century Germany. The 21st century has been less kind, however. The stock price, adjusted for splits and dividends, remains well below its 2000 peak near $95 a share. In the past 17 years, Merck has experience plenty of ups and downs, from the Vioxx recall in 2004 to its megamerger with Schering-Plough in 2009. With nearly $40 billion in annual sales, Merck remains a formidable player in the global drug business. Whether the stock can regain its former glory remains to be seen.
Ticker symbol: GOOGL
Lifetime wealth creation: $276.5 billion
Lifetime cumulative return: 1,520%
Current share price: $926.18
Current dividend yield: N/A
Current analyst ratings: 21 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell
Alphabet has certainly made the most of its relatively short time as a publicly traded company. Shares of what was then known as Google - the corporate name was changed to Alphabet in 2015 - were initially offered to the public just 13 years ago, and by the end of the first trading day in August 2004 the company was worth $27 billion. Today, Alphabet has a market value of $635 billion. The Google search engine is Alphabet's most important business, but not its only one, thus the name change two years ago. Alphabet is also home to self-driving car startup Waymo; Nest Labs, a developer of gadgets for the Internet of Things; and X, which describes itself as a "moonshot factory" trying to invent technologies that will make the world a radically better place.
Ticker symbol: DD
Lifetime wealth creation: $299.5 billion
Lifetime cumulative return: 791,980%
Current share price: $81.18
Current dividend yield: 1.9%
Current analyst ratings: 5 strong buy, 0 buy, 5 hold, 0 sell, 0 strong sell
The chemical giant got its start more than 200 years ago when E.I. du Pont bought land near Wilmington, Delaware, to set up powder mills. The company, of course, has evolved substantially since 1802, and it's about to undergo perhaps the most radical transformation in its history. Effective August 31, 2017, DuPont will officially merge with Dow Chemical. The next day, shares of the newly combined company are slated to begin trading under new ticker symbol "DWDP." DuPont's future as a component of the Dow Jones Industrial Average is uncertain once the merger is complete. The stock was first included in the Dow in 1924, but it was dropped a year later. DuPont was added back to the industrial average in 1935, where it has remained for more than 80 years.
SEE ALSO: Quiz: How Well Do You Know Wall Street Jargon?
Ticker symbol: AMZN
Lifetime wealth creation: $300.2 billion
Lifetime cumulative return: 45,060%
Current share price: $958.47
Current dividend yield: N/A
Current analyst ratings: 21 strong buy, 4 buy, 4 hold, 0 sell, 0 strong sell
Amazon.com, which began life as a modest website for book buyers, is celebrating its 20th anniversary as a publicly traded company. It's been a heck of a ride for shareholders since the 1997 market debut, as evidenced by Bessembinder's calculations of lifetime wealth creation and percentage return. The current bull market has been especially kind to Amazon investors, with the share price experiencing a 14-fold increase since March 2009. The stock now trades around $1,000, even after adjusting for three splits in the late 1990s. Amazingly, Amazon's best days may still lie ahead. In additional to evolving into the nation's largest e-commerce company, Amazon is also a leader in cloud computing. Its recent acquisition of Whole Foods is threatening to disrupt the grocery business, and package delivery by drones could become reality in the not-too-distant future.
Ticker symbol: T
Lifetime wealth creation: $302.6 billion
Lifetime cumulative return: 39,350%
Current share price: $37.37
Current dividend yield: 5.2%
Current analyst ratings: 5 strong buy, 1 buy, 13 hold, 0 sell, 0 strong sell
AT&T has a long and winding corporate history that started with Alexander Graham Bell's invention of the telephone in 1879. The company quickly came to dominate the telecommunications industry for decades. In 1984, regulators broke up AT&T into seven regional phone companies, known as Baby Bells. AT&T retained its long-distance business. Many years and many mergers later, one of those original Baby Bells, Southwestern Bell (renamed SBC Communications), acquired the original AT&T in 2005 and adopted the AT&T name. Today, AT&T is a big dividend payer and a major player in wireless, Internet and satellite-TV services, with more than $163 billion in annual revenue. The company's stock has a long and winding history, too. AT&T, then known as American Telephone and Telegraph, was first included as a component of the Dow in 1916. Over the past century, it has moved in and out of the industrial average a number of times. Most recently, Apple bumped AT&T from the Dow in 2015.
Ticker symbol: KO
Lifetime wealth creation: $327.0 billion
Lifetime cumulative return: 6,663,400%
Current share price: $45.67
Current dividend yield: 3.2%
Current analyst ratings: 3 strong buy, 0 buy, 11 hold, 0 sell, 0 strong sell
Coca-Cola (the drink) was invented in 1886, a decade before the creation of the Dow. Coca-Cola (the stock) made a brief appearance as a component of the industrial average in the 1930s. Shares were added back to the Dow in 1987, and they've remained a stalwart member ever since. Like PepsiCo, Coca-Cola (the company) is adding everything from bottled water to fruit juices to sports drinks to its product lineup to make up for slowing soda sales. Unlike PepsiCo, Coca-Cola doesn't have the equivalent of Pepsi's Frito-Lay snack business to offset slumping soda sales. Over the past five years, shares in Coca-Cola are up just 16% versus a 61% gain for PepsiCo. At least the company's commitment to its dividend should be a source of comfort to income investors. Coca-Cola has paid a dividend since 1920, and that dividend has increased annually for 54 straight years.
Ticker symbol: CVX
Lifetime wealth creation: $330.4 billion
Lifetime cumulative return: 945,430%
Current share price: $106.48
Current dividend yield: 4.1%
Current analyst ratings: 10 strong buy, 2 buy, 5 hold, 0 sell, 2 strong sell
Chevron is yet another member of the Dow delivering a disproportionate share of the stock market's total wealth creation over 90 years. It's also been a reliable deliverer of dividend income. With 31 consecutive years of annual growth in its cash payouts to shareholders, Chevron's track record instills confidence that the dividend will continue to rise well into the future. Chevron's origins as a company date back to the 19th century and run through John D. Rockefeller's legendary oil empire. Chevron operated for decades as Standard Oil of California, though the Chevron brand was used on products as far back as the 1930s. The corporate name didn't officially change to Chevron Corp. until 2005. (Immediately prior to that the company was known as ChevronTexaco in recognition of its 2001 merger with Texaco.) Chevron, under its various names, was a component of the Dow from 1930 to 1999, and then again from 2008 to the present.
Ticker symbol: PG
Lifetime wealth creation: $335.8 billion
Lifetime cumulative return: 537,700%
Current share price: $92.47
Current dividend yield: 3%
Current analyst ratings: 4 strong buy, 1 buy, 7 hold, 0 sell, 0 strong sell
When it comes to income investing, Procter & Gamble is synonymous with reliability. The company has paid shareholders a dividend since 1891 and has raised its dividend annually for 60 years in a row. P&G's inclusion in the Dow dates back to 1932. Few stocks are as venerable and dependable. P&G's products are also known for reliability. The company owns some of the best-known brands in the business including Charmin toilet paper, Crest toothpaste, Tide laundry detergent, Pampers diapers and Gillette razors. Despite selling consumer staples that are supposed to be less sensitive to the ups and downs of the economy, P&G is sensitive to competition. The growing popularity of discount retailers stocking cheaper store brands has been particularly challenging. Look to the stock price for proof: Shares in P&G have gained 39% in the last five years versus a 72% gain for the S&P 500.
SEE ALSO: 10 Small Towns With Big Millionaire Populations
Ticker symbol: WMT
Lifetime wealth creation: $337.7 billion
Lifetime cumulative return: 149,540%
Current share price: $79.31
Current dividend yield: 2.6%
Current analyst ratings: 11 strong buy, 0 buy, 10 hold, 0 sell, 2 strong sell
It stands to reason that the world's largest retailer happens to have one of the best-performing stocks over the long haul. But it's been a long road to greatness. At the close of its first day of trading on the New York Stock Exchange in 1972, Walmart was worth 4 cents a share, adjusted for splits and dividends. Today it trades north of $80 a share. From humble beginnings as a single discount store, Walmart now operates 11,695 retail locations around the globe and employs 2.3 million workers. Nimble, thy name is not Walmart. Amazon has emerged as a dangerous competitor, and although Walmart is building up its e-commerce business, it remains to be seen whether it's a case of too little, too late. A component of the Dow since 1997, Walmart has increased its dividend every year since 1974.
Ticker symbol: JNJ
Lifetime wealth creation: $383.7 billion
Lifetime cumulative return: 2,930,670%
Current share price: $132.63
Current dividend yield: 2.5%
Current analyst ratings: 5 strong buy, 1 buy, 7 hold, 0 sell, 2 strong sell
Johnson & Johnson operates in several different areas of health care including pharmaceutical products and medical devices. The company is best known, however, for its over-the-counter consumer brands including Listerine mouthwash, Tylenol pain reliever and Johnson's Baby shampoo. J&J has been at the health-care game for a very long time. Founded in 1886 by three brothers, the company created the first commercial first aid kits and it was the first to mass-produce dental floss - all before 1900. Its iconic Band-Aid bandages hit the market in 1921. Somewhat surprisingly, J&J wasn't added to the Dow until 1997, even though shares had been publicly traded since 1944. The ever-rising dividend, along with the popularity of its products, eventually made the stock too conspicuous to ignore. J&J has increased the amount of its annual payout to shareholders every year since 1963.
Ticker symbol: GM
Lifetime wealth creation: $394.1 billion
Lifetime cumulative return: 5,900%
Current share price: $34.83
Current dividend yield: 4.4%
Current analyst ratings: 4 strong buy, 1 buy, 8 hold, 0 sell, 0 strong sell
General Motors was a titan of industry in 20th century America. The auto maker's stock first joined the Dow in 1915. It was dropped from the industrial average a year later before being added back in 1925. It remained a component of the Dow until GM was forced into bankruptcy in 2009. Prior to its Chapter 11 filing and delisting from the New York Stock Exchange, the shares created an impressive amount of wealth, paying out over $64 billion in dividends to its shareholders. "GM common stock was one of the most successful stocks in terms of lifetime wealth creation for shareholders in aggregate, despite its ignoble ending," says Bessembinder. Although the original GM stock was one of the great winners of the last century, its recent fortunes haven't been as bright. Shares in the new GM are up just 6% since the 2010 initial public offering. The S&P 500 index has more than doubled over the same span.
Ticker symbol: MO
Lifetime wealth creation: $448.1 billion
Lifetime cumulative return: 202,963,040%
Current share price: $63.69
Current dividend yield: 3.8%
Current analyst ratings: 4 strong buy, 0 buy, 6 hold, 0 sell, 0 strong sell
Altria has an illustrious corporate history that can be traced back to a 19th century tobacco shop in London. Today, the company's operating businesses continue to focus on tobacco including cigarettes (Philip Morris USA), smokeless tobacco (U.S. Smokeless Tobacco) and cigars (John Middleton). Altria also owns St. Michelle Wine Estates, a major wine producer. The company is best known for its iconic Marlboro brand of cigarettes, but at one time or another Altria and its predecessors had a hand in other famous names including Miller Brewing and Kraft Foods. The stock originally joined the Dow in 1985, when the company was called Philip Morris Cos. The name changed to Altria in 2003, and the stock was replaced in the Dow in 2008. Philip Morris International is a separate publicly traded company that was spun off from Altria in 2008 to sell cigarettes outside the U.S.
Ticker symbol: IBM
Lifetime wealth creation: $487.4 billion
Lifetime cumulative return: 9,456,410%
Current share price: $139.70
Current dividend yield: 4.3%
Current analyst ratings: 4 strong buy, 1 buy, 9 hold, 1 sell, 3 strong sell
Think of IBM as the granddaddy of tech stocks. The company, which began operating under its current moniker in 1924, was originally included in the Dow from 1932 to 1939. It was added back to the industrial average in 1979 and remains a component to this day. In many ways, IBM's history is a history of 20th century technological progress. As for the current century, it's a tougher call. IBM produces computer hardware and software for businesses. Consulting is another important area of operation. However, cloud-based services appear to be the future, and IBM has no shortage of competition. Amazon, Microsoft, Google, Oracle and Cisco Systems are some of the well-known tech companies jostling for space. Warren Buffett read IBM's annual reports for decades before finally taking a stake in 2011. It's looking more and more like Buffett made a rare bad call. So far, at least, his investment in IBM has been a major disappointment.
SEE ALSO: Quiz: How Well Do You Really Know Warren Buffett?
Ticker symbol: MSFT
Lifetime wealth creation: $567.7 billion
Lifetime cumulative return: 83,440%
Current share price: $72.49
Current dividend yield: 2.2%
Current analyst ratings: 16 strong buy, 1 buy, 4 hold, 4 sell, 1 strong sell
In 1975, Bill Gates dropped out of Harvard to start a computer company with childhood friend Paul Allen. In 1985, the first Windows operating system went on sale. A year later, Microsoft went public at $21 a share (or the equivalent of 6 cents a share once the price is adjusted for stock splits and dividends). The company quickly revolutionized personal computing and created a generation of so-called Microsoft Millionaires. Not long ago, Microsoft's glory days looked to be behind it as sales of desktop PCs slipped into a seemingly irreversible decline amid the consumer shift to mobile technology. However, the company is experiencing a renaissance thanks to the move away from licensed software to cloud-based subscription software. Today, Microsoft is a top player in cloud computing and its stock reflects this success. Shares have tripled the return of the S&P 500 index over the past two years alone. Microsoft joined the Dow in 1999 at the height of the dot-com bubble.
Ticker symbol: GE
Lifetime wealth creation: $597.5 billion
Lifetime cumulative return: 922,170%
Current share price: $24.55
Current dividend yield: 3.9%
Current analyst ratings: 4 strong buy, 1 buy, 4 hold, 0 sell, 2 strong sell
General Electric holds a special place in the history of the stock market: It's one of the 12 stocks that made up the original Dow Jones Industrial Average of 1896. Perhaps even more impressive, GE is still in the Dow today. (It was dropped a couple of times in its early years before being added back for good in 1907.) The company has undergone tremendous change over time. GE's latest transformation was spawned during last decade's Great Recession. In response to tightening regulations, management was compelled to sell off the company's sprawling financial operations, a powerful source of profits. The GE of today is a pure industrial conglomerate, and investors aren't quite sure what to make of its prospects. The stock has lost 36% of its value over the last 10 years. Warren Buffett, renowned for his patience, recently threw in the towel and sold his remaining stake in GE.
Ticker symbol: AAPL
Lifetime wealth creation: $677.4 billion
Lifetime cumulative return: 20,250%
Current share price: $157.50
Current dividend yield: 1.6%
Current analyst ratings: 19 strong buy, 6 buy, 6 hold, 0 sell, 2 strong sell
What's left to say about Apple? With a market capitalization exceeding $800 billion, it's far and away the most valuable publicly traded company today. Investors can thank the iPhone for the eye-popping run-up in the value of the stock in recent years. Before Steve Jobs debuted the revolutionary smartphone in 2007, Apple was a well-regarded maker of pricey personal computers that catered to niche markets. In the 10 years since more than a billion iPhones have been sold, and shares of Apple have gained a whopping 620%. Jobs died in 2011, but the company he co-founded lives on today. The iPhone 8 is expected to be released later this year. Adding to Apple's many accolades was its inclusion in the Dow in 2015, replacing AT&T. The stock went public in 1980.
Ticker symbol: XOM
Lifetime wealth creation: $939.8 billion
Lifetime cumulative return: 2,258,470%
Current share price: $76.64
Current dividend yield: 4%
Current analyst ratings: 4 strong buy, 3 buy, 8 hold, 0 sell, 3 strong sell
ExxonMobil created a staggering amount of wealth - nearly $1 trillion - between 1926 and 2015, according to Bessembinder's research. No doubt the reliable dividend that Exxon has paid out to shareholders since 1882 has contributed mightily to the energy giant's remarkable performance. Over the last 34 years alone, amid cycles of oil booms and oil busts, the company has increased its dividend payment at an average annual rate of 6.4%. Like rival Chevron, Exxon has to contend with uncertainty regarding the future of fossil fuels, not to mention the persistently low prices for crude oil of late. The stock's performance reflects that uncertainty. Exxon's share price is lower today than it was a decade ago. (But, hey, at least the dividend checks kept coming.) Exxon has been part of the Dow ever since the industrial average expanded to 30 companies in 1928. Back then it was known as Standard Oil of New Jersey. The name officially changed to Exxon in 1972.
SEE ALSO: 25 Dividend Stocks You Can Buy and Hold Forever
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $48.74 Current dividend yield: 2.2% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. To this day, McDonald's continues to focus on healthier items to compete with new chains boasting fresher offerings, but it was the launch of all-day breakfast in 2015 that has given the Golden Arches its latest jolt of life. Shares of what was then known as Google - the corporate name was changed to Alphabet in 2015 - were initially offered to the public just 13 years ago, and by the end of the first trading day in August 2004 the company was worth $27 billion. | Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $48.74 Current dividend yield: 2.2% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. Ticker symbol: MRK Lifetime wealth creation: $265.7 billion Lifetime cumulative return: 791,780% Current share price: $61.49 Current dividend yield: 3.1% Current analyst ratings: 7 strong buy, 1 buy, 3 hold, 1 sell, 0 strong sell Merck is the top-performing drug maker on this list with lifetime wealth creation between 1926 and 2015 totaling more than a quarter-trillion dollars. Ticker symbol: CVX Lifetime wealth creation: $330.4 billion Lifetime cumulative return: 945,430% Current share price: $106.48 Current dividend yield: 4.1% Current analyst ratings: 10 strong buy, 2 buy, 5 hold, 0 sell, 2 strong sell Chevron is yet another member of the Dow delivering a disproportionate share of the stock market's total wealth creation over 90 years. | Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $48.74 Current dividend yield: 2.2% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. SEE ALSO: 25 Surprising Stocks Paying Dividends for 25 Years or More Ticker symbol: INTC Lifetime wealth creation: $246.0 billion Lifetime cumulative return: 119,590% Current share price: $35.01 Current dividend yield: 3.1% Current analyst ratings: 12 strong buy, 2 buy, 7 hold, 1 sell, 2 strong sell Intel is an old-timer among publicly traded technology companies. Ticker symbol: CVX Lifetime wealth creation: $330.4 billion Lifetime cumulative return: 945,430% Current share price: $106.48 Current dividend yield: 4.1% Current analyst ratings: 10 strong buy, 2 buy, 5 hold, 0 sell, 2 strong sell Chevron is yet another member of the Dow delivering a disproportionate share of the stock market's total wealth creation over 90 years. | Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $48.74 Current dividend yield: 2.2% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. Over the last two years, shares are up 58%. Today, Alphabet has a market value of $635 billion. |
33520.0 | 2017-08-23 00:00:00 UTC | Health Care Sector Update for 08/23/2017: JNJ, PFE, ABT, MRK, AMGN, PRTK, NVAX, RARE | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08232017-jnj-pfe-abt-mrk-amgn-prtk-nvax-rare-2017-08-23 | nan | nan | Top Health Care Stocks:
JNJ: -1.3%
PFE: -0.5%
ABT: flat
MRK: -0.02%
AMGN: -0.1%
Health care shares were mostly in the red in pre-market trade Wednesday.
In sector news, Paratek Pharmaceuticals ( PRTK ) was up 27% after media reports said the company is exploring strategic alternatives, including a potential sale. Reports said there is no certainty the company will push through with the sale.
In other sector news,
(+) NVAX (+3%) Publishes data from preclinical influenza study with Matrix-M in vaccine journal
(-) RARE(-10.8%) Late stage study on Ace-ER for GNE Pyopathy fails to meet endpoints
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat Health care shares were mostly in the red in pre-market trade Wednesday. In sector news, Paratek Pharmaceuticals ( PRTK ) was up 27% after media reports said the company is exploring strategic alternatives, including a potential sale. | ABT: flat Top Health Care Stocks: In other sector news, (+) NVAX (+3%) Publishes data from preclinical influenza study with Matrix-M in vaccine journal (-) RARE(-10.8%) Late stage study on Ace-ER for GNE Pyopathy fails to meet endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat Health care shares were mostly in the red in pre-market trade Wednesday. In sector news, Paratek Pharmaceuticals ( PRTK ) was up 27% after media reports said the company is exploring strategic alternatives, including a potential sale. | ABT: flat Top Health Care Stocks: Health care shares were mostly in the red in pre-market trade Wednesday. |
33521.0 | 2017-08-23 00:00:00 UTC | How Johnson & Johnson Makes Most of Its Money | ABT | https://www.nasdaq.com/articles/how-johnson-johnson-makes-most-its-money-2017-08-23 | nan | nan | As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in over $668 billion. To put that amount into perspective, consider that a stack of that many $1 bills would reach more than 45,000 miles into the sky -- close to one-fifth the distance to the moon.
But where does all that revenue come from? Here's how Johnson & Johnson makes most of its money.
Pharmaceutical
Around 46% of Johnson & Johnson's total revenue stems from its pharmaceutical segment. But the segment generates an even higher percentage of the company's total profit -- roughly 65% in the first half of 2017.
Close to six out of every 10 dollars in sales for J&J's pharmaceutical segment occur in the U.S. That's not surprising, considering that prescription drug prices tend to be higher in the U.S. than elsewhere. However, the company is seeing more growth in international sales so far this year.
Johnson & Johnson's top-selling drug by far is Remicade, which made nearly $7 billion last year. Sales are slipping somewhat for the autoimmune disease drug, though, in the face of competition from Pfizer 's biosimilar, Inflectra.
The company does have several blockbuster drugs for which sales are growing. Stelara and Imbruvica stand at the top of the list. Psoriasis and psoriatic arthritis drug Stelara generated $3.2 billion in sales last year and made $1.8 billion in the first half of 2017. Cancer drug Imbruvica brought in nearly $1.3 billion last year and $859 million in the first two quarters of this year.
Medical devices
Johnson & Johnson's second-largest moneymaker is its medical devices business segment. This segment contributes around 36% of total revenue and 23% of total segment profit.
The company actually makes more revenue from medical device sales outside of the U.S. than inside the country. In the first half of 2017, the medical devices segment generated $6.7 billion from international sales compared to $6.3 billion in the U.S.
Orthopedics and surgical medical devices both contribute around 36% of the segment's total revenue. Vision care, especially contact lenses, kicks in another 14%. The remaining sales for the segment stem from cardiovascular, diabetes care, and diagnostics devices.
Acquisitions have helped boost J&J's medical device segment sales. In February, the company completed the purchase of Abbott Labs ' medical optics business.
Consumer
Most Americans probably know Johnson & Johnson best for products like Band-Aid, Listerine, and Tylenol. However, the company's consumer segment is its smallest, generating 18% of total revenue and less than 12% of total segment profit.
International markets are the biggest source of revenue for J&J's consumer segment. In the first half of this year, the company sold $3.8 billion of products internationally versus $2.9 billion in the U.S.
Two areas are the primary moneymakers for the consumer segment. Over-the-counter (OTC) products and beauty products each contribute around 30% of total consumer sales. The rest of consumer revenue comes from J&J's baby care, oral care, women's health, wound care, and other products.
Where the money is moving
In 2016, J&J's pharmaceutical segment posted the strongest increase in revenue. However, so far in 2017, the company's medical devices segment contributed the highest growth. This shift is due in large part from the headwinds for Remicade.
Over the long run, though, look for pharmaceuticals to become an even more important source for revenue and profits. Johnson & Johnson claims one of the best pharmaceutical pipelines in the industry . Experimental prostate cancer drug apalutamide is a particularly promising candidate.
J&J could also reap the rewards from its acquisition earlier this year of Swiss drugmaker Actelion . Before the deal closed, Johnson & Johnson predicted that Actelion could increase its overall revenue growth rate by 1% and bump its annual earnings growth by as much as 2%.
With the impact of Actelion and its pipeline, combined with solid growth from current products including cancer drugs Darzalex and Imbruvica, Johnson & Johnson's pharmaceutical revenue should grow larger as a percentage of total sales. J&J makes a lot of money now -- but you can bet that it will make even more in the future.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | To put that amount into perspective, consider that a stack of that many $1 bills would reach more than 45,000 miles into the sky -- close to one-fifth the distance to the moon. Close to six out of every 10 dollars in sales for J&J's pharmaceutical segment occur in the U.S. That's not surprising, considering that prescription drug prices tend to be higher in the U.S. than elsewhere. Sales are slipping somewhat for the autoimmune disease drug, though, in the face of competition from Pfizer 's biosimilar, Inflectra. | Medical devices Johnson & Johnson's second-largest moneymaker is its medical devices business segment. In the first half of 2017, the medical devices segment generated $6.7 billion from international sales compared to $6.3 billion in the U.S. Orthopedics and surgical medical devices both contribute around 36% of the segment's total revenue. With the impact of Actelion and its pipeline, combined with solid growth from current products including cancer drugs Darzalex and Imbruvica, Johnson & Johnson's pharmaceutical revenue should grow larger as a percentage of total sales. | Pharmaceutical Around 46% of Johnson & Johnson's total revenue stems from its pharmaceutical segment. In the first half of 2017, the medical devices segment generated $6.7 billion from international sales compared to $6.3 billion in the U.S. Orthopedics and surgical medical devices both contribute around 36% of the segment's total revenue. With the impact of Actelion and its pipeline, combined with solid growth from current products including cancer drugs Darzalex and Imbruvica, Johnson & Johnson's pharmaceutical revenue should grow larger as a percentage of total sales. | Pharmaceutical Around 46% of Johnson & Johnson's total revenue stems from its pharmaceutical segment. Johnson & Johnson's top-selling drug by far is Remicade, which made nearly $7 billion last year. Cancer drug Imbruvica brought in nearly $1.3 billion last year and $859 million in the first two quarters of this year. |
33522.0 | 2017-08-22 00:00:00 UTC | Health Care Sector Update for 08/22/2017: JNJ, PFE, ABT, MRK, AMGN, MTBC, PFE, MDT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08222017-jnj-pfe-abt-mrk-amgn-mtbc-pfe-mdt-2017-08-22 | nan | nan | Top Health Care Stocks:
JNJ: -0.5%
PFE: +0.3%
ABT: -0.2%
MRK: +0.2%
AMGN: flat
Health care shares were mostly firmer in pre-market trade Tuesday.
In sector news, MTBC ( MTBC ) was up 13% after it said that it has been selected by Infinity Diagnostic Labs, a clinical and anatomical pathology laboratory, as its healthcare IT and revenue cycle management vendor. The company said the relationship with Infinity Diagnostic Labs will "generate significant new revenue to MTBC, but it will also provide a strong base from which to expand MTBC's niche laboratory billing services."
In other sector news,
(+) PFE (+0.4%) Wins Indian patent for pneumonia vaccine
(-) MDT (-1.4%) Fiscal Q1 EPS tops Street views while revenues miss
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMGN: flat Health care shares were mostly firmer in pre-market trade Tuesday. In sector news, MTBC ( MTBC ) was up 13% after it said that it has been selected by Infinity Diagnostic Labs, a clinical and anatomical pathology laboratory, as its healthcare IT and revenue cycle management vendor. The company said the relationship with Infinity Diagnostic Labs will "generate significant new revenue to MTBC, but it will also provide a strong base from which to expand MTBC's niche laboratory billing services." | In sector news, MTBC ( MTBC ) was up 13% after it said that it has been selected by Infinity Diagnostic Labs, a clinical and anatomical pathology laboratory, as its healthcare IT and revenue cycle management vendor. In other sector news, (+) PFE (+0.4%) Wins Indian patent for pneumonia vaccine (-) MDT (-1.4%) Fiscal Q1 EPS tops Street views while revenues miss The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) PFE (+0.4%) Wins Indian patent for pneumonia vaccine (-) MDT (-1.4%) Fiscal Q1 EPS tops Street views while revenues miss The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. Unauthorized reproduction is strictly prohibited. | Top Health Care Stocks: AMGN: flat Health care shares were mostly firmer in pre-market trade Tuesday. In sector news, MTBC ( MTBC ) was up 13% after it said that it has been selected by Infinity Diagnostic Labs, a clinical and anatomical pathology laboratory, as its healthcare IT and revenue cycle management vendor. |
33523.0 | 2017-08-21 00:00:00 UTC | Health Care Sector Update for 08/21/2017: JNJ, PFE, ABT, MRK, AMGN, AZN, NVS, TNXP | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08212017-jnj-pfe-abt-mrk-amgn-azn-nvs-tnxp-2017-08-21 | nan | nan | Top Health Care Stocks:
JNJ: flat
PFE: +0.6%
ABT: flat
MRK: flat
AMGN: +0.1%
Health care shares were mostly flat in pre-market trade Monday.
In sector news, AstraZeneca ( AZN ) was down 0.5% after it its biologics research and development arm MedImmune entered into a five-year strategic research collaboration with Ethris, a German developer of mRNA-based drugs with a focus on pulmonary disease. The collaboration will target the development of RNA therapies for respiratory diseases using Ethris' proprietary SNIM RNA technology, Ethris said in a statement. Under the agreement, AstraZeneca will pay Ethris EUR25 million ($29.4 million) upfront and will provide research funding. Ethris will also be eligible for future research and development milestones, including sales royalties when products are commercialized. Both companies will have the option to take exclusive worldwide licenses when research plans are completed for each target within the collaboration.
In other sector news,
(+) NVS (+0.3%) Launches clinical testing of malaria drug in Africa
TNXP (flat) To present additional data on drug Tonmya for the treatment of post-traumatic stress disorder
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Ethris will also be eligible for future research and development milestones, including sales royalties when products are commercialized. Both companies will have the option to take exclusive worldwide licenses when research plans are completed for each target within the collaboration. | ABT: flat MRK: flat The collaboration will target the development of RNA therapies for respiratory diseases using Ethris' proprietary SNIM RNA technology, Ethris said in a statement. In other sector news, (+) NVS (+0.3%) Launches clinical testing of malaria drug in Africa TNXP (flat) To present additional data on drug Tonmya for the treatment of post-traumatic stress disorder The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat In sector news, AstraZeneca ( AZN ) was down 0.5% after it its biologics research and development arm MedImmune entered into a five-year strategic research collaboration with Ethris, a German developer of mRNA-based drugs with a focus on pulmonary disease. The collaboration will target the development of RNA therapies for respiratory diseases using Ethris' proprietary SNIM RNA technology, Ethris said in a statement. | ABT: flat MRK: flat Top Health Care Stocks: JNJ: flat In sector news, AstraZeneca ( AZN ) was down 0.5% after it its biologics research and development arm MedImmune entered into a five-year strategic research collaboration with Ethris, a German developer of mRNA-based drugs with a focus on pulmonary disease. |
33524.0 | 2017-08-21 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Pfizer Inc. | ABT | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-pfizer-inc-2017-08-21 | nan | nan | There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer.
But, as the statements read on mutual fund, past performance is no guarantee of future results. Which stock is the better pick for long-term investors now? Here's how AbbVie and Pfizer compare.
The case for AbbVie
Investors have three major reasons to like AbbVie. One is the big biotech's dividend. AbbVie's dividend yield currently stands at 3.61%. What's even better, the company has increased its dividend by 60% since being spun off by Abbott Labs in 2013. Future dividend hikes seem likely, considering that AbbVie uses less than 60% of earnings to fund its dividend program.
Another big plus for AbbVie is its growth potential. Wall Street analysts project the company will be able to grow earnings by nearly 14% annually over the next few years. That estimate seems realistic. AbbVie's top-selling drug, Humira, continues to enjoy solid sales momentum. The company has a rising star in cancer drug Imbruvica. AbbVie also recently won Food and Drug Administration approval for Mavyret. The drug, which treats all genotypes of hepatitis C, should be a big winner for the biotech.
AbbVie's pipeline also should help drive growth. Market research firm EvaluatePharma ranked that pipeline third out of all big pharma companies . AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids.
The third big reason to like AbbVie is its valuation. AbbVie stock currently trades at less than 11 times expected earnings. Factoring in the biotech's growth prospects make AbbVie's valuation look even more attractive.
The case for Pfizer
If you like AbbVie's dividend, you'll probably love Pfizer's. The big pharma company's dividend currently yields 3.84%. And although Pfizer's payout ratio is a little high right now, the drugmaker's strong cash flow should mean those nice dividends keep on coming for a long time to come.
Pfizer isn't likely to enjoy the heady growth that AbbVie will in the near term. However, the consensus among Wall Street analysts is that the company will increase its earnings by close to 6% over the next five years. That's nearly twice the rate that Pfizer grew earnings over the past five years, a period in which the stock climbed more than 30%.
There are several reasons to expect good things for Pfizer in the future. The company's product lineup includes strong performers such as cancer drug Ibrance, anticoagulant Eliquis, and autoimmune disease drug Xeljanz. In addition, Pfizer's pipeline has 32 late-stage programs and several more awaiting regulatory approval, including potential big winners like cancer drug Bavencio, chronic pain drug tanezumab, and diabetes drug ertugliflozin.
Pfizer's valuation doesn't look too shabby, either. The stock currently trades at 12 times expected earnings.
Better buy
Now that you've heard the positives about both companies, you should also know about the negatives. For AbbVie, the primary concern relates to competition for Humira. A biosimilar to the drug has already been approved by the FDA. However, AbbVie thinks that its patent portfolio will enable to it to hold off U.S. competition through 2022.
As for Pfizer, loss of exclusivity for multiple products is hurting the drugmaker and will continue to do so for a while. Pfizer is also encountering headwinds for its top-selling product, pneumococcal vaccine Prevnar 13.
With all the pros and cons weighed against each other, which stock is the better pick for long-term investors? I own both of them, but my view is that AbbVie is the winner. It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy. | AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. AbbVie's top-selling drug, Humira, continues to enjoy solid sales momentum. It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. | AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. The case for Pfizer If you like AbbVie's dividend, you'll probably love Pfizer's. | AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. In addition, Pfizer's pipeline has 32 late-stage programs and several more awaiting regulatory approval, including potential big winners like cancer drug Bavencio, chronic pain drug tanezumab, and diabetes drug ertugliflozin. |
33525.0 | 2017-08-21 00:00:00 UTC | Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report? | ABT | https://www.nasdaq.com/articles/why-is-abbott-laboratories-abt-down-3.1-since-the-last-earnings-report-2017-08-21 | nan | nan | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Shares have lost about 3.1% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Q2 Earnings
Abbott reported second-quarter 2017 adjusted earnings from continuing operations of $0.62 per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. This adjusted quarterly number also remained ahead of the company's guidance range of $0.59 to $0.61.
Reported earnings for the quarter came in at $0.15 per share, way below the year-ago number of $0.40.
Second-quarter worldwide sales came in at $6.63 billion, up 24.4% year over year on a reported basis. This quarterly figure also marginally in line with the Zacks Consensus Estimate of $6.62 billion.
On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 2.9% year over year in the reported quarter.
Quarter in Detail
Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 4.1% on a reported basis (up 3.5% on comparable operational basis) to $1,021 billion. There was a positive impact of 0.6% on the back of currency fluctuations. Sales in key emerging markets increased 5.8% (up 4.6%), driven by strong growth in Russia, China and several countries across Latin America. However, this positive effect was partially offset by the impact associated with implementation of a new Goods and Services Tax (GST) system in India.
The Medical Devices business sales spiked 89.2% on a reported basis to $2.59 billion. However, on a comparable operational basisexcluding the impact from the favorable resolution of a third-party royalty agreement last year, sales increased 3.2%.
Cardiovascular and Neuromodulation sales soared 189% on a reported basis (up 0.9% on comparable operational basis) on growth in Electrophysiology, Structural Heart and Neuromodulation. Vascular product sales were up 6%, while Structural Heart business grew 9.1% year over yearon a comparable operational basis.
Diabetes Care sales improved 18.7% on a reported basis (up 21.3%), driven by double-digit international sales growth, led by continued consumer uptake of FreeStyle Libre - the revolutionary continuous glucose monitoring system of Abbott Labs.
Nutrition sales slipped 0.6% year over year on a reported basis (up 0.5% on a comparable operational basis). Unfavorable foreign exchange impacted sales by a marginal 1.1%. Pediatric Nutrition sales increased 2.5% on a comparable operational basis. Adult Nutrition sales however, decreased 2% on a comparable operational basis.
Diagnostics sales rose 3.8% year over year (up 5.4% on a comparable operational basis). While Core Laboratory sales increased 6.1%, Point of Care Diagnostics sales grew 8.9%, both on a comparable operational basis. Molecular Diagnostics sales were down 4.1% as strong growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
2017 Guidance
Abbott Labs raised its full-year 2017 guidance. The company forecasts earnings per share from continuing operations to remain within the range of $1.03 to $1.13 from earlier range of $0.92 to $1.02. Adjusting certain net specified items for the full year, the adjusted earnings per share from continuing operations are expected to stay within a band of $2.43-$2.53 (earlier guidance was $2.40-$2.50). The current Zacks Consensus Estimate is pegged at $2.47, at the midpoint of the projected range.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
VGM Scores
At this time, Abbott Laboratories' stock has a nice Growth Score of B, though it is lagging a bit on the momentum front with a C. Charting a similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for growth investors than value and momentum investors.
Outlook
Notably, the stock has a Zacks Rank #3 (Hold). We are looking for an inline return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Q2 Earnings Abbott reported second-quarter 2017 adjusted earnings from continuing operations of $0.62 per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Q2 Earnings Abbott reported second-quarter 2017 adjusted earnings from continuing operations of $0.62 per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Q2 Earnings Abbott reported second-quarter 2017 adjusted earnings from continuing operations of $0.62 per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. |
33526.0 | 2017-08-17 00:00:00 UTC | Tandem Investment Advisors, Inc. Buys FactSet Research Systems Inc, National Retail Properties ... | ABT | https://www.nasdaq.com/articles/tandem-investment-advisors-inc-buys-factset-research-systems-inc-national-retail | nan | nan | Tandem Investment Advisors, Inc.
New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL,
Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD,
Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL,
Sold Out:QCOM,
For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc.
These are the top 5 holdings of Tandem Investment Advisors, Inc.
Walgreens Boots Alliance Inc ( WBA ) - 149,226 shares, 4.64% of the total portfolio. Shares added by 8.91%
Republic Services Inc ( RSG ) - 179,631 shares, 4.54% of the total portfolio. Shares added by 18.21%
Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Shares added by 1.78%
AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Shares added by 3.35%
Scripps Networks Interactive Inc ( SNI ) - 153,670 shares, 4.17% of the total portfolio. Shares added by 7.97%
New Purchase: FactSet Research Systems Inc (FDS)
Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc. The purchase prices were between $157.92 and $171.63, with an estimated average price of $163.5. The stock is now traded at around $163.66. The impact to the portfolio due to this purchase was 3.58%. The holdings were 54,332 shares as of 2017-06-30.
New Purchase: Dollar General Corp (DG)
Tandem Investment Advisors, Inc. initiated holdings in Dollar General Corp. The purchase prices were between $68.35 and $78.91, with an estimated average price of $71.99. The stock is now traded at around $74.50. The impact to the portfolio due to this purchase was 0.72%. The holdings were 25,195 shares as of 2017-06-30.
New Purchase: Verisk Analytics Inc (VRSK)
Tandem Investment Advisors, Inc. initiated holdings in Verisk Analytics Inc. The purchase prices were between $76.75 and $84.06, with an estimated average price of $80.9. The stock is now traded at around $81.65. The impact to the portfolio due to this purchase was 0.2%. The holdings were 5,981 shares as of 2017-06-30.
New Purchase: Johnson & Johnson (JNJ)
Tandem Investment Advisors, Inc. initiated holdings in Johnson & Johnson. The purchase prices were between $121.37 and $136.43, with an estimated average price of $127.47. The stock is now traded at around $134.17. The impact to the portfolio due to this purchase was 0.13%. The holdings were 2,445 shares as of 2017-06-30.
New Purchase: The Kraft Heinz Co (KHC)
Tandem Investment Advisors, Inc. initiated holdings in The Kraft Heinz Co. The purchase prices were between $85.76 and $93.77, with an estimated average price of $90.76. The stock is now traded at around $86.50. The impact to the portfolio due to this purchase was 0.09%. The holdings were 2,521 shares as of 2017-06-30.
New Purchase: Apple Inc (AAPL)
Tandem Investment Advisors, Inc. initiated holdings in Apple Inc. The purchase prices were between $140.68 and $156.1, with an estimated average price of $147.76. The stock is now traded at around $160.95. The impact to the portfolio due to this purchase was 0.08%. The holdings were 1,484 shares as of 2017-06-30.
Added: National Retail Properties Inc (NNN)
Tandem Investment Advisors, Inc. added to the holdings in National Retail Properties Inc by 108.87%. The purchase prices were between $36.72 and $45.53, with an estimated average price of $40.5. The stock is now traded at around $41.11. The impact to the portfolio due to this purchase was 1.19%. The holdings were 147,015 shares as of 2017-06-30.
Added: Signature Bank (SBNY)
Tandem Investment Advisors, Inc. added to the holdings in Signature Bank by 32.52%. The purchase prices were between $136.06 and $152.96, with an estimated average price of $141.86. The stock is now traded at around $130.43. The impact to the portfolio due to this purchase was 0.14%. The holdings were 10,326 shares as of 2017-06-30.
Added: Dollar Tree Inc (DLTR)
Tandem Investment Advisors, Inc. added to the holdings in Dollar Tree Inc by 73.77%. The purchase prices were between $66.6 and $83.13, with an estimated average price of $77.33. The stock is now traded at around $74.44. The impact to the portfolio due to this purchase was 0.06%. The holdings were 4,916 shares as of 2017-06-30.
Added: Fiserv Inc (FISV)
Tandem Investment Advisors, Inc. added to the holdings in Fiserv Inc by 23.19%. The purchase prices were between $115.19 and $125.71, with an estimated average price of $120.86. The stock is now traded at around $124.83. The impact to the portfolio due to this purchase was 0.02%. The holdings were 2,247 shares as of 2017-06-30.
Sold Out: Qualcomm Inc (QCOM)
Tandem Investment Advisors, Inc. sold out the holdings in Qualcomm Inc. The sale prices were between $52.5 and $59.28, with an estimated average price of $55.9.
Warning! GuruFocus has detected 3 Warning Signs with NNN. Click here to check it out.
NNN 15-Year Financial Data
The intrinsic value of NNN
Peter Lynch Chart of NNN
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 18.21% Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. These are the top 5 holdings of Tandem Investment Advisors, Inc. Walgreens Boots Alliance Inc ( WBA ) - 149,226 shares, 4.64% of the total portfolio. | Shares added by 18.21% Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. Shares added by 7.97% New Purchase: FactSet Research Systems Inc (FDS) Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc. | Shares added by 18.21% Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. Shares added by 7.97% New Purchase: FactSet Research Systems Inc (FDS) Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc. | Shares added by 18.21% Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. |
33527.0 | 2017-08-16 00:00:00 UTC | Abbott-North West London Pathology Expand in Diagnostics | ABT | https://www.nasdaq.com/articles/abbott-north-west-london-pathology-expand-in-diagnostics-2017-08-16 | nan | nan | Illinois-based global medical device company Abbott LaboratoriesABT recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Abbott expects this alliance to solidify its footprint in the rapidly growing diagnostics market.
Per the terms of the collaboration, Abbott will be the authorized supplier of all analytical equipment and consumables, covering Abbott's Alinity ci and Alinity h series diagnostics instruments and AlinIQ, which provides professional services and informatics solutions.
Also, per NWLP, the alliance which presently covers 6% of the pathology market in the U.K. is expected to execute 26 million tests per year in the future.
Abbott has been focusing on gaining traction in the diagnostics segment. In June 2017, the company received CE Mark for Alinity hq, which has become the fifth new diagnostic system to be launched in Europe along with the ongoing rollout of four instruments in the areas of immunoassay, clinical chemistry, blood screening and point-of-care.
Interestingly, Abbott raked in 19.2% of total revenues from the diagnostics segment in the recently reported second quarter. This recent development is expected to help the company gain further traction in this space.
Per a report by MarketsAndMarkets , theglobal marketfor molecular diagnostics is projected to reach a value of $10.12 billion by 2021 at a CAGR of 9.1%.
Considering the market potential and Abbott's current developments in the diagnostics space, this collaboration seems to be a strategic one.
We believe an ageing population, unhealthy lifestyle and rising awareness and expenditure in healthcare will continue to drive growth in the diagnostics market. However, this market is dominated by well established players like Quest Diagnostics Inc. DGX and QIAGEN N.V. QGEN .
Moreover, Abbott has been gaining investor confidence on consistent positive results. Over the past three months, the company's share price has outperformed the broader industry . The stock has gained 11.7%, higher than the broader industry's gain of 3.7%. The company has also outperformed the 2.6% gain of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
Abbott currently has a Zacks Rank #3 (Hold). A better-ranked medical stock is Edwards Lifesciences Corporation EW , with a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 2.7% over the last three months.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early .
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Qiagen N.V. (QGEN): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Illinois-based global medical device company Abbott LaboratoriesABT recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. In June 2017, the company received CE Mark for Alinity hq, which has become the fifth new diagnostic system to be launched in Europe along with the ongoing rollout of four instruments in the areas of immunoassay, clinical chemistry, blood screening and point-of-care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. However, this market is dominated by well established players like Quest Diagnostics Inc. DGX and QIAGEN N.V. QGEN . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Abbott expects this alliance to solidify its footprint in the rapidly growing diagnostics market. | Illinois-based global medical device company Abbott LaboratoriesABT recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. This recent development is expected to help the company gain further traction in this space. |
33528.0 | 2017-08-14 00:00:00 UTC | VIG, MDT, ABT, CVS: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/vig-mdt-abt-cvs-large-inflows-detected-etf-2017-08-14 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $64.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 265,873,303 to 266,573,385). Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 1.2%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.2%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $81.24 per share, with $94.53 as the 52 week high point - that compares with a last trade of $93.43. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 1.2%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.2%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $81.24 per share, with $94.53 as the 52 week high point - that compares with a last trade of $93.43. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 1.2%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.2%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $81.24 per share, with $94.53 as the 52 week high point - that compares with a last trade of $93.43. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 1.2%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $64.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 265,873,303 to 266,573,385). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $81.24 per share, with $94.53 as the 52 week high point - that compares with a last trade of $93.43. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 1.2%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $64.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 265,873,303 to 266,573,385). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $81.24 per share, with $94.53 as the 52 week high point - that compares with a last trade of $93.43. |
33529.0 | 2017-08-14 00:00:00 UTC | Keeley Funds Comments on Abbott Labs | ABT | https://www.nasdaq.com/articles/keeley-funds-comments-abbott-labs-2017-08-14 | nan | nan | Abbott Labs ( NYSE:ABT ) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. Abbott also cleared the last hurdle to complete the long-delayed purchase of Alere ( ALR ) which should close in the third quarter of 2017.
From Keeley All Cap Value Fund second quarter 2017 shareholder commentary .
Warning! GuruFocus has detected 2 Warning Sign with WMGI. Click here to check it out.
WMGI 15-Year Financial Data
The intrinsic value of WMGI
Peter Lynch Chart of WMGI
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( NYSE:ABT ) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. Abbott also cleared the last hurdle to complete the long-delayed purchase of Alere ( ALR ) which should close in the third quarter of 2017. | Abbott Labs ( NYSE:ABT ) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( NYSE:ABT ) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. WMGI 15-Year Financial Data The intrinsic value of WMGI Peter Lynch Chart of WMGI Premium Members This article first appeared on GuruFocus . | Abbott Labs ( NYSE:ABT ) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. GuruFocus has detected 2 Warning Sign with WMGI. |
33530.0 | 2017-08-04 00:00:00 UTC | Noteworthy ETF Inflows: IWD, T, USB, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-iwd-t-usb-abt-2017-08-04 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $187.4 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 313,550,000 to 315,150,000). Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is trading flat, US Bancorp (Symbol: USB) is up about 1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $117.40. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is trading flat, US Bancorp (Symbol: USB) is up about 1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $117.40. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is trading flat, US Bancorp (Symbol: USB) is up about 1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $117.40. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is trading flat, US Bancorp (Symbol: USB) is up about 1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $187.4 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 313,550,000 to 315,150,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $117.40. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is trading flat, US Bancorp (Symbol: USB) is up about 1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $187.4 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 313,550,000 to 315,150,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $117.40. |
33531.0 | 2017-08-04 00:00:00 UTC | Health Care Sector Update for 08/04/2017: JNJ, PFE, ABT, MRK, AMGN, MDRX, CFRX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08042017-jnj-pfe-abt-mrk-amgn-mdrx-cfrx-2017-08-04 | nan | nan | Top Health Care Stocks:
JNJ: +0.5%
PFE: +0.2%
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly flat in pre-market trade Friday.
In sector news, Allscripts Healthcare Solutions ( MDRX ) was up 11.8% after it posted Q2 adjusted EPS increased to $0.15 from $0.14 a year earlier, meeting Capital IQ's poll estimate for the quarter. Revenues rose to $426.1 million from $386.5 million, exceeding the $424.9 million estimate. The company said it now expects 2017 revenue of between $1.79 billion and $1.82 billion, up from $1.71 billion and $1.74 billion previously. It kept its adjusted EPS growth target of between 10% to 15% for the year. Allscripts said it would acquire the hospital and health system business from McKesson Corporation ( MCK ) to advance its strategy to offer the most comprehensive, high performing health information technology and solutions.
In other sector news,
(+) CFRX (+3.7%) Gets US patent for new approach to treat influenza using inhaled antibodies
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trade Friday. In sector news, Allscripts Healthcare Solutions ( MDRX ) was up 11.8% after it posted Q2 adjusted EPS increased to $0.15 from $0.14 a year earlier, meeting Capital IQ's poll estimate for the quarter. Allscripts said it would acquire the hospital and health system business from McKesson Corporation ( MCK ) to advance its strategy to offer the most comprehensive, high performing health information technology and solutions. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trade Friday. In other sector news, (+) CFRX (+3.7%) Gets US patent for new approach to treat influenza using inhaled antibodies The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trade Friday. In sector news, Allscripts Healthcare Solutions ( MDRX ) was up 11.8% after it posted Q2 adjusted EPS increased to $0.15 from $0.14 a year earlier, meeting Capital IQ's poll estimate for the quarter. In other sector news, (+) CFRX (+3.7%) Gets US patent for new approach to treat influenza using inhaled antibodies The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trade Friday. Top Health Care Stocks: In sector news, Allscripts Healthcare Solutions ( MDRX ) was up 11.8% after it posted Q2 adjusted EPS increased to $0.15 from $0.14 a year earlier, meeting Capital IQ's poll estimate for the quarter. |
33532.0 | 2017-08-04 00:00:00 UTC | Vanguard Health Care Fund Gains 4 International Stocks in 2nd Quarter | ABT | https://www.nasdaq.com/articles/vanguard-health-care-fund-gains-4-international-stocks-2nd-quarter-2017-08-04 | nan | nan | Vanguard Health Care Fund ( Trades , Portfolio ) portfolio manager Jean Hynes invested in four international health care companies during the second quarter. Her new holdings are in Sysmex Corp. (TSE:6869), Terumo Corp. (TSE:4543), WuXi Biologics(Cayman) Inc. (HKSE:02269) and Idorsia Ltd. (XSWX:IDIA).
Hynes manages a portfolio of 74 stocks, which mostly consists of companies in the health care sector.
Sysmex
Hynes purchased 1.5 million shares of Sysmex for an average price of 6,704.15 yen per share ($60.95), giving it 0.2% portfolio space.
The Japanese clinical testing devices manufacturer has a market cap of 1.36 trillion yen; its shares were trading around 6,640 yen on Friday with a price-earnings (P/E) ratio of 33.42, a price-book (P/B) ratio of 6.47 and a price-sales (P/S) ratio of 5.44.
The Peter Lynch chart below shows the stock is trading above its fair value.
GuruFocus ranked the company's financial strength 9 of 10 and its profitability and growth 8 of 10. The company's trailing dividend yield is 0.89% and its forward dividend yield is 0.92%. The dividend payout ratio is 30%.
With its purchase, Vanguard became the company's largest shareholder among the gurus with 0.75% of outstanding shares. The Matthews Japan Fund (Trades, Portfolio) also owns the stock.
Terumo
The fund bought 1.18 million shares of Terumo for an average price of 4,245.54 yen per share, expanding the portfolio 0.1%.
The Japanese manufacturer of pharmaceuticals, medical tools and equipment has a market cap of 1.47 trillion yen; its shares were trading around 4,325 yen on Friday with a P/E ratio of 29.77, a P/B ratio of 3 and a P/S ratio of 3.24.
According to the Peter Lynch chart below, the stock is trading above its fair value.
GuruFocus ranked Terumo's financial strength 6 of 10 and its profitability and growth 7 of 10. The trailing dividend yield is 1.01% and the forward dividend yield is 1.06%. The dividend payout ratio is 30%.
With its purchase, the fund became the company's largest guru shareholder with 0.34% of outstanding shares. The Hennessy Japan Fund (Trades, Portfolio) also owns the stock.
WuXi Biologics
The fund manager established a holding in Wuxi Biologics, buying 2.6 million shares for an average price of 27.71 Hong Kong dollars ($3.54) per share, giving it a portfolio weight of 0.02%.
The Chinese biologics company, which went public earlier this year, has a market cap of HK$37.14 billion; its shares were trading around HK$33.05 on Friday with a P/E ratio of 233.93, a P/B ratio of 122.66 and a P/S ratio of 33.49.
The graph below shows the trend in the stock's price since its initial public offering in June.
Vanguard is the only guru invested in the company, holding 0.23% of its outstanding shares.
Idorsia
Hynes smallest new position is a 478,519-share stake in Idorsia, occupying just 0.02% of the portfolio. She paid an average price of 15.64 Swiss francs ($16.08) per share.
The Swiss biopharmaceutical company, which was spun off of Actelion in June, has a market cap of 2.11 billion francs; its shares were trading around 17.75 francs on Friday with a P/B ratio of 5.22.
The graph below shows the trend in the stock's price since its June IPO.
Vanguard is the only guru shareholder with 0.4% of outstanding shares.
Other positions the fund added to during the quarter include Abbott Laboratories ( ABT ), Novartis AG ( NOVN ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Baxter International Inc. ( BAX ), Becton, Dickinson and Co. ( BDX ) and Cardinal Health Inc. (CAH).
Disclosure: I do not own any stocks mentioned.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other positions the fund added to during the quarter include Abbott Laboratories ( ABT ), Novartis AG ( NOVN ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Baxter International Inc. ( BAX ), Becton, Dickinson and Co. ( BDX ) and Cardinal Health Inc. (CAH). Hynes manages a portfolio of 74 stocks, which mostly consists of companies in the health care sector. The graph below shows the trend in the stock's price since its initial public offering in June. | Other positions the fund added to during the quarter include Abbott Laboratories ( ABT ), Novartis AG ( NOVN ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Baxter International Inc. ( BAX ), Becton, Dickinson and Co. ( BDX ) and Cardinal Health Inc. (CAH). Vanguard Health Care Fund ( Trades , Portfolio ) portfolio manager Jean Hynes invested in four international health care companies during the second quarter. Sysmex Hynes purchased 1.5 million shares of Sysmex for an average price of 6,704.15 yen per share ($60.95), giving it 0.2% portfolio space. | Other positions the fund added to during the quarter include Abbott Laboratories ( ABT ), Novartis AG ( NOVN ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Baxter International Inc. ( BAX ), Becton, Dickinson and Co. ( BDX ) and Cardinal Health Inc. (CAH). The Japanese clinical testing devices manufacturer has a market cap of 1.36 trillion yen; its shares were trading around 6,640 yen on Friday with a price-earnings (P/E) ratio of 33.42, a price-book (P/B) ratio of 6.47 and a price-sales (P/S) ratio of 5.44. The Japanese manufacturer of pharmaceuticals, medical tools and equipment has a market cap of 1.47 trillion yen; its shares were trading around 4,325 yen on Friday with a P/E ratio of 29.77, a P/B ratio of 3 and a P/S ratio of 3.24. | Other positions the fund added to during the quarter include Abbott Laboratories ( ABT ), Novartis AG ( NOVN ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Baxter International Inc. ( BAX ), Becton, Dickinson and Co. ( BDX ) and Cardinal Health Inc. (CAH). Vanguard Health Care Fund ( Trades , Portfolio ) portfolio manager Jean Hynes invested in four international health care companies during the second quarter. Sysmex Hynes purchased 1.5 million shares of Sysmex for an average price of 6,704.15 yen per share ($60.95), giving it 0.2% portfolio space. |
33533.0 | 2017-08-02 00:00:00 UTC | Health Care Sector Update for 08/02/2017: JNJ, PFE, ABT, MRK, AMGN, EYES, OCUL | ABT | https://www.nasdaq.com/articles/health-care-sector-update-08022017-jnj-pfe-abt-mrk-amgn-eyes-ocul-2017-08-02 | nan | nan | Top Health Care Stocks:
JNJ: +0.2%
PFE: -0.3%
ABT: flat
MRK: flat
AMGN: -0.7%
Health care shares were mixed in pre-market trade Wednesday.
In sector news, Second Sight Medical Products ( EYES ) rose 7.4% after it said late Tuesday its Q2 loss per share narrowed to $0.12 per share from $0.17 loss per share a year earlier, less than Capital IQ's poll estimate of $0.14 loss per share, helping its shares up over 4% in after-hours trading. Sales rose to $2.2 million in the second quarter of 2017 compared to $1.0 million in the second quarter of 2016, also coming ahead of the $1.43 million estimate.
In other sector news,
(+) OCUL (+2%) Appointed Antony Mattesich as CEO
(-) PFE (-0.3%) BMO Capital upgrades shares to outperform from market perform
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Top Health Care Stocks: Health care shares were mixed in pre-market trade Wednesday. | ABT: flat MRK: flat Health care shares were mixed in pre-market trade Wednesday. In other sector news, (+) OCUL (+2%) Appointed Antony Mattesich as CEO (-) PFE (-0.3%) BMO Capital upgrades shares to outperform from market perform The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat In sector news, Second Sight Medical Products ( EYES ) rose 7.4% after it said late Tuesday its Q2 loss per share narrowed to $0.12 per share from $0.17 loss per share a year earlier, less than Capital IQ's poll estimate of $0.14 loss per share, helping its shares up over 4% in after-hours trading. In other sector news, (+) OCUL (+2%) Appointed Antony Mattesich as CEO (-) PFE (-0.3%) BMO Capital upgrades shares to outperform from market perform The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Health care shares were mixed in pre-market trade Wednesday. In other sector news, (+) OCUL (+2%) Appointed Antony Mattesich as CEO (-) PFE (-0.3%) BMO Capital upgrades shares to outperform from market perform The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33534.0 | 2017-07-30 00:00:00 UTC | AbbVie Inc. Posted 2nd Quarter Numbers | ABT | https://www.nasdaq.com/articles/abbvie-inc-posted-2nd-quarter-numbers-2017-07-30 | nan | nan | AbbVie Inc. ( ABBV ) released its second-quarter 2017 financial results yesterday, July 28.
The U.S. pharmaceutical company, an Abbott Laboratories ( ABT ) spinoff, closed the quarter with non-GAAP EPS - on a diluted basis - of $1.42, a 12.7% increase from the comparable quarter of 2016. The company beat analysts' expectations by two cents, generating a positive 1.43% surprise.
The average analyst forecasted an EPS of $1.4, ranging between a low of $1.35 and a high of $1.42. The operating income for the quarter was $2.674 billion, a 12% increase from $2.387 billion in the same quarter of the previous year. The net income was $1.915 billion at the end of the second quarter of 2017 versus net income of $1.610 billion at the end of second-quarter 2016. Non-GAAP net income - adjusted to one-time charges - was $2.837 billion, up 24% from the comparable quarter of 2016.
Revenue came in at $6.944 billion, a 7.6% increase on a year-over-year basis. The American pharmaceutical company beat expectations by $14 million.
The average analyst forecasted AbbVie's revenue would come in at $6.93 billion, ranging between a low of $6.87 billion and a high of $7.01 billion. For the next quarter, analysts forecast revenue will come in at $6.9 billion on average. For the year, analysts expect an 8.60% increase to $27.77 billion from $25.56 billion of full fiscal 2016.
Total sales of Humira, the company's flagship drug and used mainly as a treatment for rheumatoid arthritis patients, were $4.716 billion, up 13.7% year over year. Imbruvica, the company's drug used in the treatment for marginal zone lymphoma (MZL), generated sales of $626 million, up 42.6% on a year-over-year basis. Viekira Pak, a drug used for the treatment of people infected with hepatitis C, sales were down 46.4% at $225 million. Sales of Lupron, which treats men with prostate cancer and women with endometriosis, were $210 million, down 3.8% on a year-over-year basis. Creon, a drug prescribed to patients suffering from exocrine pancreatic insufficiency ( EPI ), sales were up 9.5% year over year at $196 million. Synthroid, a treatment for hypothyroidism and goitre, generated sales of $193 million, up 2.3% year over year. Sales of AndroGel, the company's product for the treatment of hypogonadism, were $154 million, down 10.3% year over year. Kaletra, an antiretroviral drug used for the treatment of hiv positive people, sales were $110 million, down 24.7% year over year. Sales of Sevoflurane, an anaesthetic ether, were $104M, down 8% year over year.
AbbVie closed at $70.44 per share yesterday, down $1.29 or 1.80% from the previous trading day, with a volume of 8,012,352 shares traded on the New York Stock Exchange versus an average volume of 5.52 million shares traded over the last three trading months and versus an average volume of 5.78 million shares traded over the last 10 trading days.
The stock has gained 12.5% year to date. It is currently trading with a price-earnings (P/E) ratio of 18.26, a price-book (P/B) ratio of 22.43 and a price-sales (P/S) ratio of 4.28. The forward P/E ratio is 10.77.
When multiplying the forward P/E ratio by the forecasted EPS of $5.53 for 2017, the stock looks overvalued with a value of $59.56 per share. However, if we multiply the forward P/E ratio by the EPS of $6.54 - as forecasted by analysts for the entire year of 2018 - we obtain a value of $70.43 which is in line with the current market valuation of AbbVie Inc.
Despite the stock may look overvalued by the stock market at the moment, the average analyst set a target price of $75.41 per AbbVie's share, which represents a 7% upside's chances from the current market valuation of this stock. The target price ranges between a low of $60 and a high of $95.
The recommendation rating is 2.4. The rating ranges between 1.0 (Strong Buy) and 5.0 (Sell).
This year June 22, AbbVie was upgraded by Societe Generale from a hold rating to buy.
As of March. 31, 2017, AbbVie had approximately $6.25 billion in cash and securities. Total debt amounted to $37.3 billion for a total debt to Equity ratio of 746.38 versus an industry average of 14.39. As of the first quarter of fiscal 2017, the Interest Coverage ratio - computed over the last twelve trailing months' timeframe - was 7.19 versus an industry average of 38.28.
GuruFocus gives AbbVie a financial strength rating of 4 out of 10 and a profitability & growth rating of 8 out of a total of 10.
AbbVie distributes an annual dividend of $2.56, through quarterly payments of 64 cents to its shareholders for a dividend yield of 3.57% according to the latest close price and to a pay-out ratio of 60.88%.
For full fiscal 2017, AbbVie reconfirms an EPS - on a diluted basis and according to GAAP measures - ranging between $4.55 and $4.65. While the non-GAAP EPS - on a diluted basis and adjusted to one-time charges - is expected by the company to range between $5.44 and $5.54. The latter represents an average 13.9% growth from the range released by AbbVie with the previous guidance on earnings for full fiscal 2017.
Disclosure: I have no positions in any stock mentioned in this article.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The U.S. pharmaceutical company, an Abbott Laboratories ( ABT ) spinoff, closed the quarter with non-GAAP EPS - on a diluted basis - of $1.42, a 12.7% increase from the comparable quarter of 2016. Imbruvica, the company's drug used in the treatment for marginal zone lymphoma (MZL), generated sales of $626 million, up 42.6% on a year-over-year basis. However, if we multiply the forward P/E ratio by the EPS of $6.54 - as forecasted by analysts for the entire year of 2018 - we obtain a value of $70.43 which is in line with the current market valuation of AbbVie Inc. | The U.S. pharmaceutical company, an Abbott Laboratories ( ABT ) spinoff, closed the quarter with non-GAAP EPS - on a diluted basis - of $1.42, a 12.7% increase from the comparable quarter of 2016. Non-GAAP net income - adjusted to one-time charges - was $2.837 billion, up 24% from the comparable quarter of 2016. AbbVie closed at $70.44 per share yesterday, down $1.29 or 1.80% from the previous trading day, with a volume of 8,012,352 shares traded on the New York Stock Exchange versus an average volume of 5.52 million shares traded over the last three trading months and versus an average volume of 5.78 million shares traded over the last 10 trading days. | The U.S. pharmaceutical company, an Abbott Laboratories ( ABT ) spinoff, closed the quarter with non-GAAP EPS - on a diluted basis - of $1.42, a 12.7% increase from the comparable quarter of 2016. The average analyst forecasted AbbVie's revenue would come in at $6.93 billion, ranging between a low of $6.87 billion and a high of $7.01 billion. Total sales of Humira, the company's flagship drug and used mainly as a treatment for rheumatoid arthritis patients, were $4.716 billion, up 13.7% year over year. | The U.S. pharmaceutical company, an Abbott Laboratories ( ABT ) spinoff, closed the quarter with non-GAAP EPS - on a diluted basis - of $1.42, a 12.7% increase from the comparable quarter of 2016. The average analyst forecasted AbbVie's revenue would come in at $6.93 billion, ranging between a low of $6.87 billion and a high of $7.01 billion. For the year, analysts expect an 8.60% increase to $27.77 billion from $25.56 billion of full fiscal 2016. |
33535.0 | 2017-07-28 00:00:00 UTC | USMV, FTXH: Big ETF Outflows | ABT | https://www.nasdaq.com/articles/usmv-ftxh-big-etf-outflows-2017-07-28 | nan | nan | Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Edge MSCI Min Vol USA ETF ( USMV ), where 4,500,000 units were destroyed, or a 1.6% decrease week over week. Among the largest underlying components of USMV, in morning trading today Becton Dickinson & Company ( BDX ) is down about 0.4%, and McDonalds Corporation ( MCD ) is lower by about 0.8%.
And on a percentage change basis, the ETF with the biggest outflow was the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), which lost 50,000 of its units, representing a 33.3% decline in outstanding units compared to the week prior. Among the largest underlying components of FTXH, in morning trading today Abbott Labs ( ABT ) is down about 1.1%, and Abbvie Incorporated (ABBV) is lower by about 3.1%.
VIDEO: USMV, FTXH: Big ETF Outflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of FTXH, in morning trading today Abbott Labs ( ABT ) is down about 1.1%, and Abbvie Incorporated (ABBV) is lower by about 3.1%. Among the largest underlying components of USMV, in morning trading today Becton Dickinson & Company ( BDX ) is down about 0.4%, and McDonalds Corporation ( MCD ) is lower by about 0.8%. And on a percentage change basis, the ETF with the biggest outflow was the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), which lost 50,000 of its units, representing a 33.3% decline in outstanding units compared to the week prior. | Among the largest underlying components of FTXH, in morning trading today Abbott Labs ( ABT ) is down about 1.1%, and Abbvie Incorporated (ABBV) is lower by about 3.1%. Among the largest underlying components of USMV, in morning trading today Becton Dickinson & Company ( BDX ) is down about 0.4%, and McDonalds Corporation ( MCD ) is lower by about 0.8%. VIDEO: USMV, FTXH: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of FTXH, in morning trading today Abbott Labs ( ABT ) is down about 1.1%, and Abbvie Incorporated (ABBV) is lower by about 3.1%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Edge MSCI Min Vol USA ETF ( USMV ), where 4,500,000 units were destroyed, or a 1.6% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), which lost 50,000 of its units, representing a 33.3% decline in outstanding units compared to the week prior. | Among the largest underlying components of FTXH, in morning trading today Abbott Labs ( ABT ) is down about 1.1%, and Abbvie Incorporated (ABBV) is lower by about 3.1%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Edge MSCI Min Vol USA ETF ( USMV ), where 4,500,000 units were destroyed, or a 1.6% decrease week over week. Among the largest underlying components of USMV, in morning trading today Becton Dickinson & Company ( BDX ) is down about 0.4%, and McDonalds Corporation ( MCD ) is lower by about 0.8%. |
33536.0 | 2017-07-28 00:00:00 UTC | Health Care Sector Update for 07/28/2017: JNJ, PFE, ABT, MRK, AMGN, ABBV, NUVA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07282017-jnj-pfe-abt-mrk-amgn-abbv-nuva-2017-07-28 | nan | nan | Top Health Care Stocks:
JNJ: -0.1%
PFE: +0.3%
ABT: -0.6%
MRK: +3.5%
AMGN: -2.1%
Health care shares were mixed in pre-market trade Friday.
In sector news, Merck ( MRK ) was up 3.5% after the pharmaceutical company reported Q2 adjusted earnings of $1.01, up from $0.93 in the same period a year ago and topping the estimate of $0.87 from analysts polled by CapIQ. Total revenues of $9.93 billion were up from $9.84 billion in the same period a year ago and exceeded the Street projection of $9.75 billion. Merck maintained its FY adjusted EPS guidance in the range of $3.76 to $3.88, straddling the Street estimate of $3.85. The company narrowed and raised its FY revenue range to between $39.40 billion and $40.40 billion from prior guidance of $39.10 billion and $40.30 billion, straddling the Street projection of $40.05 billion.
In other sector news,
(+) ABBV (+1.8%) Reports Q2 EPS beat and revenues in line with estimates; reaffirms 2017 guidance
(-) NUVA (-10.5%) President and COO Jason Hannon resigns
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Merck ( MRK ) was up 3.5% after the pharmaceutical company reported Q2 adjusted earnings of $1.01, up from $0.93 in the same period a year ago and topping the estimate of $0.87 from analysts polled by CapIQ. Merck maintained its FY adjusted EPS guidance in the range of $3.76 to $3.88, straddling the Street estimate of $3.85. In other sector news, (+) ABBV (+1.8%) Reports Q2 EPS beat and revenues in line with estimates; reaffirms 2017 guidance (-) NUVA (-10.5%) President and COO Jason Hannon resigns The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Merck ( MRK ) was up 3.5% after the pharmaceutical company reported Q2 adjusted earnings of $1.01, up from $0.93 in the same period a year ago and topping the estimate of $0.87 from analysts polled by CapIQ. Merck maintained its FY adjusted EPS guidance in the range of $3.76 to $3.88, straddling the Street estimate of $3.85. The company narrowed and raised its FY revenue range to between $39.40 billion and $40.40 billion from prior guidance of $39.10 billion and $40.30 billion, straddling the Street projection of $40.05 billion. | Total revenues of $9.93 billion were up from $9.84 billion in the same period a year ago and exceeded the Street projection of $9.75 billion. The company narrowed and raised its FY revenue range to between $39.40 billion and $40.40 billion from prior guidance of $39.10 billion and $40.30 billion, straddling the Street projection of $40.05 billion. In other sector news, (+) ABBV (+1.8%) Reports Q2 EPS beat and revenues in line with estimates; reaffirms 2017 guidance (-) NUVA (-10.5%) President and COO Jason Hannon resigns The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Merck ( MRK ) was up 3.5% after the pharmaceutical company reported Q2 adjusted earnings of $1.01, up from $0.93 in the same period a year ago and topping the estimate of $0.87 from analysts polled by CapIQ. Merck maintained its FY adjusted EPS guidance in the range of $3.76 to $3.88, straddling the Street estimate of $3.85. In other sector news, (+) ABBV (+1.8%) Reports Q2 EPS beat and revenues in line with estimates; reaffirms 2017 guidance (-) NUVA (-10.5%) President and COO Jason Hannon resigns The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33537.0 | 2017-07-27 00:00:00 UTC | Noteworthy ETF Outflows: IWD, T, ABT, USB | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iwd-t-abt-usb-2017-07-27 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $70.2 million dollar outflow -- that's a 0.2% decrease week over week (from 314,150,000 to 313,550,000). Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is up about 2.7%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and US Bancorp (Symbol: USB) is relatively unchanged. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $116.99. Comparing the most recent share price to the 200 day moving average can also be a useful technical ana | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is up about 2.7%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and US Bancorp (Symbol: USB) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $70.2 million dollar outflow -- that's a 0.2% decrease week over week (from 314,150,000 to 313,550,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $116.99. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is up about 2.7%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and US Bancorp (Symbol: USB) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $70.2 million dollar outflow -- that's a 0.2% decrease week over week (from 314,150,000 to 313,550,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $116.99. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is up about 2.7%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and US Bancorp (Symbol: USB) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $70.2 million dollar outflow -- that's a 0.2% decrease week over week (from 314,150,000 to 313,550,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $116.99. | Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is up about 2.7%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and US Bancorp (Symbol: USB) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $70.2 million dollar outflow -- that's a 0.2% decrease week over week (from 314,150,000 to 313,550,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $116.99. |
33538.0 | 2017-07-27 00:00:00 UTC | Health Care Sector Update for 07/27/2017: JNJ, PFE, ABT, MRK, AMGN, BMY, EW, VAR | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07272017-jnj-pfe-abt-mrk-amgn-bmy-ew-var-2017-07-27 | nan | nan | Top Health Care Stocks:
JNJ: +0.6%
PFE: flat
ABT: +0.2%
MRK: +4%
AMGN: -2.8%
Health care shares were mixed in pre-market trade Thursday.
In sector news, Bristol-Myers Squibb Company ( BMY ) was down 6.2% after it reported Q2 adjusted earnings of $0.74 per diluted share compared with an income of $0.69 per share a year ago, beating the $0.73 average estimate from analysts polled by Capital IQ. Total revenue jumped to $5.14 billion from $4.87 billion a year ago, coming in above the $5.09-billion consensus. Raising the lower end of its earnings guidance range for the FY, the company said non-GAAP EPS will remain between $2.90 and $3.00, straddling the Street's forecast of $2.94. Earlier the company had forecast a range of $2.85 - $3.00, according to a statement.
In other sector news,
(+) EW (+2.9%) Reports Q2 EPS and revenues above estimates and raises 2017 guidance
(-) VAR (-2.5%) Posts Fiscal Q3 EPS above Street views but revenues fall short; guides Q4 EPS in line
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Bristol-Myers Squibb Company ( BMY ) was down 6.2% after it reported Q2 adjusted earnings of $0.74 per diluted share compared with an income of $0.69 per share a year ago, beating the $0.73 average estimate from analysts polled by Capital IQ. Raising the lower end of its earnings guidance range for the FY, the company said non-GAAP EPS will remain between $2.90 and $3.00, straddling the Street's forecast of $2.94. In other sector news, (+) EW (+2.9%) Reports Q2 EPS and revenues above estimates and raises 2017 guidance (-) VAR (-2.5%) Posts Fiscal Q3 EPS above Street views but revenues fall short; guides Q4 EPS in line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mixed in pre-market trade Thursday. In other sector news, (+) EW (+2.9%) Reports Q2 EPS and revenues above estimates and raises 2017 guidance (-) VAR (-2.5%) Posts Fiscal Q3 EPS above Street views but revenues fall short; guides Q4 EPS in line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat In sector news, Bristol-Myers Squibb Company ( BMY ) was down 6.2% after it reported Q2 adjusted earnings of $0.74 per diluted share compared with an income of $0.69 per share a year ago, beating the $0.73 average estimate from analysts polled by Capital IQ. In other sector news, (+) EW (+2.9%) Reports Q2 EPS and revenues above estimates and raises 2017 guidance (-) VAR (-2.5%) Posts Fiscal Q3 EPS above Street views but revenues fall short; guides Q4 EPS in line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mixed in pre-market trade Thursday. Raising the lower end of its earnings guidance range for the FY, the company said non-GAAP EPS will remain between $2.90 and $3.00, straddling the Street's forecast of $2.94. In other sector news, (+) EW (+2.9%) Reports Q2 EPS and revenues above estimates and raises 2017 guidance (-) VAR (-2.5%) Posts Fiscal Q3 EPS above Street views but revenues fall short; guides Q4 EPS in line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33539.0 | 2017-07-26 00:00:00 UTC | MMM a Top Socially Responsible Dividend Stock With 2.4% Yield | ABT | https://www.nasdaq.com/articles/mmm-top-socially-responsible-dividend-stock-24-yield-2017-07-26 | nan | nan | 3M Co (Symbol: MMM) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 2.4% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources. Social criteria include elements such as human rights, child labor, corporate diversity, and the company's impact on society - for instance, taken into consideration would be business activities tied to weapons, gambling, tobacco, and alcohol.
According to the ETF Finder at ETF Channel , 3M Co is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 4.50% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where MMM makes up 1.21% of the underlying holdings of the fund.
The annualized dividend paid by 3M Co is $4.70/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 05/17/2017. Below is a long-term dividend history chart for MMM, which the DividendRank report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
MMM operates in the Medical Instruments & Supplies sector, among companies like Medtronic PLC ( MDT ), and Abbott Laboratories ( ABT ).
Top 25 Socially Responsible Dividend Stocks - Income To Feel Good About »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MMM operates in the Medical Instruments & Supplies sector, among companies like Medtronic PLC ( MDT ), and Abbott Laboratories ( ABT ). Social criteria include elements such as human rights, child labor, corporate diversity, and the company's impact on society - for instance, taken into consideration would be business activities tied to weapons, gambling, tobacco, and alcohol. Below is a long-term dividend history chart for MMM, which the DividendRank report stressed as being of key importance. | MMM operates in the Medical Instruments & Supplies sector, among companies like Medtronic PLC ( MDT ), and Abbott Laboratories ( ABT ). 3M Co (Symbol: MMM) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 2.4% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , 3M Co is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 4.50% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where MMM makes up 1.21% of the underlying holdings of the fund. | MMM operates in the Medical Instruments & Supplies sector, among companies like Medtronic PLC ( MDT ), and Abbott Laboratories ( ABT ). 3M Co (Symbol: MMM) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 2.4% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , 3M Co is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 4.50% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where MMM makes up 1.21% of the underlying holdings of the fund. | MMM operates in the Medical Instruments & Supplies sector, among companies like Medtronic PLC ( MDT ), and Abbott Laboratories ( ABT ). Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue. |
33540.0 | 2017-07-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-oracle-pfizer-abbott-alphabet-and-schlumberger-2017-07 | nan | nan | For Immediate Release
Chicago, IL - July 26, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ), Abbott (NYSE: ABT - Free Report ), Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday's Analyst Blog:
Top Analyst Reports for Today: Oracle, Pfizer and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ) and Abbott (NYSE: ABT - Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all oftoday's research reports here >>>
Buy-rated Oracle 's shares have outperformed the Zacks Technology Sector year-to-date, gaining +32% vs. +18%. The company's offerings in SaaS and PaaS have gained significant momentum in the past few quarters, which improves the company's competitive position in the red hot cloud space, particularly against salesforce.com and Workday.
The Zacks analyst likes the company's growing cloud market share and sees the positive momentum in this area as a notable top-line growth driver. Moreover, Oracle continues to win new customers in HCM, ERP and CX. However, high investments in IaaS will affect gross margin expansion in the near-term. Further, a strong U.S. dollar remains a headwind.
(You can read the full research report on Oracle here >>> ) .
Pfizer 's shares have underperformed the peer group as well as the broader market over the past year (the stock is down -9.5% over the last year vs. a -1.2% decline for the Zacks Large-Cap Pharmaceuticals industry and the +13.9% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election.
These headwinds notwithstanding, the Zacks analyst is pointing out that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. However, genericization of key drugs, lost alliance revenues, pricing pressure and rising competition remain potent headwinds. Mounting competition in the immuno-oncology market is also a significant concern.
The company has a mixed record of earnings surprises in recent quarters. Estimate movement has been mixed ahead of its second-quarter earnings release.
(You can read the full research report on Pfizer here >>> ) .
Buy-rated Abbott 's shares have outperformed the Zacks Medical sector in the year-to-date period (the stock is up +32.3% vs. +13.1% gain for the sector) on the back of greater appreciation for the company's strategic repositioning through acquisitions/divestitures. A case in point is the St. Jude Medical buyout that complements the company cardiovascular devices business.
All in all, market participants like management's strategic focus on core therapeutic areas. Abbott's second-quarter 2017 performance was promising with the bottom line exceeding expectations. Although revenues were in line with estimates, the raised guidance for 2017 is indicative of brighter prospects. On the flip side, the analyst identifies weakness in the nutrition business in China and sluggish growth in the Venezuelan market as areas of concern.
(You can read the full research report on Abbott here >>> ) .
Other noteworthy reports we are featuring today include Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on ABT - FREE
Get the full Report on ORCL - FREE
Get the full Report on PFE - FREE
Get the full Report on GOOGL - FREE
Get the full Report on SLB - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Oracle Corporation (ORCL): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
Schlumberger N.V. (SLB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ), Abbott (NYSE: ABT - Free Report ), Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ) and Abbott (NYSE: ABT - Free Report ). Get the full Report on ABT - FREE Get the full Report on ORCL - FREE Get the full Report on PFE - FREE Get the full Report on GOOGL - FREE Get the full Report on SLB - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ), Abbott (NYSE: ABT - Free Report ), Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ) and Abbott (NYSE: ABT - Free Report ). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Schlumberger N.V. (SLB): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ), Abbott (NYSE: ABT - Free Report ), Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ). Get the full Report on ABT - FREE Get the full Report on ORCL - FREE Get the full Report on PFE - FREE Get the full Report on GOOGL - FREE Get the full Report on SLB - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Schlumberger N.V. (SLB): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ), Abbott (NYSE: ABT - Free Report ), Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ) and Abbott (NYSE: ABT - Free Report ). Get the full Report on ABT - FREE Get the full Report on ORCL - FREE Get the full Report on PFE - FREE Get the full Report on GOOGL - FREE Get the full Report on SLB - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33541.0 | 2017-07-26 00:00:00 UTC | Perkins Capital Management Inc Buys AmerisourceBergen Corp, Pentair PLC, Zagg Inc, Sells ... | ABT | https://www.nasdaq.com/articles/perkins-capital-management-inc-buys-amerisourcebergen-corp-pentair-plc-zagg-inc-sells-2017 | nan | nan | Perkins Capital Management Inc
New Purchases: ABC , PNR , ZAGG , VERI, HDP, TEAR, DE, XPO, CTG, CDXS,
Added Positions:CYTX, BX, INWK, VG, MRK, ENTL, VCEL, T, DAVE, JBLU,
Reduced Positions:CSII, ATRS, NEO, LMAT, BIOS, AXGN, CGNT, RMTI, ARCI, LLY,
Sold Out:TCMD, OOMA, STX, SPSC, MMSI, JCI, RIG, EGHT, DRAD, GEOS,
For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC
These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC
AxoGen Inc ( AXGN ) - 554,792 shares, 10.31% of the total portfolio. Shares reduced by 6.31%
Abbott Laboratories ( ABT ) - 82,710 shares, 4.46% of the total portfolio. Shares reduced by 1%
Rockwell Medical Inc ( RMTI ) - 440,134 shares, 3.87% of the total portfolio. Shares reduced by 9.33%
AtriCure Inc ( ATRC ) - 135,368 shares, 3.64% of the total portfolio. Shares reduced by 1.35%
Cancer Genetics Inc ( CGIX ) - 828,366 shares, 3.63% of the total portfolio. Shares reduced by 1.02%
New Purchase: AmerisourceBergen Corp (ABC)
Perkins Capital Management Inc initiated holdings in AmerisourceBergen Corp. The purchase prices were between $80.94 and $96.38, with an estimated average price of $88.96. The stock is now traded at around $93.88. The impact to the portfolio due to this purchase was 1.09%. The holdings were 10,400 shares as of 2017-06-30.
New Purchase: Pentair PLC (PNR)
Perkins Capital Management Inc initiated holdings in Pentair PLC. The purchase prices were between $62.16 and $67.73, with an estimated average price of $65.01. The stock is now traded at around $63.02. The impact to the portfolio due to this purchase was 0.88%. The holdings were 11,950 shares as of 2017-06-30.
New Purchase: Zagg Inc (ZAGG)
Perkins Capital Management Inc initiated holdings in Zagg Inc. The purchase prices were between $6.65 and $9, with an estimated average price of $7.95. The stock is now traded at around $8.80. The impact to the portfolio due to this purchase was 0.67%. The holdings were 69,600 shares as of 2017-06-30.
New Purchase: Veritone Inc (VERI)
Perkins Capital Management Inc initiated holdings in Veritone Inc. The purchase prices were between $11.33 and $14.91, with an estimated average price of $13.12. The stock is now traded at around $9.67. The impact to the portfolio due to this purchase was 0.55%. The holdings were 42,500 shares as of 2017-06-30.
New Purchase: Hortonworks Inc (HDP)
Perkins Capital Management Inc initiated holdings in Hortonworks Inc. The purchase prices were between $9.81 and $13.88, with an estimated average price of $11.95. The stock is now traded at around $13.87. The impact to the portfolio due to this purchase was 0.47%. The holdings were 32,675 shares as of 2017-06-30.
New Purchase: TearLab Corp (TEAR)
Perkins Capital Management Inc initiated holdings in TearLab Corp. The purchase prices were between $1.57 and $2.84, with an estimated average price of $2.05. The stock is now traded at around $2.91. The impact to the portfolio due to this purchase was 0.42%. The holdings were 225,589 shares as of 2017-06-30.
Added: Cytori Therapeutics Inc (CYTX)
Perkins Capital Management Inc added to the holdings in Cytori Therapeutics Inc by 98.99%. The purchase prices were between $0.92 and $1.72, with an estimated average price of $1.08. The stock is now traded at around $0.47. The impact to the portfolio due to this purchase was 0.53%. The holdings were 874,896 shares as of 2017-06-30.
Added: Blackstone Group LP (BX)
Perkins Capital Management Inc added to the holdings in Blackstone Group LP by 75.54%. The purchase prices were between $28.86 and $33.69, with an estimated average price of $31.27. The stock is now traded at around $34.75. The impact to the portfolio due to this purchase was 0.45%. The holdings were 28,350 shares as of 2017-06-30.
Added: InnerWorkings Inc (INWK)
Perkins Capital Management Inc added to the holdings in InnerWorkings Inc by 85.00%. The purchase prices were between $9.69 and $11.86, with an estimated average price of $10.72. The stock is now traded at around $11.77. The impact to the portfolio due to this purchase was 0.44%. The holdings were 74,000 shares as of 2017-06-30.
Added: Vonage Holdings Corp (VG)
Perkins Capital Management Inc added to the holdings in Vonage Holdings Corp by 83.49%. The purchase prices were between $5.99 and $7.15, with an estimated average price of $6.68. The stock is now traded at around $6.67. The impact to the portfolio due to this purchase was 0.23%. The holdings were 69,450 shares as of 2017-06-30.
Added: Merck & Co Inc (MRK)
Perkins Capital Management Inc added to the holdings in Merck & Co Inc by 36.30%. The purchase prices were between $61.89 and $66.16, with an estimated average price of $63.79. The stock is now traded at around $62.11. The impact to the portfolio due to this purchase was 0.17%. The holdings were 9,200 shares as of 2017-06-30.
Added: Amarin Corp PLC (AMRN)
Perkins Capital Management Inc added to the holdings in Amarin Corp PLC by 20.29%. The purchase prices were between $2.87 and $3.86, with an estimated average price of $3.1. The stock is now traded at around $4.12. The impact to the portfolio due to this purchase was 0.03%. The holdings were 41,500 shares as of 2017-06-30.
Sold Out: Tactile Systems Technology Inc (TCMD)
Perkins Capital Management Inc sold out the holdings in Tactile Systems Technology Inc. The sale prices were between $17.11 and $29.32, with an estimated average price of $22.36.
Sold Out: Ooma Inc (OOMA)
Perkins Capital Management Inc sold out the holdings in Ooma Inc. The sale prices were between $8.1 and $12.3, with an estimated average price of $10.23.
Sold Out: Seagate Technology PLC (STX)
Perkins Capital Management Inc sold out the holdings in Seagate Technology PLC. The sale prices were between $38.91 and $50.51, with an estimated average price of $43.76.
Sold Out: SPS Commerce Inc (SPSC)
Perkins Capital Management Inc sold out the holdings in SPS Commerce Inc. The sale prices were between $55.26 and $64.07, with an estimated average price of $59.25.
Sold Out: Merit Medical Systems Inc (MMSI)
Perkins Capital Management Inc sold out the holdings in Merit Medical Systems Inc. The sale prices were between $28.2 and $38, with an estimated average price of $33.27.
Sold Out: Johnson Controls International PLC (JCI)
Perkins Capital Management Inc sold out the holdings in Johnson Controls International PLC. The sale prices were between $40.6 and $43.2, with an estimated average price of $41.84.
Reduced: Cardiovascular Systems Inc (CSII)
Perkins Capital Management Inc reduced to the holdings in Cardiovascular Systems Inc by 49.61%. The sale prices were between $28.11 and $32.89, with an estimated average price of $30.41. The stock is now traded at around $32.76. The impact to the portfolio due to this sale was -1.98%. Perkins Capital Management Inc still held 68,550 shares as of 2017-06-30.
Reduced: Antares Pharma Inc (ATRS)
Perkins Capital Management Inc reduced to the holdings in Antares Pharma Inc by 98.34%. The sale prices were between $2.43 and $3.23, with an estimated average price of $2.83. The stock is now traded at around $3.18. The impact to the portfolio due to this sale was -1.75%. Perkins Capital Management Inc still held 10,000 shares as of 2017-06-30.
Reduced: NeoGenomics Inc (NEO)
Perkins Capital Management Inc reduced to the holdings in NeoGenomics Inc by 40.65%. The sale prices were between $7.24 and $8.97, with an estimated average price of $7.92. The stock is now traded at around $9.33. The impact to the portfolio due to this sale was -1.74%. Perkins Capital Management Inc still held 308,800 shares as of 2017-06-30.
Reduced: LeMaitre Vascular Inc (LMAT)
Perkins Capital Management Inc reduced to the holdings in LeMaitre Vascular Inc by 21.56%. The sale prices were between $24.16 and $32.57, with an estimated average price of $28.77. The stock is now traded at around $29.04. The impact to the portfolio due to this sale was -0.6%. Perkins Capital Management Inc still held 85,250 shares as of 2017-06-30.
Reduced: BioScrip Inc (BIOS)
Perkins Capital Management Inc reduced to the holdings in BioScrip Inc by 77.29%. The sale prices were between $1.4 and $2.99, with an estimated average price of $1.88. The stock is now traded at around $2.98. The impact to the portfolio due to this sale was -0.43%. Perkins Capital Management Inc still held 70,500 shares as of 2017-06-30.
Reduced: Cogentix Medical Inc (CGNT)
Perkins Capital Management Inc reduced to the holdings in Cogentix Medical Inc by 22.75%. The sale prices were between $1.6 and $1.95, with an estimated average price of $1.72. The stock is now traded at around $1.83. The impact to the portfolio due to this sale was -0.36%. Perkins Capital Management Inc still held 645,303 shares as of 2017-06-30.
Warning! GuruFocus has detected 3 Warning Signs with CYTX. Click here to check it out.
CYTX 15-Year Financial Data
The intrinsic value of CYTX
Peter Lynch Chart of CYTX
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares reduced by 6.31% Abbott Laboratories ( ABT ) - 82,710 shares, 4.46% of the total portfolio. Perkins Capital Management Inc New Purchases: ABC , PNR , ZAGG , VERI, HDP, TEAR, DE, XPO, CTG, CDXS, Added Positions:CYTX, BX, INWK, VG, MRK, ENTL, VCEL, T, DAVE, JBLU, Reduced Positions:CSII, ATRS, NEO, LMAT, BIOS, AXGN, CGNT, RMTI, ARCI, LLY, Sold Out:TCMD, OOMA, STX, SPSC, MMSI, JCI, RIG, EGHT, DRAD, GEOS, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 554,792 shares, 10.31% of the total portfolio. Sold Out: Seagate Technology PLC (STX) Perkins Capital Management Inc sold out the holdings in Seagate Technology PLC. | Shares reduced by 6.31% Abbott Laboratories ( ABT ) - 82,710 shares, 4.46% of the total portfolio. Perkins Capital Management Inc New Purchases: ABC , PNR , ZAGG , VERI, HDP, TEAR, DE, XPO, CTG, CDXS, Added Positions:CYTX, BX, INWK, VG, MRK, ENTL, VCEL, T, DAVE, JBLU, Reduced Positions:CSII, ATRS, NEO, LMAT, BIOS, AXGN, CGNT, RMTI, ARCI, LLY, Sold Out:TCMD, OOMA, STX, SPSC, MMSI, JCI, RIG, EGHT, DRAD, GEOS, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 554,792 shares, 10.31% of the total portfolio. Shares reduced by 1.02% New Purchase: AmerisourceBergen Corp (ABC) Perkins Capital Management Inc initiated holdings in AmerisourceBergen Corp. | Shares reduced by 6.31% Abbott Laboratories ( ABT ) - 82,710 shares, 4.46% of the total portfolio. Perkins Capital Management Inc New Purchases: ABC , PNR , ZAGG , VERI, HDP, TEAR, DE, XPO, CTG, CDXS, Added Positions:CYTX, BX, INWK, VG, MRK, ENTL, VCEL, T, DAVE, JBLU, Reduced Positions:CSII, ATRS, NEO, LMAT, BIOS, AXGN, CGNT, RMTI, ARCI, LLY, Sold Out:TCMD, OOMA, STX, SPSC, MMSI, JCI, RIG, EGHT, DRAD, GEOS, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 554,792 shares, 10.31% of the total portfolio. Shares reduced by 1.02% New Purchase: AmerisourceBergen Corp (ABC) Perkins Capital Management Inc initiated holdings in AmerisourceBergen Corp. | Shares reduced by 6.31% Abbott Laboratories ( ABT ) - 82,710 shares, 4.46% of the total portfolio. Perkins Capital Management Inc New Purchases: ABC , PNR , ZAGG , VERI, HDP, TEAR, DE, XPO, CTG, CDXS, Added Positions:CYTX, BX, INWK, VG, MRK, ENTL, VCEL, T, DAVE, JBLU, Reduced Positions:CSII, ATRS, NEO, LMAT, BIOS, AXGN, CGNT, RMTI, ARCI, LLY, Sold Out:TCMD, OOMA, STX, SPSC, MMSI, JCI, RIG, EGHT, DRAD, GEOS, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 554,792 shares, 10.31% of the total portfolio. Shares reduced by 1.02% New Purchase: AmerisourceBergen Corp (ABC) Perkins Capital Management Inc initiated holdings in AmerisourceBergen Corp. |
33542.0 | 2017-07-26 00:00:00 UTC | Diamond Hill Capital Buys Discover Financial Services, Molson Coors Brewing Co, First Republic ... | ABT | https://www.nasdaq.com/articles/diamond-hill-capital-buys-discover-financial-services-molson-coors-brewing-co-first | nan | nan | Diamond Hill Capital
New Purchases: VRSK , AVT , ENDP , BK,
Added Positions:DFS, TAP, FRC, JNPR, PNC, JPM, JCI, VR, TGNA, KEX,
Reduced Positions:WFC, WLTW, CSCO, COF, ITW, PFE, C, NWL, AAN, DE,
Sold Out:UAM, CARS, ESS, GSOL, NVTR, T,
For the details of Diamond Hill Capital's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Diamond+Hill+Capital
These are the top 5 holdings of Diamond Hill Capital
Citigroup Inc ( C ) - 9,184,967 shares, 3.31% of the total portfolio. Shares reduced by 5.12%
Abbott Laboratories ( ABT ) - 11,964,081 shares, 3.14% of the total portfolio. Shares reduced by 2.66%
Alphabet Inc ( GOOGL ) - 466,073 shares, 2.34% of the total portfolio. Shares added by 1.21%
United Technologies Corp ( UTX ) - 3,517,626 shares, 2.32% of the total portfolio. Shares added by 0.56%
JPMorgan Chase & Co ( JPM ) - 4,668,366 shares, 2.3% of the total portfolio. Shares added by 12.98%
New Purchase: Verisk Analytics Inc (VRSK)
Diamond Hill Capital initiated holdings in Verisk Analytics Inc. The purchase prices were between $76.75 and $84.06, with an estimated average price of $80.9. The stock is now traded at around $86.95. The impact to the portfolio due to this purchase was 0.29%. The holdings were 634,263 shares as of 2017-06-30.
New Purchase: Avnet Inc (AVT)
Diamond Hill Capital initiated holdings in Avnet Inc. The purchase prices were between $35.96 and $45.76, with an estimated average price of $39.73. The stock is now traded at around $39.10. The impact to the portfolio due to this purchase was 0.14%. The holdings were 645,615 shares as of 2017-06-30.
New Purchase: Endo International PLC (ENDP)
Diamond Hill Capital initiated holdings in Endo International PLC. The purchase prices were between $10.29 and $13.78, with an estimated average price of $11.74. The stock is now traded at around $11.31. The impact to the portfolio due to this purchase was 0.03%. The holdings were 488,244 shares as of 2017-06-30.
New Purchase: Bank of New York Mellon Corp (BK)
Diamond Hill Capital initiated holdings in Bank of New York Mellon Corp. The purchase prices were between $46.2 and $51.02, with an estimated average price of $47.79. The stock is now traded at around $53.39. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 17,370 shares as of 2017-06-30.
Added: Discover Financial Services (DFS)
Diamond Hill Capital added to the holdings in Discover Financial Services by 1458.55%. The purchase prices were between $58.69 and $68.39, with an estimated average price of $62.04. The stock is now traded at around $63.14. The impact to the portfolio due to this purchase was 1.11%. The holdings were 3,559,909 shares as of 2017-06-30.
Added: Molson Coors Brewing Co (TAP)
Diamond Hill Capital added to the holdings in Molson Coors Brewing Co by 353.71%. The purchase prices were between $85.77 and $96.86, with an estimated average price of $92.8. The stock is now traded at around $88.89. The impact to the portfolio due to this purchase was 0.95%. The holdings were 2,627,608 shares as of 2017-06-30.
Added: First Republic Bank (FRC)
Diamond Hill Capital added to the holdings in First Republic Bank by 154.34%. The purchase prices were between $89.39 and $101.45, with an estimated average price of $94.41. The stock is now traded at around $100.29. The impact to the portfolio due to this purchase was 0.52%. The holdings were 1,600,977 shares as of 2017-06-30.
Added: Juniper Networks Inc (JNPR)
Diamond Hill Capital added to the holdings in Juniper Networks Inc by 39.96%. The purchase prices were between $27.56 and $30.89, with an estimated average price of $29.07. The stock is now traded at around $28.06. The impact to the portfolio due to this purchase was 0.49%. The holdings were 11,378,124 shares as of 2017-06-30.
Added: PNC Financial Services Group Inc (PNC)
Diamond Hill Capital added to the holdings in PNC Financial Services Group Inc by 62.70%. The purchase prices were between $115.8 and $125.25, with an estimated average price of $120.55. The stock is now traded at around $127.36. The impact to the portfolio due to this purchase was 0.41%. The holdings were 1,566,171 shares as of 2017-06-30.
Added: Johnson Controls International PLC (JCI)
Diamond Hill Capital added to the holdings in Johnson Controls International PLC by 20208.48%. The purchase prices were between $40.6 and $43.2, with an estimated average price of $41.84. The stock is now traded at around $43.35. The impact to the portfolio due to this purchase was 0.26%. The holdings were 1,120,419 shares as of 2017-06-30.
Sold Out: Universal American Corp (UAM)
Diamond Hill Capital sold out the holdings in Universal American Corp. The sale prices were between $9.97 and $9.99, with an estimated average price of $9.98.
Sold Out: Nuvectra Corp (NVTR)
Diamond Hill Capital sold out the holdings in Nuvectra Corp. The sale prices were between $6.36 and $13.89, with an estimated average price of $9.38.
Sold Out: Essex Property Trust Inc (ESS)
Diamond Hill Capital sold out the holdings in Essex Property Trust Inc. The sale prices were between $230.87 and $268.39, with an estimated average price of $250.97.
Sold Out: AT&T Inc (T)
Diamond Hill Capital sold out the holdings in AT&T Inc. The sale prices were between $37.46 and $41.69, with an estimated average price of $39.09.
Sold Out: Cars.com Inc (CARS)
Diamond Hill Capital sold out the holdings in Cars.com Inc. The sale prices were between $24.6 and $29.14, with an estimated average price of $26.62.
Sold Out: Global Sources Ltd (GSOL)
Diamond Hill Capital sold out the holdings in Global Sources Ltd. The sale prices were between $8.25 and $21.45, with an estimated average price of $14.22.
Reduced: Wells Fargo & Co (WFC)
Diamond Hill Capital reduced to the holdings in Wells Fargo & Co by 89.64%. The sale prices were between $51.14 and $55.78, with an estimated average price of $53.58. The stock is now traded at around $54.83. The impact to the portfolio due to this sale was -1.17%. Diamond Hill Capital still held 434,532 shares as of 2017-06-30.
Reduced: Willis Towers Watson PLC (WLTW)
Diamond Hill Capital reduced to the holdings in Willis Towers Watson PLC by 45.83%. The sale prices were between $126.28 and $149.65, with an estimated average price of $139.46. The stock is now traded at around $148.51. The impact to the portfolio due to this sale was -0.67%. Diamond Hill Capital still held 1,085,280 shares as of 2017-06-30.
Reduced: Cisco Systems Inc (CSCO)
Diamond Hill Capital reduced to the holdings in Cisco Systems Inc by 32.37%. The sale prices were between $31.21 and $34.39, with an estimated average price of $32.62. The stock is now traded at around $31.58. The impact to the portfolio due to this sale was -0.45%. Diamond Hill Capital still held 4,989,744 shares as of 2017-06-30.
Reduced: Illinois Tool Works Inc (ITW)
Diamond Hill Capital reduced to the holdings in Illinois Tool Works Inc by 33.8%. The sale prices were between $130.17 and $150.18, with an estimated average price of $139.3. The stock is now traded at around $140.07. The impact to the portfolio due to this sale was -0.37%. Diamond Hill Capital still held 964,119 shares as of 2017-06-30.
Reduced: Aaron's Inc (AAN)
Diamond Hill Capital reduced to the holdings in Aaron's Inc by 22.64%. The sale prices were between $29.25 and $40.12, with an estimated average price of $35.28. The stock is now traded at around $39.74. The impact to the portfolio due to this sale was -0.14%. Diamond Hill Capital still held 2,838,617 shares as of 2017-06-30.
Warning! GuruFocus has detected 2 Warning Signs with DFS. Click here to check it out.
DFS 15-Year Financial Data
The intrinsic value of DFS
Peter Lynch Chart of DFS
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares reduced by 5.12% Abbott Laboratories ( ABT ) - 11,964,081 shares, 3.14% of the total portfolio. Diamond Hill Capital New Purchases: VRSK , AVT , ENDP , BK, Added Positions:DFS, TAP, FRC, JNPR, PNC, JPM, JCI, VR, TGNA, KEX, Reduced Positions:WFC, WLTW, CSCO, COF, ITW, PFE, C, NWL, AAN, DE, Sold Out:UAM, CARS, ESS, GSOL, NVTR, T, For the details of Diamond Hill Capital's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Diamond+Hill+Capital These are the top 5 holdings of Diamond Hill Capital Citigroup Inc ( C ) - 9,184,967 shares, 3.31% of the total portfolio. Added: Johnson Controls International PLC (JCI) Diamond Hill Capital added to the holdings in Johnson Controls International PLC by 20208.48%. | Shares reduced by 5.12% Abbott Laboratories ( ABT ) - 11,964,081 shares, 3.14% of the total portfolio. Diamond Hill Capital New Purchases: VRSK , AVT , ENDP , BK, Added Positions:DFS, TAP, FRC, JNPR, PNC, JPM, JCI, VR, TGNA, KEX, Reduced Positions:WFC, WLTW, CSCO, COF, ITW, PFE, C, NWL, AAN, DE, Sold Out:UAM, CARS, ESS, GSOL, NVTR, T, For the details of Diamond Hill Capital's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Diamond+Hill+Capital These are the top 5 holdings of Diamond Hill Capital Citigroup Inc ( C ) - 9,184,967 shares, 3.31% of the total portfolio. Added: Johnson Controls International PLC (JCI) Diamond Hill Capital added to the holdings in Johnson Controls International PLC by 20208.48%. | Shares reduced by 5.12% Abbott Laboratories ( ABT ) - 11,964,081 shares, 3.14% of the total portfolio. Diamond Hill Capital New Purchases: VRSK , AVT , ENDP , BK, Added Positions:DFS, TAP, FRC, JNPR, PNC, JPM, JCI, VR, TGNA, KEX, Reduced Positions:WFC, WLTW, CSCO, COF, ITW, PFE, C, NWL, AAN, DE, Sold Out:UAM, CARS, ESS, GSOL, NVTR, T, For the details of Diamond Hill Capital's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Diamond+Hill+Capital These are the top 5 holdings of Diamond Hill Capital Citigroup Inc ( C ) - 9,184,967 shares, 3.31% of the total portfolio. Shares added by 12.98% New Purchase: Verisk Analytics Inc (VRSK) Diamond Hill Capital initiated holdings in Verisk Analytics Inc. | Shares reduced by 5.12% Abbott Laboratories ( ABT ) - 11,964,081 shares, 3.14% of the total portfolio. Diamond Hill Capital New Purchases: VRSK , AVT , ENDP , BK, Added Positions:DFS, TAP, FRC, JNPR, PNC, JPM, JCI, VR, TGNA, KEX, Reduced Positions:WFC, WLTW, CSCO, COF, ITW, PFE, C, NWL, AAN, DE, Sold Out:UAM, CARS, ESS, GSOL, NVTR, T, For the details of Diamond Hill Capital's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Diamond+Hill+Capital These are the top 5 holdings of Diamond Hill Capital Citigroup Inc ( C ) - 9,184,967 shares, 3.31% of the total portfolio. Sold Out: AT&T Inc (T) Diamond Hill Capital sold out the holdings in AT&T Inc. |
33543.0 | 2017-07-25 00:00:00 UTC | Health Care Sector Update for 07/25/2017: JNJ, PFE, ABT, MRK, AMGN, NVAX, BIIB, LLY | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07252017-jnj-pfe-abt-mrk-amgn-nvax-biib-lly-2017-07-25 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: -0.2%
ABT: flat
MRK: +0.2%
AMGN: +0.5%
Health care shares were mostly higher in pre-market trade Tuesday.
In sector news, Novavax ( NVAX ) slumped 19.2% after the company said l;ate Monday topline data were positive from its phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, but some investors were skeptical the data were as positive as the company said. Respected reporter Adam Feuerstein with STAT News tweeted the release is smoke and mirrors, as the positive news pertained to safety rather than efficacy. The company said new preclinical data on its RSV F Vaccine construct showed the company's construct is a stable prefusogenic RSV F antigen, distinctive from other candidates, that elicits potent neutralizing antibody responses to multiple key epitopes. But it also said a Phase 2 safety and immunogenicity study of its RSV F vaccine in 300 older adults showed that two doses were better than one in increasing immune responses. The company said it expects to initiate a Phase 2 efficacy trial in older adults in 2018.
In other sector news,
(+) BIIB (+4.1%) Posts Q2 results above Street marks, and lifts FY17 EPS guidance
(-) LLY (-0.8%) To delay resubmission of the new drug application for baricitinib to FDA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In sector news, Novavax ( NVAX ) slumped 19.2% after the company said l;ate Monday topline data were positive from its phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, but some investors were skeptical the data were as positive as the company said. But it also said a Phase 2 safety and immunogenicity study of its RSV F vaccine in 300 older adults showed that two doses were better than one in increasing immune responses. | ABT: flat In sector news, Novavax ( NVAX ) slumped 19.2% after the company said l;ate Monday topline data were positive from its phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, but some investors were skeptical the data were as positive as the company said. The company said new preclinical data on its RSV F Vaccine construct showed the company's construct is a stable prefusogenic RSV F antigen, distinctive from other candidates, that elicits potent neutralizing antibody responses to multiple key epitopes. | ABT: flat In sector news, Novavax ( NVAX ) slumped 19.2% after the company said l;ate Monday topline data were positive from its phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, but some investors were skeptical the data were as positive as the company said. The company said new preclinical data on its RSV F Vaccine construct showed the company's construct is a stable prefusogenic RSV F antigen, distinctive from other candidates, that elicits potent neutralizing antibody responses to multiple key epitopes. | ABT: flat Top Health Care stocks: In sector news, Novavax ( NVAX ) slumped 19.2% after the company said l;ate Monday topline data were positive from its phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, but some investors were skeptical the data were as positive as the company said. |
33544.0 | 2017-07-25 00:00:00 UTC | 3 Dividend Stocks That Are Perfect for Retirement | ABT | https://www.nasdaq.com/articles/3-dividend-stocks-are-perfect-retirement-2017-07-25 | nan | nan | If you're at the point in your investing life where you're adjusting your portfolio from higher-risk growth mode toward a safer asset allocation -- one designed to support you dependably through your retirement -- you'll probably appreciate low-volatility stocks that supply reliable, steadily rising streams of income.
We asked three Motley Fool investors to identify stocks that fit that bill, and they chose Lowe's (NYSE: LOW) , Johnson & Johnson (NYSE: JNJ) , and Altria (NYSE: MO) . Read on to learn why.
A strong dividend with a fair valuation
Brian Stoffel(Lowe's): Investors recently got spooked about the future of this home improvement retailer after Amazon (NASDAQ: AMZN) announced it would be partnering with Sears (NASDAQ: SHLD) to sell some Kenmore-branded appliances.
While that could cut into some business at Lowe's, I still consider the chain to be largely Amazon-proof. People aren't going to order two-by-fours and large appliances over the Internet when they have the option of visiting a store and seeing for their own eyes what they're paying for. Given that Lowes is half of a national near-duopoly in home improvement -- along with Home Depot -- I think its stock is a perfect pick for retirees.
And when it comes to valuation and dividends, I find Lowe's to be the better bet of the two. Lowe's currently trades at just 14 times free cash flow, while Home Depot sports a P/FCF ratio of almost 20. Moreover, while Lowe's current 2.1% dividend yield slightly trails Home Depot's, Lowe's has only had to use 26% of its free cash flow over the past year to cover it. And management has gone on record to say it plans to continue upping its payout.
Big cash flow, little drama
Keith Speights (Johnson & Johnson) : I'm not at the point of retirement yet. When I do retire, though, there are two major things I'll look for in a stock: solid cash flow and low volatility. The cash flow is important for a company to keep those nice dividend checks flowing. The low volatility will allow me to sleep well without worrying that the stock is likely to crash.
Johnson & Johnson is one of the best stocks around that meets both of these criteria. It's a bona fide cash cow , with free cash flow over the last 12 months of over $16 billion. This enables J&J to pay a nice dividend, which currently yields 2.54%. The healthcare giant also boasts an enviable track record of increasing its dividend -- it has done so for 54 years in a row.
That cash flow also allows Johnson & Johnson to invest for future growth. It plows nearly 12% of sales back into research and development. It has also been busy on the acquisition front, with buyouts this year of Abbott Labs ' (NYSE: ABT) medical optics business and the purchase of Swiss drugmaker Actelion.
What about volatility? J&J's beta is 0.68. Beta compares a stock's movement to that of the overall market. Values below 1.0 reflect an asset that is less volatile than average. Based on its beta value, J&J is roughly a third less volatile than the broader market. That's good.
There's probably no such thing as the "perfect stock" for retirees. However, with its big cash flow and little drama, Johnson & Johnson might come close.
No smoke, but it can still be on fire
Rich Duprey(Altria): Cigarette smoking is a dying habit, but millions of people still light up every day, and Altria remains the biggest U.S. producer of cigarettes, generating billions of dollars in sales and profits every year. And, with U.S. marketing rights for the MarkTen electronic cigarettes developed by its offspring, Philip Morris International (NYSE: PM) , as well as a collaborative agreement to market its new heat-not-burn (HNB) tobacco technology iQOS under the Marlboro brand, Altria can also cash in on Philip Morris' " smoke-free future ."
Were it not for regulators in most countries, this is where the tobacco industry would be hurrying. Because heating tobacco doesn't produce the kind of toxic chemicals burning it does, it is a safer way for smokers to get the tobacco flavor and nicotine hit they crave. Yet regulatory authorities have erected hurdles that make the process of proving that to their satisfaction much more difficult to achieve, and they're attempting to regulate e-cigs in the same way as they now regulate traditional, combustible cigarettes.
However, Philip Morris has surmounted those barriers and submitted to the FDA an application to have its iQOS HNB e-cig designated as a "reduced risk" product. Should the agency sign off on the label, it will give the company a huge competitive advantage over its rivals. While the competition would likely enjoy something of a halo effect from the designation, it would be Philip Morris and Altria that gain directly from being able to say their product is safer.
Tobacco stocks have always been attractive for their dividends and yields, and Altria with a payout of $2.44 a year that currently yields 3.3% is no different. It has raised its dividend every year since it spun off Philip Morris, and made a special dividend payment to shareholders following Anheuser-Busch InBev 's (NYSE: BUD) acquisition of SABMiller, in which it held a 10% stake. With its tobacco portfolio still throwing off cash, and with a stake in the new technology that could be smoking's future, Altria is a dividend stock retirees can be comfortable with.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Brian Stoffel owns shares of Amazon. Keith Speights has no position in any stocks mentioned. Rich Duprey has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Amazon, Anheuser-Busch InBev NV, and Johnson & Johnson. The Motley Fool recommends Home Depot and Lowe's. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has also been busy on the acquisition front, with buyouts this year of Abbott Labs ' (NYSE: ABT) medical optics business and the purchase of Swiss drugmaker Actelion. If you're at the point in your investing life where you're adjusting your portfolio from higher-risk growth mode toward a safer asset allocation -- one designed to support you dependably through your retirement -- you'll probably appreciate low-volatility stocks that supply reliable, steadily rising streams of income. However, Philip Morris has surmounted those barriers and submitted to the FDA an application to have its iQOS HNB e-cig designated as a "reduced risk" product. | It has also been busy on the acquisition front, with buyouts this year of Abbott Labs ' (NYSE: ABT) medical optics business and the purchase of Swiss drugmaker Actelion. We asked three Motley Fool investors to identify stocks that fit that bill, and they chose Lowe's (NYSE: LOW) , Johnson & Johnson (NYSE: JNJ) , and Altria (NYSE: MO) . Big cash flow, little drama Keith Speights (Johnson & Johnson) : I'm not at the point of retirement yet. | It has also been busy on the acquisition front, with buyouts this year of Abbott Labs ' (NYSE: ABT) medical optics business and the purchase of Swiss drugmaker Actelion. We asked three Motley Fool investors to identify stocks that fit that bill, and they chose Lowe's (NYSE: LOW) , Johnson & Johnson (NYSE: JNJ) , and Altria (NYSE: MO) . Moreover, while Lowe's current 2.1% dividend yield slightly trails Home Depot's, Lowe's has only had to use 26% of its free cash flow over the past year to cover it. | It has also been busy on the acquisition front, with buyouts this year of Abbott Labs ' (NYSE: ABT) medical optics business and the purchase of Swiss drugmaker Actelion. Big cash flow, little drama Keith Speights (Johnson & Johnson) : I'm not at the point of retirement yet. That cash flow also allows Johnson & Johnson to invest for future growth. |
33545.0 | 2017-07-25 00:00:00 UTC | Profit from the Dollar's Dip with These 5 S&P 500 Stocks | ABT | https://www.nasdaq.com/articles/profit-dollars-dip-these-5-sp-500-stocks-2017-07-25 | nan | nan | The Trump administration's failure to push through a new healthcare law has possibly sandbagged hopes of policy measures boosting stocks in the near future. In fact, investors now have little confidence left in the President's pre-poll promises and are starting to bank on fundamental concerns when evaluating investment options. Needless to say, earnings performance and the state of the economy feature at the top of a list of such factors.
Meanwhile, market watchers now believe that a falling dollar is just the tonic markets need. The decline in the greenback could provide equities with fresh upside by boosting earnings of commodity-centric and multinational companies. In a volatile scenario, investing in stocks of this nature, which are large enough to be included in the S&P 500, makes for a profitable option.
Policy Paralysis Fells Dollar
The dollar's recent set of declines has provided analysts with an opportunity to determine whether it could have a positive effect on corporate earnings. To understand the gravity of the situation, one need to look no further than the U.S. Dollar Index, which is down 8% year to date. In comparison, the S&P 500% has already gained 10.3% over the same period.
Immediately after Trump's surprise victory, the dollar soared on hopes that the President's growth-oriented and industry-friendly policies would boost the economy and earnings. However, repeated failures at pushing through policy proposals have left investors somewhat disenchanted. With little headway made on tax reforms, fiscal stimulus measures and a new healthcare law, the so called "Trump Trade" has experienced a reversal, leading to the greenback's decline.
Falling Dollar to Boost Earnings
Instead, investors have chosen to focus on the state of the economy, the reluctance of the Fed to raise rates and a likely strong second quarter earnings season. And a clutch of analysts now feel that a softer dollar is just the tonic earnings need.
While earnings felt the heat of a soaring dollar last year, a decline could be extremely beneficial this time around. Additionally, this phenomenon illustrates how expectations about the extent to which the Fed could hike rates have undergone a change.
A fall in the dollar usually has a positive impact on the price of commodities. This is why companies which stand to gain handsomely from the dollar's decline are those whose businesses are commodity centric or multinationals with significant overseas exposure. According to analysts at Morgan Stanley MS , S&P 500 earnings could increase by 0.5% for every 1% decline in the dollar.
The financial major explained that this factor impacts earnings on a rolling basis and its effects could become apparent in the second half of the year. By this logic, an 8% decline in the dollar's value by the end of the current year could boost 2018 earnings by 4%. If, as Morgan Stanley projects, the dollar declines by an additional 5%, earnings could grow by around 6.5%
Our Choices
Corporate earnings are likely to receive a welcome boost from the plunge in the dollar's value. This is likely to be especially beneficial to those companies which deal in commodities or those with primarily multinational operations.
Adding stocks of companies with a high percentage of overseas sales, according to Strategas Research Partners, and which make up the S&P 500 looks like a smart option at this juncture. We have narrowed down our search to the following stocks based on a good Zacks Rank and other relevant metrics.
Micron Technology, Inc.MU is one of the leading worldwide providers of semiconductor memory solutions.
Micron Technology has a Zacks Rank #1 (Strong Buy). Its expected earnings growth for the current year is more than 100%. Its earnings estimate for the current year has improved by 11.1% over the last 30 days.
NVIDIA CorporationNVDA offers digital media processors and related software for a wide range of visual computing platforms.
NVIDIA has a Zacks Rank #1. The company has expected earnings growth of 19.9% for the current year. Its earnings estimate for the current year has improved by 0.1% over the last 30 days.
Lam Research Corp.LRCX supplies wafer fabrication equipment and services to the semiconductor industry.
Lam Research has expected earnings growth of 11% for the current year. Its earnings estimate for the current year has improved by 1.9% over the last 30 days. The stock has a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Applied Materials, Inc.AMAT is one of the world's largest suppliers of equipment for the fabrication of semiconductor, flat panel liquid crystal displays (LCDs), and solar photovoltaic (PV) cells and modules.
Applied Materials has a Zacks Rank #2 (Buy). Its expected earnings growth for the current year is 77.1%. Its earnings estimate for the current year has improved by 0.3% over the last 30 days.
Abbott LaboratoriesABT discovers, develops, manufactures and sells a diversified line of health care products.
Abbott Laboratories has a Zacks Rank #2. The company has expected earnings growth of 12.3% for the current year. Its earnings estimate for the current year has improved by 0.5% over the last 30 days.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
NVIDIA Corporation (NVDA): Free Stock Analysis Report
Micron Technology, Inc. (MU): Free Stock Analysis Report
Lam Research Corporation (LRCX): Free Stock Analysis Report
Applied Materials, Inc. (AMAT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT discovers, develops, manufactures and sells a diversified line of health care products. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. With little headway made on tax reforms, fiscal stimulus measures and a new healthcare law, the so called "Trump Trade" has experienced a reversal, leading to the greenback's decline. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT discovers, develops, manufactures and sells a diversified line of health care products. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT discovers, develops, manufactures and sells a diversified line of health care products. By this logic, an 8% decline in the dollar's value by the end of the current year could boost 2018 earnings by 4%. | Abbott LaboratoriesABT discovers, develops, manufactures and sells a diversified line of health care products. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. By this logic, an 8% decline in the dollar's value by the end of the current year could boost 2018 earnings by 4%. |
33546.0 | 2017-07-24 00:00:00 UTC | Health Care Sector Update for 07/24/2017: JNJ, PFE, ABT, MRK, AMGN, WBMD, BMY, SRPT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07242017-jnj-pfe-abt-mrk-amgn-wbmd-bmy-srpt-2017-07-24 | nan | nan | Top Health Care stocks:
JNJ: -0.01%
PFE: +0.1%
ABT: -0.7%
MRK: +0.4%
AMGN: +0.2%
Health care shares were mostly higher in pre-market trade Monday.
In sector news, WebMD Health Corp ( WBMD ) was up 19.8% after it confirmed it has agreed to be bought by KKR's ( KKR ) Internet Brands, in a deal worth approximately $2.8 billion. Internet Brands will pay $66.50 per share in cash, a 30% premium to the share price on Feb. 15, the day before WebMD said it was starting a process to explore and evaluate potential strategic alternatives, and a 20% premium to the closing price on July 21. The deal is seen closing in Q4. Separately, WebMD said preliminary Q2 sales are approximately $176 million, up 5% from the year-ago period and above the CapIQ mean for $171.6 million. The company said its prior Q2 sales guidance was for $170 million to $173 million. Net income is seen approximately $18.9 million, an increase of approximately 6% from the prior year period.
In other sector news,
(+) BMY (+0.7%) Melanoma drug Yervoy secures expanded FDA indication to Include pediatric patients
(-) SRPT (-2.1%) To raise $250 million in stock offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly higher in pre-market trade Monday. Internet Brands will pay $66.50 per share in cash, a 30% premium to the share price on Feb. 15, the day before WebMD said it was starting a process to explore and evaluate potential strategic alternatives, and a 20% premium to the closing price on July 21. In other sector news, (+) BMY (+0.7%) Melanoma drug Yervoy secures expanded FDA indication to Include pediatric patients (-) SRPT (-2.1%) To raise $250 million in stock offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, WebMD Health Corp ( WBMD ) was up 19.8% after it confirmed it has agreed to be bought by KKR's ( KKR ) Internet Brands, in a deal worth approximately $2.8 billion. In other sector news, (+) BMY (+0.7%) Melanoma drug Yervoy secures expanded FDA indication to Include pediatric patients (-) SRPT (-2.1%) To raise $250 million in stock offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, WebMD Health Corp ( WBMD ) was up 19.8% after it confirmed it has agreed to be bought by KKR's ( KKR ) Internet Brands, in a deal worth approximately $2.8 billion. Internet Brands will pay $66.50 per share in cash, a 30% premium to the share price on Feb. 15, the day before WebMD said it was starting a process to explore and evaluate potential strategic alternatives, and a 20% premium to the closing price on July 21. In other sector news, (+) BMY (+0.7%) Melanoma drug Yervoy secures expanded FDA indication to Include pediatric patients (-) SRPT (-2.1%) To raise $250 million in stock offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly higher in pre-market trade Monday. Internet Brands will pay $66.50 per share in cash, a 30% premium to the share price on Feb. 15, the day before WebMD said it was starting a process to explore and evaluate potential strategic alternatives, and a 20% premium to the closing price on July 21. The deal is seen closing in Q4. |
33547.0 | 2017-07-24 00:00:00 UTC | Better Buy: Johnson & Johnson vs. AbbVie | ABT | https://www.nasdaq.com/articles/better-buy-johnson-johnson-vs-abbvie-2017-07-24 | nan | nan | It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right now? The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Here's how Johnson & Johnson and AbbVie compare.
Current products
Johnson & Johnson is basically three huge healthcare businesses rolled into one. None of them, though, is growing at impressive rates. J&J's consumer segment's revenue increased only 1.7% year over year in the second quarter. Medical devices performed better, with sales 4.9% higher than the prior-year period. However, the company's pharmaceuticals segment is struggling, with revenue slipping slightly in the second quarter compared with the same period in 2016.
What's going on with J&J's pharmaceuticals group? The biggest problem is that sales for its top-selling drug, Remicade, are falling as a result of competition from a new biosimilar . Although several other top drugs are performing exceptionally well, especially cancer drugs Darzalex and Imbruvica, the drag from Remicade is too much to offset.
AbbVie, on the other hand, continues to enjoy solid growth from its top product, Humira. The big biotech also makes more money off Imbruvica than J&J does. There have been mixed results for AbbVie's other products, but because their sales are low relative to Humira, the company is in great shape overall.
Winner: AbbVie.
Growth prospects
Johnson & Johnson has been busy buying other businesses to fuel its growth. Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. J&J also should continue to benefit from growth from several of the drugs in its current lineup. It also recently won approval for promising psoriasis drug Tremfya.
In addition, the healthcare giant's pipeline includes nearly 30 late-stage programs. Several of those are pursuing additional indications for already-approved drugs such as Darzalex and Xarelto. However, J&J also has new candidates in the development, including experimental prostate cancer drug apalutamide. Wall Street analysts project that the company will grow earnings by 6% annually over the next few years.
AbbVie hasn't made any big deals so far this year, but its past acquisitions activity has added several strong products to its pipeline. Perhaps the most important of these is experimental cancer drug Rova-T, which AbbVie picked up with its acquisition last year of Stemcentrx.
The company's pipeline also includes several other candidates with blockbuster sales potential. Elagolix is in late-stage studies for treating endometriosis and uterine fibroids. AbbVie has two promising late-stage autoimmune-disease candidates with risankizumab and upadacitinib. Thanks to expectations of sustained momentum for Humira and Imbruvica and these new products potentially on the way, Wall Street estimated AbbVie will grow earnings by more than 14% annually over the next five years.
Winner:AbbVie.
Dividend
Johnson & Johnson has been a longtime favorite for dividend investors. Its dividend currently yields 2.5%. J&J uses around 54% of earnings to fund the dividend program. The company has increased its dividend for 54 consecutive years.
AbbVie is also attractive when it comes to dividends, with a 3.54% yield. The biotech uses roughly 61% of earnings to fund its dividend. And if you count the period where AbbVie was part of its parent Abbott Labs, the company claims a track record of 45 years in a row of dividend increases.
Winner: AbbVie.
Valuation
Johnson & Johnson stock trades at just under 18 times expected earnings. AbbVie's shares trade at a little over 11 times expected earnings.
Winner: AbbVie.
Better buy
Based on the criteria we've examined, it's pretty clear that AbbVie emerges as the better pick right now. However, Johnson & Johnson has been a great stock to own in past years and is likely to continue its winning ways into the future.
The primary challenge for AbbVie is one that J&J is already facing: the threat of biosimilar competition for its top-selling drug. AbbVie is fighting in court to prevent biosimilars from entering the market. The company thinks it can hold off competition in the U.S. through 2022. If it's able to do so, that should give AbbVie ample time for its pipeline candidates to step up.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Thanks to expectations of sustained momentum for Humira and Imbruvica and these new products potentially on the way, Wall Street estimated AbbVie will grow earnings by more than 14% annually over the next five years. | Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Growth prospects Johnson & Johnson has been busy buying other businesses to fuel its growth. | Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. Here's how Johnson & Johnson and AbbVie compare. | Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. Although several other top drugs are performing exceptionally well, especially cancer drugs Darzalex and Imbruvica, the drag from Remicade is too much to offset. In addition, the healthcare giant's pipeline includes nearly 30 late-stage programs. |
33548.0 | 2017-07-22 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-07-22 | nan | nan | U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls for hard caps on prescription drug prices, and his administration continues to push for corporate tax reform that could bring back hundreds of billions in foreign profits currently stored overseas.
The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. With this in mind, let's consider which of these top dividend pharma stocks is the better buy right now.
AbbVie: Is the best yet to come?
AbbVie, a dividend aristocrat by virtue of its separation from Abbott Laboratories in 2013, has more than proven its value to shareholders by producing industry-leading levels of both top-line and dividend growth over the past four years. But the drugmaker has reached a crossroads of sorts following the patent expiration of its main growth driver Humira. Long story short, AbbVie is banking on its deliberate pivot to oncology to keep the growth party rolling.
Through a number of acquisitions in recent years, AbbVie has built one of the most valuable oncology pipelines in the industry. Exciting experimental products like Rova-T for small-cell lung cancer, for instance, are expected to complement the drugmaker's high-value blood cancer drug Imbruvica in the near future. The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022.
AbbVie, though, does have some other extremely promising growth drivers outside of oncology. The drugmaker's next-generation hepatitis C therapy, composed of glecaprevir and pibrentasvir, appears primed to take a big chunk out of Gilead Sciences ' market share. This novel combo, after all, is likely to gain approval as an eight-week regimen across a variety of genotypes -- giving it a distinct competitive advantage over most of Gilead's therapies that typically require at least 12 weeks of treatment.
Now that AbbVie no longer has to seriously worry about a hard cap on Humira's ever-growing price tag, and the possibility of deleveraging its balance sheet following corporate tax reform in the U.S. remains in play, this drugmaker's best days may indeed be yet to come.
Johnson & Johnson: The power of diversification
It's no secret that biosimilars are having a negative impact on J&J's all-important pharmaceutical segment. Sales of the company's blockbuster anti-inflammatory medicine Remicade, for instance, have been slipping in recent quarters, presumably because of competition from Pfizer 's copycat medicine Inflectra.
Most importantly, though, the considerable drag emanating from Remicade's downward trend has also been offsetting the spectacular growth from newer products, such as the multiple myeloma drug Darzalex. As proof, J&J reported that total pharma sales only grew by 1% in the second quarter of 2017, despite Darzalex's sales rising by a whopping 177% to $299 million for the three-month period.
The good news is that J&J has addressed this issue head on by first spending $30 billion to acquire Actelion's portfolio of pulmonary arterial hypertension medicines, as well as maintaining a top-flight clinical pipeline that sports numerous blockbuster candidates. In fact, J&J's late-stage pipeline is currently ranked second in terms of net present value, falling behind only AbbVie's on this particular metric.
The point is that J&J's highly diversified pipeline and pharma product portfolio have clearly been an important counterbalance to the ongoing patent cliff, as well as the emergence of unexpectedly strong disruptive competitive threats in the past few years. And corporate tax reform, if instituted, should allow J&J to further diversify its pharma segment through additional M&A activity.
Which stock is the better buy?
This is a really tough matchup. Both companies offer stellar growth prospects, top notch dividends, and best-in-class clinical pipelines. So in a sense, you really can't go wrong with either stock. Having said that, J&J is probably the better buy simply because of its far more diversified product portfolio. AbbVie, after all, still relies on Humira for about 60% of its total sales . So while this unbalanced revenue mix should flatten out as the company's oncology pipeline matures, J&J is already proving beyond the shadow of a doubt that there's safety in numbers.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
George Budwell owns shares of Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. The Motley Fool has the following options: short August 2017 $75 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Now that AbbVie no longer has to seriously worry about a hard cap on Humira's ever-growing price tag, and the possibility of deleveraging its balance sheet following corporate tax reform in the U.S. remains in play, this drugmaker's best days may indeed be yet to come. The good news is that J&J has addressed this issue head on by first spending $30 billion to acquire Actelion's portfolio of pulmonary arterial hypertension medicines, as well as maintaining a top-flight clinical pipeline that sports numerous blockbuster candidates. The point is that J&J's highly diversified pipeline and pharma product portfolio have clearly been an important counterbalance to the ongoing patent cliff, as well as the emergence of unexpectedly strong disruptive competitive threats in the past few years. | The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. | The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. 10 stocks we like better than Johnson & Johnson When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | AbbVie: Is the best yet to come? The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. |
33549.0 | 2017-07-21 00:00:00 UTC | Company News for July 21, 2017 | ABT | https://www.nasdaq.com/articles/company-news-for-july-21-2017-2017-07-21 | nan | nan | • Shares of Abbott Laboratories ABT gained 2.9% after the company reported second-quarter 2017 earnings of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate
• Shares of Kinder Morgan Inc KMI soared 4.5% after the company announced a dividend hike and a share-buyback plan
• Shares of Philip Morris International Inc. PM declined 1.5% after the company reported second quarter earnings per share of $1.14 that missed the Zacks Consensus Estimate of $1.23
• Shares of Travelers Companies Inc TRV dropped 1.5% after the company posted second-quarter 2017 earnings of $1.92 per share that missed the Zacks Consensus Estimate of $2.07
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
The Travelers Companies, Inc. (TRV): Free Stock Analysis Report
Kinder Morgan, Inc. (KMI): Free Stock Analysis Report
Philip Morris International Inc (PM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT gained 2.9% after the company reported second-quarter 2017 earnings of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate • Shares of Kinder Morgan Inc KMI soared 4.5% after the company announced a dividend hike and a share-buyback plan • Shares of Philip Morris International Inc. PM declined 1.5% after the company reported second quarter earnings per share of $1.14 that missed the Zacks Consensus Estimate of $1.23 • Shares of Travelers Companies Inc TRV dropped 1.5% after the company posted second-quarter 2017 earnings of $1.92 per share that missed the Zacks Consensus Estimate of $2.07 Want the latest recommendations from Zacks Investment Research? Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report The Travelers Companies, Inc. (TRV): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report Philip Morris International Inc (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT gained 2.9% after the company reported second-quarter 2017 earnings of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate • Shares of Kinder Morgan Inc KMI soared 4.5% after the company announced a dividend hike and a share-buyback plan • Shares of Philip Morris International Inc. PM declined 1.5% after the company reported second quarter earnings per share of $1.14 that missed the Zacks Consensus Estimate of $1.23 • Shares of Travelers Companies Inc TRV dropped 1.5% after the company posted second-quarter 2017 earnings of $1.92 per share that missed the Zacks Consensus Estimate of $2.07 Want the latest recommendations from Zacks Investment Research? Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report The Travelers Companies, Inc. (TRV): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report Philip Morris International Inc (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT gained 2.9% after the company reported second-quarter 2017 earnings of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate • Shares of Kinder Morgan Inc KMI soared 4.5% after the company announced a dividend hike and a share-buyback plan • Shares of Philip Morris International Inc. PM declined 1.5% after the company reported second quarter earnings per share of $1.14 that missed the Zacks Consensus Estimate of $1.23 • Shares of Travelers Companies Inc TRV dropped 1.5% after the company posted second-quarter 2017 earnings of $1.92 per share that missed the Zacks Consensus Estimate of $2.07 Want the latest recommendations from Zacks Investment Research? Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report The Travelers Companies, Inc. (TRV): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report Philip Morris International Inc (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ABT gained 2.9% after the company reported second-quarter 2017 earnings of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate • Shares of Kinder Morgan Inc KMI soared 4.5% after the company announced a dividend hike and a share-buyback plan • Shares of Philip Morris International Inc. PM declined 1.5% after the company reported second quarter earnings per share of $1.14 that missed the Zacks Consensus Estimate of $1.23 • Shares of Travelers Companies Inc TRV dropped 1.5% after the company posted second-quarter 2017 earnings of $1.92 per share that missed the Zacks Consensus Estimate of $2.07 Want the latest recommendations from Zacks Investment Research? Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report The Travelers Companies, Inc. (TRV): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report Philip Morris International Inc (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
33550.0 | 2017-07-21 00:00:00 UTC | Health Care Sector Update for 07/21/2017: JNJ, PFE, ABT, MRK, AMGN, AEZS, BCLI, RH | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07212017-jnj-pfe-abt-mrk-amgn-aezs-bcli-rh-2017-07-21 | nan | nan | Top Health Care stocks:
JNJ: -0.6%
PFE: +0.03%
ABT: +0.3%
MRK: flat
AMGN: flat
Health care shares were mostly mixed in pre-market trade Friday.
In sector news, Aeterna Zentaris ( AEZS ) was up 14.3% after saying it has formed a special committee of independent directors to consider and evaluate various strategic and financing alternatives available to the company. The alternatives include continuing to execute on its existing business plan and/or considering and recommending changes to the company's management and governance. On July 18, the company said that it has been notified by the U.S. Food and Drug Administration that a new drug application seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults has been accepted as a complete response to the FDA's Nov. 5, 2014 complete response letter and granted a PDUFA date of Dec. 30. The company said it has reached an important point in its evolution and wishes to conduct a strategic review of its plans, resources and opportunities, in order to best position itself to maximize stakeholder value.
In other sector news,
(+) BCLI (+0.5%) Wins $16 million grant to study ALS treatment
(-) RH (-1.1%) Deutsche Bank downgrades shares to hold from buy with an $80 price target due to valuation
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Aeterna Zentaris ( AEZS ) was up 14.3% after saying it has formed a special committee of independent directors to consider and evaluate various strategic and financing alternatives available to the company. The company said it has reached an important point in its evolution and wishes to conduct a strategic review of its plans, resources and opportunities, in order to best position itself to maximize stakeholder value. In other sector news, (+) BCLI (+0.5%) Wins $16 million grant to study ALS treatment (-) RH (-1.1%) Deutsche Bank downgrades shares to hold from buy with an $80 price target due to valuation The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat AMGN: flat Health care shares were mostly mixed in pre-market trade Friday. In other sector news, (+) BCLI (+0.5%) Wins $16 million grant to study ALS treatment (-) RH (-1.1%) Deutsche Bank downgrades shares to hold from buy with an $80 price target due to valuation The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat AMGN: flat Health care shares were mostly mixed in pre-market trade Friday. On July 18, the company said that it has been notified by the U.S. Food and Drug Administration that a new drug application seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults has been accepted as a complete response to the FDA's Nov. 5, 2014 complete response letter and granted a PDUFA date of Dec. 30. In other sector news, (+) BCLI (+0.5%) Wins $16 million grant to study ALS treatment (-) RH (-1.1%) Deutsche Bank downgrades shares to hold from buy with an $80 price target due to valuation The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: MRK: flat AMGN: flat Health care shares were mostly mixed in pre-market trade Friday. In sector news, Aeterna Zentaris ( AEZS ) was up 14.3% after saying it has formed a special committee of independent directors to consider and evaluate various strategic and financing alternatives available to the company. |
33551.0 | 2017-07-20 00:00:00 UTC | Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q2-earnings-and-sales-view-up-2017-07-20 | nan | nan | Abbott LaboratoriesABT reported second-quarter 2017 adjusted earnings from continuing operations of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. This adjusted quarterly number also remained ahead of the company's guidance range of 59 cents to 61 cents.
Reported earnings for the quarter came in at 15 cents per share, way below the year-ago number of 40 cents.
Second-quarter worldwide sales came in at $6.63 billion, up 24.4% year over year on a reported basis. This quarterly figure also remains slightly ahead of the Zacks Consensus Estimate of $6.62 billion.
On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 2.9% year over year in the reported quarter.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
Quarter in Detail
Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 4.1% on a reported basis (up 3.5% on comparable operational basis) to $1,021 billion. There was a positive impact of 0.6% on the back of currency fluctuations. Sales in key emerging markets increased 5.8% (up 4.6%), driven by strong growth in Russia, China and several countries across Latin America. However, this positive effect was partially offset by the impact associated with implementation of a new Goods and Services Tax (GST) system in India.
The Medical Devices business sales spiked 89.2% on a reported basis to $2.59 billion. However, on a comparable operational basisexcluding the impact from the favorable resolution of a third-party royalty agreement last year, sales increased 3.2%.
Cardiovascular and Neuromodulation sales soared 189% on a reported basis (up 0.9% on comparable operational basis) on growth in Electrophysiology, Structural Heart and Neuromodulation. Vascular product sales were up 6%, while Structural Heart business grew 9.1% year over yearon a comparable operational basis.
Diabetes Care sales improved 18.7% on a reported basis (up 21.3%), driven by double-digit international sales growth, led by continued consumer uptake of FreeStyle Libre - the revolutionary continuous glucose monitoring system of Abbott Labs.
Nutrition sales slipped 0.6% year over year on a reported basis (up 0.5% on a comparable operational basis). Unfavorable foreign exchange impacted sales by a marginal 1.1%. Pediatric Nutrition sales increased 2.5% on a comparable operational basis. Adult Nutrition sales however, decreased 2% on a comparable operational basis.
Diagnostics sales rose 3.8% year over year (up 5.4% on a comparable operational basis). While Core Laboratory sales increased 6.1%, Point of Care Diagnostics sales grew 8.9%, both on a comparable operational basis. Molecular Diagnostics sales were down 4.1% as strong growth in the infectious disease testing business was partially offset by the planned scale-down of the genetics business.
2017 Guidance
Abbott Labs raised its full-year 2017 guidance. The company forecasts earnings per share from continuing operations to remain within the range of $1.03 to $1.13 from earlier range of 92 cents to $1.02. Adjusting certain net specified items for the full year, the adjusted earnings per share from continuing operations are expected to stay within a band of $2.43-$2.53 (earlier guidance was $2.40-$2.50). The current Zacks Consensus Estimate is pegged at $2.47, at the midpoint of the projected range.
Our Take
One more time, Abbott Labs successfully exceeded the Zacks Consensus Estimate on both earnings and sales front. We are optimistic about the company's strong and consistent EPD and Medical Devices performance. However, these strong performances were to some extent offset by sluggish Nutrition business.
However, the company stands to benefit from the recently completed acquisition of St. Jude Medical, which has already started offering it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. Looking forward to achieving synergy benefits, the company has raised its 2017 outlook buoying investors' confidence on the stock.
In 2017, the company plans to execute its existing operating model which focuses on selling portfolio in core therapeutic areas. This will lead to the creation of unique channel opportunities in differentiated relationships with physicians, retailers and pharmacies, looking to offer a complete line of solutions to treat prominent local health conditions. Also, Abbott Labs has plans to beef up its development capabilities with an expanded EPD innovation center in India.
However, India's transition to new tax system has significantly hampered growth during the reported quarter. Per the company, if this transitory impact of a new GST could be eliminated, the total EPD sales would have grown in the high-single digits in the reported quarter.
Abbott Labs currently carries a Zacks Rank #2 (Buy).
Stocks to Consider
Better-ranked medical stocks are Mesa Laboratories, Inc. MLAB , INSYS Therapeutics, Inc. INSY and Align Technology, Inc. ALGN . Notably, INSYS Therapeutics sports a Zacks Rank #1 (Strong Buy), while Mesa Laboratories and Align Technology carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% for the last four quarters. The stock has added roughly 8.9% over the last three months.
INSYS Therapeutics has long-term expected earnings growth rate of 20%. The stock has rallied around 24.3% over the last three months.
Align Technology has expected long-term adjusted earnings growth of almost 24.1%. The stock has surged roughly 34.5% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report
Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported second-quarter 2017 adjusted earnings from continuing operations of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company stands to benefit from the recently completed acquisition of St. Jude Medical, which has already started offering it an industry leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported second-quarter 2017 adjusted earnings from continuing operations of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Quarter in Detail Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported second-quarter 2017 adjusted earnings from continuing operations of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 2.9% year over year in the reported quarter. | Abbott LaboratoriesABT reported second-quarter 2017 adjusted earnings from continuing operations of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. EPD sales were up 4.1% on a reported basis (up 3.5% on comparable operational basis) to $1,021 billion. |
33552.0 | 2017-07-20 00:00:00 UTC | Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales | ABT | https://www.nasdaq.com/articles/abbott-abt-tops-earnings-estimates-in-q2-misses-on-sales-2017-07-20 | nan | nan | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.67%.
Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's second quarter 2017 earnings report which was just released. (You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : The Zacks Consensus Estimate remained steady at 60 cents per share over the last 60 days. Abbott Labs' second quarter 2017 earnings per share from continuing operations of 62 cents outpaced this estimate by 3.33%.
Revenues : Abbott Labs posted second quarter revenues of $6.60 billion lagging behind the Zacks Consensus Estimate for revenues of $6.62 billion.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Key Stats: Worldwide Nutrition sales decreased 0.6% on a reported basis in the second quarter to $1.73 billion while worldwide Diagnostics sales increased 3.8% on a reported basis to $1.27 billion while total Established Pharmaceuticals sales increased 4.1% on a reported basis to $1.02 billion. Revenues of Worldwide Medical Devices increased 89.2% on a reported basis to $2.59 billion.
Major Factors: Per management, Abbott's second quarter performance reflects a strong start to the year 2017. Management raised its guidance range for reported EPS from continuing operations in the range of $2.43 to $2.53 . The integration of St. Jude is currently going on and its recently launched products are contributing to double-digit sales growth across several areas of Abbott's Medical Devices business.
Stock Price: Following the earnings release, share prices rose 1.15% during the pre-market trading session.
Check back later for our full write up on this Abbott Labs earnings report later!
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce d"the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's second quarter 2017 earnings report which was just released. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs' second quarter 2017 earnings per share from continuing operations of 62 cents outpaced this estimate by 3.33%. |
33553.0 | 2017-07-20 00:00:00 UTC | Health Care Sector Update for 07/20/2017: JNJ, PFE, ABT, MRK, AMGN, BVXV, GSK, PFE | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07202017-jnj-pfe-abt-mrk-amgn-bvxv-gsk-pfe-2017-07-20 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: -0.6%
ABT: +0.3%
MRK: flat
AMGN: flat
Health care shares were mostly inactive in pre-market trade Thursday.
In sector news, BiondVax Pharmaceuticals ( BVXV ) rose 11.7% after it said its mid-stage study of flu vaccine candidate M-001 has shown positive results, meeting its endpoints of safety and influenza-specific cellular immune responses. The company said it is considering taking the opportunity to proceed directly to testing the clinical efficacy of the experimental vaccine alone in a pivotal phase 3 clinical trial, with clinical efficacy planned to be assessed by measuring reduction of flu illness rate and severity.
In other sector news,
(+) GSK (+0.5%) Sells raxibacumab to Emergent Biosolutions for upfront payment of $76 million
(-) PFE (-0.6%) Obtains Europe right to Cresemba for life-threatening fungal infections in immunocompromised patients
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, BiondVax Pharmaceuticals ( BVXV ) rose 11.7% after it said its mid-stage study of flu vaccine candidate M-001 has shown positive results, meeting its endpoints of safety and influenza-specific cellular immune responses. The company said it is considering taking the opportunity to proceed directly to testing the clinical efficacy of the experimental vaccine alone in a pivotal phase 3 clinical trial, with clinical efficacy planned to be assessed by measuring reduction of flu illness rate and severity. In other sector news, (+) GSK (+0.5%) Sells raxibacumab to Emergent Biosolutions for upfront payment of $76 million (-) PFE (-0.6%) Obtains Europe right to Cresemba for life-threatening fungal infections in immunocompromised patients The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trade Thursday. In other sector news, (+) GSK (+0.5%) Sells raxibacumab to Emergent Biosolutions for upfront payment of $76 million (-) PFE (-0.6%) Obtains Europe right to Cresemba for life-threatening fungal infections in immunocompromised patients The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trade Thursday. The company said it is considering taking the opportunity to proceed directly to testing the clinical efficacy of the experimental vaccine alone in a pivotal phase 3 clinical trial, with clinical efficacy planned to be assessed by measuring reduction of flu illness rate and severity. In other sector news, (+) GSK (+0.5%) Sells raxibacumab to Emergent Biosolutions for upfront payment of $76 million (-) PFE (-0.6%) Obtains Europe right to Cresemba for life-threatening fungal infections in immunocompromised patients The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: JNJ: flat MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trade Thursday. In sector news, BiondVax Pharmaceuticals ( BVXV ) rose 11.7% after it said its mid-stage study of flu vaccine candidate M-001 has shown positive results, meeting its endpoints of safety and influenza-specific cellular immune responses. |
33554.0 | 2017-07-19 00:00:00 UTC | Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More | ABT | https://www.nasdaq.com/articles/medical-product-stocks-earnings-on-jul-20%3A-abt-isrg-more-2017-07-19 | nan | nan | The second-quarter earnings season is in its nascent stage with 30 S&P 500 participants having reported results as of Jul 14. According to the latest Earnings Preview , the earnings cycle has witnessed an encouraging start, courtesy of stable bank results. Total earnings for these members have gone up 13.8% on 6.0% increase in revenues. The uptrend was the result of reduced regulatory burden, tax law changes and an improved outlook for the domestic economy.
Per the latest Earnings Preview report, the second-quarter earnings for the S&P 500 companies are expected to be up 6.6% from the year-ago quarter on 4.5% higher revenues. With the majority of earnings yet to be released, the next fortnight will be crucial in deciding whether this quarter will turn out to be a game changer. Irrespective of the outcome, investors focusing on the Medical sector can expect good news.
The medical sector, one of the 16 broader Zacks sectors, is expected to witness 3.7% higher revenues in the quarter along with a decline of 1.0% in revenues. Investors are adopting a wait and watch about the space as the Zacks categorized Medical - Products industry has registered growth of 0.55% in the last one month, underperforming the S&P 500 Index that gained around 0.86%. The market remained jittery for a major part of the month due to uncertainties surrounding the future of the healthcare act.
Let's take a sneak peek into the performance of four major medical product companies that are expected to report earnings early next week.
Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott has been on a healthy growth trajectory in Established Pharmaceuticals Division (EPD) business. The company has delivered encouraging operational sales growth in the trailing few quarters. However, the absence of any substantial advancement in this division in the recent past has compelled the company to maintain low expectations at high single-digit growth in the yet-to-be reported quarter. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Our proven model does not conclusively show that Abbott is likely to beat earnings this quarter. This is because Abbott Laboratories has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). That is because both the Most Accurate estimate and the Zacks Consensus Estimate are at 60 cents. Abbott's Zacks Rank #2 increases the predictive power of ESP. However, the company's 0.00% ESP makes surprise prediction difficult. (Read more: Can Abbott Laboratories Pull a Surprise in Q2 Earnings? )
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Intuitive Surgical Inc.ISRG is set to report second-quarter results after the closing bell. We believe that growing adoption of Intuitive Surgical's da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key growth catalyst for the company. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter. This is because Intuitive Surgical currently has an Earnings ESP of 0.00% and a Zacks Rank #3 (Hold). This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $4.86. (Read more: Will Intuitive Surgical Surprise in Q2 Earnings? ).
Intuitive Surgical, Inc. Price and EPS Surprise
Intuitive Surgical, Inc. Price and EPS Surprise | Intuitive Surgical, Inc. Quote
Headquartered in Watertown, MA, athenahealth Inc.ATHN , through its cloud-based network provides services that manage the administrative duties of medical providers. The company's software platform handles billing management, quality measurement and reporting, clinical documentation and data exchange, patient communication and referrals and many other related tasks.
The company is scheduled to report second-quarter earnings. We believe that the company's strong product portfolio, expanding physician base and unique business model will boost prospects for the company. However, our proven model does not conclusively show that the company is likely to beat on earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%. (Read more: What's in Store for athenahealth in Q2 Earnings? ).
athenahealth, Inc. Price and EPS Surprise
athenahealth, Inc. Price and EPS Surprise | athenahealth, Inc. Quote
Abaxis, Inc.ABAX is scheduled to report its second-quarter 2017. It is a California-based manufacturer of portable Medical (human) and Veterinary (animal) blood analysis systems that provide clinicians with rapid blood constituent measurements in medical and veterinarian markets worldwide.
Abaxis currently carries a Zacks Rank #3 (Hold) and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 32 cents.
ABAXIS, Inc. Price and EPS Surprise
ABAXIS, Inc. Price and EPS Surprise | ABAXIS, Inc. Quote
Irrespective of an earnings beat or miss, investors should focus on companies' fundamentals to make investment decisions. Therefore, don't forget to check our full write-up on earnings releases of these stocks later.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
athenahealth, Inc. (ATHN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
ABAXIS, Inc. (ABAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. We believe that growing adoption of Intuitive Surgical's da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key growth catalyst for the company. | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Intuitive Surgical Inc.ISRG is set to report second-quarter results after the closing bell. | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Intuitive Surgical Inc.ISRG is set to report second-quarter results after the closing bell. | Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. Per the latest Earnings Preview report, the second-quarter earnings for the S&P 500 companies are expected to be up 6.6% from the year-ago quarter on 4.5% higher revenues. |
33555.0 | 2017-07-19 00:00:00 UTC | Pre-Market Earnings Report for July 20, 2017 : PM, UNP, ABT, DHR, BK, BBT, TRV, SHW, PPG, BX, KEY, RCI | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-july-20-2017-pm-unp-abt-dhr-bk-bbt-trv-shw-ppg-bx-key-rci-2017 | nan | nan | The following companies are expected to report earnings prior to market open on 07/20/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Philip Morris International Inc ( PM ) is reporting for the quarter ending June 30, 2017. The tobacco company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.23. This value represents a 6.96% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for PM is 24.42 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Union Pacific Corporation ( UNP ) is reporting for the quarter ending June 30, 2017. The transportation (rail) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.37. This value represents a 17.09% increase compared to the same quarter last year. UNP missed the consensus earnings per share in the 3rd calendar quarter of 2016 by -2.16%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for UNP is 19.03 vs. an industry ratio of 18.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2017. The medical products company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.60. This value represents a 9.09% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 11.63%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 19.73 vs. an industry ratio of -5.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Danaher Corporation ( DHR ) is reporting for the quarter ending June 30, 2017. The diversified operations company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.97. This value represents a 22.40% decrease compared to the same quarter last year. In the past year DHR has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1.19%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for DHR is 21.81 vs. an industry ratio of 14.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Bank Of New York Mellon Corporation ( BK ) is reporting for the quarter ending June 30, 2017. The bank company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.84. This value represents a 10.53% increase compared to the same quarter last year. BK missed the consensus earnings per share in the 4th calendar quarter of 2016 by -1.28%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BK is 15.29 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry.
BB&T Corporation ( BBT ) is reporting for the quarter ending June 30, 2017. The bank company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.77. This value represents a 8.45% increase compared to the same quarter last year. In the past year BBT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BBT is 14.39 vs. an industry ratio of 14.90.
The Travelers Companies, Inc. ( TRV ) is reporting for the quarter ending June 30, 2017. The insurance (property & casualty) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $2.08. This value represents a 5.45% decrease compared to the same quarter last year. TRV missed the consensus earnings per share in the 1st calendar quarter of 2017 by -10%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for TRV is 13.90 vs. an industry ratio of 18.50.
Sherwin-Williams Company ( SHW ) is reporting for the quarter ending June 30, 2017. The paint company's consensus earnings per share forecast from the 8 analysts that follow the stock is $4.55. This value represents a 12.07% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for SHW is 24.15 vs. an industry ratio of 22.40, implying that they will have a higher earnings growth than their competitors in the same industry.
PPG Industries, Inc. ( PPG ) is reporting for the quarter ending June 30, 2017. The chemical company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.80. This value represents a 2.70% decrease compared to the same quarter last year. In the past year PPG has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for PPG is 18.37 vs. an industry ratio of 16.80, implying that they will have a higher earnings growth than their competitors in the same industry.
The Blackstone Group L.P. ( BX ) is reporting for the quarter ending June 30, 2017. The finance/investment management company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.60. This value represents a 36.36% increase compared to the same quarter last year. In the past year BX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 18.84%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BX is 12.55 vs. an industry ratio of 11.40, implying that they will have a higher earnings growth than their competitors in the same industry.
KeyCorp ( KEY ) is reporting for the quarter ending June 30, 2017. The bank company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.34. This value represents a 25.93% increase compared to the same quarter last year. KEY missed the consensus earnings per share in the 2nd calendar quarter of 2016 by -3.57%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for KEY is 13.54 vs. an industry ratio of 14.90.
Rogers Communication, Inc. ( RCI ) is reporting for the quarter ending June 30, 2017. The cable tv company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.71. This value represents a 14.52% increase compared to the same quarter last year. In the past year RCI Zacks Investment Research reports that the 2017 Price to Earnings ratio for RCI is 19.63 vs. an industry ratio of 12.00, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 19.73 vs. an industry ratio of -5.70, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 19.73 vs. an industry ratio of -5.70, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 19.73 vs. an industry ratio of -5.70, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2017. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2017. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 19.73 vs. an industry ratio of -5.70, implying that they will have a higher earnings growth than their competitors in the same industry. |
33556.0 | 2017-07-19 00:00:00 UTC | The Hottest Earnings Charts of the Week | ABT | https://www.nasdaq.com/articles/hottest-earnings-charts-week-2017-07-19 | nan | nan | Earnings season is picking up steam.
This week is key because there will be a big cross section of names reporting earnings from many different sectors including the railroads, big industrials, technology and regional banks.
We should get a good look at the US and global economy through these reports. Is it as good as everyone has been saying?
It's not easy to beat the estimate nearly every quarter for years. But these companies have been doing just that.
But just because you have a great track record doesn't mean you will always continue to beat.
Who will keep their earnings streaks alive this quarter?
5 Hot Earnings Charts
1. Abbott Labs ABT hasn't missed in five years. Shares have been in a narrow trading range for most of that time but recently have started to trickle up. Could this finally be the breakout everyone has been waiting for?
2. PPG Industries PPG has a great track record, with just 1 miss in 2013. Shares have been stuck the last 2 years. Is it time for the industrials to make a move higher?
3. Snap-On SNA hasn't missed in 5 years but investors have grown leery of the shares as they have been treading water. What will it take for them to resume their upward momentum?
4. Microsoft MSFT has become an important earnings report again as shares trade at 5-year highs. Everyone will be watching the Cloud.
5. eBay EBAY hasn't missed since it spun off Paypal in 2015. Is this overlooked online retailer ready to head back into the spotlight?
Want to Learn How to Trade Options?
Have you always wanted to trade stock options but are unsure where to begin or what to look for?
Each week, Zacks' Dave Bartosiak will bring you a detailed explanation of the trades "live" on YouTube.
Watch him go through the trade as he answers your questions in real time.
Become one of Dave's minions. Join the Zacks Live Trader community today. Click here for a free 14-day trial >>>
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
eBay Inc. (EBAY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
PPG Industries, Inc. (PPG): Free Stock Analysis Report
Microsoft Corporation (MSFT): Free Stock Analysis Report
Snap-On Incorporated (SNA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT hasn't missed in five years. Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Snap-On SNA hasn't missed in 5 years but investors have grown leery of the shares as they have been treading water. | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in five years. PPG Industries PPG has a great track record, with just 1 miss in 2013. | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in five years. Microsoft MSFT has become an important earnings report again as shares trade at 5-year highs. | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in five years. Have you always wanted to trade stock options but are unsure where to begin or what to look for? |
33557.0 | 2017-07-19 00:00:00 UTC | Health Care Sector Update for 07/19/2017: JNJ, PFE, ABT, MRK, AMGN, MDGS, GSK, INO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07192017-jnj-pfe-abt-mrk-amgn-mdgs-gsk-ino-2017-07-19 | nan | nan | Top Health Care stocks:
JNJ: +0.4%
PFE: +0.8%
ABT: +0.4%
MRK: -0.1%
AMGN: +0.4%
Health care shares were mostly higher in pre-market trade Wednesday.
In other sector news, Medigus ( MDGS ) American depository shares were 5.8% higher after the medical device company said Wednesday it has signed a five-year commercialization agreement in Spain with Izasa Hospital, SLU, a distributor of medical products in the hospital sector. The agreement took effect July 1. Izasa Hospital SLU is required to purchase a minimum of EUR1.4 million ($1.6 million) of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement. The MUSE system, cleared by the U.S. Food and Drug Administration and CE marked, is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication--the procedure intended to treat the anatomical cause of gastroesophageal reflux disease.
(+) GSK (+0.4%) Said to eye sale of Horlicks business in UK
INO (flat) Plans $75 million share offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, Medigus ( MDGS ) American depository shares were 5.8% higher after the medical device company said Wednesday it has signed a five-year commercialization agreement in Spain with Izasa Hospital, SLU, a distributor of medical products in the hospital sector. The MUSE system, cleared by the U.S. Food and Drug Administration and CE marked, is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication--the procedure intended to treat the anatomical cause of gastroesophageal reflux disease. | Izasa Hospital SLU is required to purchase a minimum of EUR1.4 million ($1.6 million) of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement. (+) GSK (+0.4%) Said to eye sale of Horlicks business in UK INO (flat) Plans $75 million share offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, Medigus ( MDGS ) American depository shares were 5.8% higher after the medical device company said Wednesday it has signed a five-year commercialization agreement in Spain with Izasa Hospital, SLU, a distributor of medical products in the hospital sector. Izasa Hospital SLU is required to purchase a minimum of EUR1.4 million ($1.6 million) of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement. (+) GSK (+0.4%) Said to eye sale of Horlicks business in UK INO (flat) Plans $75 million share offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly higher in pre-market trade Wednesday. In other sector news, Medigus ( MDGS ) American depository shares were 5.8% higher after the medical device company said Wednesday it has signed a five-year commercialization agreement in Spain with Izasa Hospital, SLU, a distributor of medical products in the hospital sector. Izasa Hospital SLU is required to purchase a minimum of EUR1.4 million ($1.6 million) of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement. |
33558.0 | 2017-07-19 00:00:00 UTC | What To Watch For In Abbott's Q2 Earnings | ABT | https://www.nasdaq.com/articles/what-watch-abbotts-q2-earnings-2017-07-19 | nan | nan | Abbott Labs ( ABT ) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. First, Abbott's nutritional business has suffered some headwinds in China due to weakness in the country's pediatric nutrition market. This may persist, even though China's GDP growth accelerated in the second quarter. Abbott has continued to launch new nutritional products to offset the weakness, but it may not be enough yet. The nutritional segment accounts for nearly 30% of Abbott's value, per our estimates, making it the biggest business for the company. Second, the expansion of Abbott's diabetes business is likely to continue. The company got a Health Canada license for Freestyle Libre, its glucose monitoring system, at the end of June. The impact of Canadian expansion will be visible in the 3rd quarter. Additionally, the company has signed an agreement with Bigfoot Biomedical whereby the latter will leverage the former's glucose sensing technology. It should be noted, though, that this is a fairly small business for Abbott.
Third, it will be interesting to see how Abbott's existing point-of-care diagnostics business performs in the second quarter. This segment is growing, driven by improvement in convenience, and adoption in emerging markets. Encouraging results can help create positive sentiment among investors and offset doubts stemming from recent issues surrounding Abbott's negotiation of the Alere acquisition. After months of legal battles, the two companies finally reached an agreement in April when Abbott announced that it will acquire Alere for a little over $5 billion. The acquisition is expected to strengthen Abbott's diagnostics business, which accounts for roughly 20% of its value according to our estimates.
While controversies have surrounded Abbott ever since it announced two big acquisitions in succession, we expect that investors will still be drawn to the stock given its fairly consistent performance and its dividend payment history. The credit downgrade early this year hasn't impacted the company much to this point. As controversies and legal issues are put to rest, we expect market to reward the strategic fit of the acquisitions.
Our price estimate of $45 for Abbott Laboratories is slightly below the market.
Please let us know your views by commenting in the box below.
See More at Trefis|View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. Encouraging results can help create positive sentiment among investors and offset doubts stemming from recent issues surrounding Abbott's negotiation of the Alere acquisition. After months of legal battles, the two companies finally reached an agreement in April when Abbott announced that it will acquire Alere for a little over $5 billion. | Abbott Labs ( ABT ) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. The acquisition is expected to strengthen Abbott's diagnostics business, which accounts for roughly 20% of its value according to our estimates. See More at Trefis|View Interactive Institutional Research(Powered by Trefis) Get Trefis Technology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. First, Abbott's nutritional business has suffered some headwinds in China due to weakness in the country's pediatric nutrition market. The nutritional segment accounts for nearly 30% of Abbott's value, per our estimates, making it the biggest business for the company. | Abbott Labs ( ABT ) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. The nutritional segment accounts for nearly 30% of Abbott's value, per our estimates, making it the biggest business for the company. The impact of Canadian expansion will be visible in the 3rd quarter. |
33559.0 | 2017-07-18 00:00:00 UTC | UPRO, BMY, ABT, GS: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/upro-bmy-abt-gs-etf-outflow-alert-2017-07-18 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $32.5 million dollar outflow -- that's a 3.5% decrease week over week (from 8,500,000 to 8,200,000). Among the largest underlying components of UPRO, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 1.8%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $65.51 per share, with $109.05 as the 52 week high point - that compares with a last trade of $108.08. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $32.5 million dollar outflow -- that's a 3.5% decrease week over week (from 8,500,000 to 8,200,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 1.8%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $65.51 per share, with $109.05 as the 52 week high point - that compares with a last trade of $108.08. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of UPRO, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $32.5 million dollar outflow -- that's a 3.5% decrease week over week (from 8,500,000 to 8,200,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $65.51 per share, with $109.05 as the 52 week high point - that compares with a last trade of $108.08. | Among the largest underlying components of UPRO, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $32.5 million dollar outflow -- that's a 3.5% decrease week over week (from 8,500,000 to 8,200,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $65.51 per share, with $109.05 as the 52 week high point - that compares with a last trade of $108.08. |
33560.0 | 2017-07-18 00:00:00 UTC | Here's Why Quidel Corporation Is Rising Today | ABT | https://www.nasdaq.com/articles/heres-why-quidel-corporation-rising-today-2017-07-18 | nan | nan | What happened
Shares of Quidel Corporation (NASDAQ: QDEL) , a company focused on diagnostic testing equipment, rose 11% as of 11:45 a.m. EDT on Tuesday in response to the announcement that it is acquiring a few product lines from Alere (NYSE: ALR) .
So what
Quidel stated on Monday that it has signed a deal to buy Alere's Triage MeterPro cardiovascular and toxicology assets as well as the company's B-type Naturietic Peptide (BNP) assay business. Alere is divesting these product lines in an effort to appease regulators so they will bless the company's upcoming takeover by Abbott Laboratories .
This represents a sizable deal for Quidel since Alere's Triage and BNP business lines generated about $197 million in total revenue last year. For comparison, Quidel's revenue in 2016 was only $191 million, so this deal will single handily double the company's top line. What's more, Quidel negotiated a price of only $400 million for this transaction plus another $40 million in contingent consideration, which values this deal at about 2.2 times sales. That's less than half of Quidel's current price-to-sales ratio of 5.9, so it appears that the company is buying these product lines at a very good price.
Douglas Bryant, Quidel's CEO, offered up the following commentary on the deal:
Traders appear to share Bryant's optimism, which is why Quidel's stock is jumping Tuesday.
Now what
Quidel expects to fund this transaction with cash on hand and through "committed financing." The deal is expected to close in the third quarter of 2017, though it is worth noting that it is contingent on Abbott's merger with Alere going through as well. That fact adds an additional layer of risk that potential shareholders need to carefully consider.
Nonetheless, this deal promises to instantly double Quidel's revenue, enhance its product lineup, and extend its geographic diversity. Given those advantages and the reasonable $440 million price tag, it is easy to understand why shares are soaring on Tuesday.
10 stocks we like better than Quidel
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Quidel wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Quidel Corporation (NASDAQ: QDEL) , a company focused on diagnostic testing equipment, rose 11% as of 11:45 a.m. EDT on Tuesday in response to the announcement that it is acquiring a few product lines from Alere (NYSE: ALR) . So what Quidel stated on Monday that it has signed a deal to buy Alere's Triage MeterPro cardiovascular and toxicology assets as well as the company's B-type Naturietic Peptide (BNP) assay business. This represents a sizable deal for Quidel since Alere's Triage and BNP business lines generated about $197 million in total revenue last year. | This represents a sizable deal for Quidel since Alere's Triage and BNP business lines generated about $197 million in total revenue last year. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Quidel Corporation (NASDAQ: QDEL) , a company focused on diagnostic testing equipment, rose 11% as of 11:45 a.m. EDT on Tuesday in response to the announcement that it is acquiring a few product lines from Alere (NYSE: ALR) . Douglas Bryant, Quidel's CEO, offered up the following commentary on the deal: Traders appear to share Bryant's optimism, which is why Quidel's stock is jumping Tuesday. 10 stocks we like better than Quidel When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What's more, Quidel negotiated a price of only $400 million for this transaction plus another $40 million in contingent consideration, which values this deal at about 2.2 times sales. That's right -- they think these 10 stocks are even better buys. The Motley Fool has no position in any of the stocks mentioned. |
33561.0 | 2017-07-17 00:00:00 UTC | 3 Big Stock Charts for Monday: Qualcomm, Inc. (QCOM), Abbott Laboratories (ABT) and Microsoft Corporation (MSFT) | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-monday%3A-qualcomm-inc.-qcom-abbott-laboratories-abt-and-microsoft | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
This week, we'll start to see a steady flow of earnings reports from Wall Street as the second-quarter season gets underway. For reference, the S&P 500 index will see 68, or 13%, of its component companies report their results.
The earnings season always offers opportunities for those watching the charts, which is why today's three big stock charts will take a look at the technical for Qualcomm, Inc. (NASDAQ: QCOM ), Abbott Laboratories (NYSE: ABT ) and software heavyweight Microsoft Corporation (NASDAQ: MSFT ).
Qualcomm, Inc. (QCOM)
Semiconductor companies have been leading the market higher as the Philadelphia Semiconductor Sector Index is trading more than 20% higher for the year, but the performance has been bifurcated as there has been a clear group of "haves" and "have nots" within the sector.
With its loss of 11% for the year, Qualcomm has been in the latter group, but their recent technical turns have put it on the radar of trading bulls. QCOM reports later this week and the report may be the catalyst to juice the stock as it transitions to a bullish outlook.
After a test and consolidation at $55, Qualcomm shares are now making a bullish cross above their 50- and 100-day moving averages. Both of these trendlines are already ascending, which is bullish.
QCOM shares officially moved into a long-term bull market trend earlier this year as they move above their 20-month moving average. This trendline should provide support if this week's earnings report were to underestimate expectations. This support is at $56.81.
Overhead, Qualcomm could face some resistance, or profit-taking, at $59.35 as this is where the stock's 200-day resides. This will be the next test for the technical traders, but a crow above the 200-day moving average opens QCOM up to considerable upside potential.
Abbott Laboratories (ABT)
Healthcare companies have been playing catch-up in 2017 and Abbott Labs has been leading the way as it trades to new highs with a 30% year-to-date return.
The 5 Best (And 5 Worst) Tech Stocks to Buy Now
The company will report earnings later this week and a successful report will push ABT stock into new high territory, something that chart watchers should be focusing on.
Abbott stock is ready to break to new highs with only 70% of the analysts covering it as a buy. This extremely bullish move will bring more upgrades and buying power to the stock.
ABT shares are poised to make a move above their top Bollinger Band (approximately $49), which will trigger a volatility rally as the stock is moving to new highs.
The recent consolidation has brought Abbott out of its overbought status, which means that the stock now has room to move higher from the perspective of "technical valuation." We often see these situations result in very bullish post-earnings moves.
Microsoft Corporation (MSFT)
Microsoft's shift to focus on their software platforms, subscription models and cloud computing have helped the company take a leadership role in the technology sector. MSFT is trading almost 20% higher for the year, in-line with the Nasdaq 100 Index .
Alibaba Group Holding Ltd (BABA) Stock Proves Bubbles Can Last Awhile
Microsoft is following a very familiar pre-earnings pattern that caught our eye and is worth pointing out.
Over the last week, MSFT shares have rallied 7%, putting them back near their highs. This is something that we've seen the last two quarters as the traders appear to be "buying the news" ahead of earnings.
The rally is taking Microsoft shares into technically overbought territory, an indication that the stock is expanding too far ahead of the report. This often triggers profit-taking after an earnings report.
MSFT shares remain a buy according to our model, but the stock appears ready to see a "Rally and Recoil" reaction to the earnings report, if it is positive. Any negative report will see the stock make a dramatic pullback. Either way that you cut it, Microsoft is a stock worth selling at its highs ahead of earnings with the strategy of buying them back after the report at lower prices.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
More From InvestorPlace
10 Stocks That Will Rocket Higher on Short Squeeze Power
7 Stocks With Momentum on Their Side
7 Stocks to Buy Before Their Earnings Breakout
The post 3 Big Stock Charts for Monday: Qualcomm, Inc. (QCOM), Abbott Laboratories (ABT) and Microsoft Corporation (MSFT) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The earnings season always offers opportunities for those watching the charts, which is why today's three big stock charts will take a look at the technical for Qualcomm, Inc. (NASDAQ: QCOM ), Abbott Laboratories (NYSE: ABT ) and software heavyweight Microsoft Corporation (NASDAQ: MSFT ). Abbott Laboratories (ABT) Healthcare companies have been playing catch-up in 2017 and Abbott Labs has been leading the way as it trades to new highs with a 30% year-to-date return. The 5 Best (And 5 Worst) Tech Stocks to Buy Now The company will report earnings later this week and a successful report will push ABT stock into new high territory, something that chart watchers should be focusing on. | The earnings season always offers opportunities for those watching the charts, which is why today's three big stock charts will take a look at the technical for Qualcomm, Inc. (NASDAQ: QCOM ), Abbott Laboratories (NYSE: ABT ) and software heavyweight Microsoft Corporation (NASDAQ: MSFT ). More From InvestorPlace 10 Stocks That Will Rocket Higher on Short Squeeze Power 7 Stocks With Momentum on Their Side 7 Stocks to Buy Before Their Earnings Breakout The post 3 Big Stock Charts for Monday: Qualcomm, Inc. (QCOM), Abbott Laboratories (ABT) and Microsoft Corporation (MSFT) appeared first on InvestorPlace . Abbott Laboratories (ABT) Healthcare companies have been playing catch-up in 2017 and Abbott Labs has been leading the way as it trades to new highs with a 30% year-to-date return. | The earnings season always offers opportunities for those watching the charts, which is why today's three big stock charts will take a look at the technical for Qualcomm, Inc. (NASDAQ: QCOM ), Abbott Laboratories (NYSE: ABT ) and software heavyweight Microsoft Corporation (NASDAQ: MSFT ). The 5 Best (And 5 Worst) Tech Stocks to Buy Now The company will report earnings later this week and a successful report will push ABT stock into new high territory, something that chart watchers should be focusing on. More From InvestorPlace 10 Stocks That Will Rocket Higher on Short Squeeze Power 7 Stocks With Momentum on Their Side 7 Stocks to Buy Before Their Earnings Breakout The post 3 Big Stock Charts for Monday: Qualcomm, Inc. (QCOM), Abbott Laboratories (ABT) and Microsoft Corporation (MSFT) appeared first on InvestorPlace . | The 5 Best (And 5 Worst) Tech Stocks to Buy Now The company will report earnings later this week and a successful report will push ABT stock into new high territory, something that chart watchers should be focusing on. The earnings season always offers opportunities for those watching the charts, which is why today's three big stock charts will take a look at the technical for Qualcomm, Inc. (NASDAQ: QCOM ), Abbott Laboratories (NYSE: ABT ) and software heavyweight Microsoft Corporation (NASDAQ: MSFT ). Abbott Laboratories (ABT) Healthcare companies have been playing catch-up in 2017 and Abbott Labs has been leading the way as it trades to new highs with a 30% year-to-date return. |
33562.0 | 2017-07-17 00:00:00 UTC | Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings? | ABT | https://www.nasdaq.com/articles/can-abbott-laboratories-abt-pull-a-surprise-in-q2-earnings-2017-07-17 | nan | nan | Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Last quarter, the company's earnings exceeded the Zacks Consensus Estimate remarkably by 11.63%. Also, the company posted an average beat of 4.67% in the trailing four quarters. Let's sneak a peek how things are shaping up prior to this announcement.
Factors at Play
Abbott has been on a healthy growth trajectory in Established Pharmaceuticals Division (EPD) business, delivering encouraging operational sales growth in the trailing few quarters. Major part of this growth was stimulated by a series of strategic actions, including the sale of Abbott's developed market businesses along with the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia.
However, the absence of any substantial advancement in this division in the recent past has compelled the company to maintain low expectations at high single-digit growth in the yet-to-be reported quarter.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
On a positive note, with a strong market position in several geographies, including China, Latin America and several markets in Southeast Asia, EPD is well positioned for sustained above-market growth in some of the largest and fastest growing pharmaceutical markets in the world.
Abbott initiated the implementation of its operational model within the EPD space in the first quarter, as planned. Per the model, the company will focus on selling its highly diversified line of products in core therapeutic areas to treat local health conditions. This in turn will allow the company to widen its customer base by creating unique relationship with physicians, retailers and pharmacies. Also, Abbott plans to strengthen its developmental capabilities by expanding its EPD innovation center in India.
There have been a slew of developments within medical device as well. The market is upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System prospects post the receipt of full or partial reimbursement by the French Health Ministry in May 2017.
At this platform, the company also announced Health Canada License for FreeStyle Libre in Jun 2017.
Notably, all these developments are expected to drive the company's traction in the Diabetes Care segment, which saw sales growth of 20.2% in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally.
This apart, the market is bullish on Abbott's Confirm Rx Insertable Cardiac Monitor after it received CE Mark in May 2017. Post-approval, the product has seen strong consumer acceptance with implants taking place in 10 countries across Europe. In May 2017, the company announced CE Mark for its Tacticath Contact Force Ablation Catheter which is another key positive.
Continuing with its trend of extensive research and new product developmet, the company, launched two science-based nutrition drinks for better recovery from surgeries - Ensure Surgery Immunonutrition Shake and EnsurePre- Surgery Clear Nutrition Drink - in Apr 2017.
We are also bullish about the ongoing synergies from the acquisition of St. Jude Medical on Jan 4. The comprehensive combined portfolio is quite promising..
Notably, Abbott projects annual pre-tax synergies of $500 million by 2020, including revenue expansion opportunities as well as operational and SG&A efficiencies.
Overall, for the second quarter of 2017, the company forecasts adjusted earnings per share of 59 cents to 61 cents. Comparable operational sales growth for the quarter is projected in low to mid-single digits.
Earnings Whispers
Our proven model does not conclusively show that Abbott is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP : Earnings ESP for Abbott is 0.00% since both the Most Accurate estimate and the Zacks Consensus Estimate are at 60 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Abbott has a Zacks Rank #2, which increases the predictive power of ESP. However, the company's 0.00% ESP makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter:
Thermo Fisher Scientific Inc. TMO has an Earnings ESP of 0.44% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Dextera Surgical Inc. DXTR has an Earnings ESP of +9.09% and a Zacks Rank #2.
Telefex Incorporated TFX has an Earnings ESP of +1.06% and a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
Dextera Surgical Inc. (DXTR): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Dextera Surgical Inc. (DXTR): Free Stock Analysis Report To read this article on Zacks.com click here. Major part of this growth was stimulated by a series of strategic actions, including the sale of Abbott's developed market businesses along with the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Dextera Surgical Inc. (DXTR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote On a positive note, with a strong market position in several geographies, including China, Latin America and several markets in Southeast Asia, EPD is well positioned for sustained above-market growth in some of the largest and fastest growing pharmaceutical markets in the world. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Dextera Surgical Inc. (DXTR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote On a positive note, with a strong market position in several geographies, including China, Latin America and several markets in Southeast Asia, EPD is well positioned for sustained above-market growth in some of the largest and fastest growing pharmaceutical markets in the world. | Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Dextera Surgical Inc. (DXTR): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company's earnings exceeded the Zacks Consensus Estimate remarkably by 11.63%. |
33563.0 | 2017-07-14 00:00:00 UTC | Abbott Partners Bigfoot Biomedical to Expand in Diabetics | ABT | https://www.nasdaq.com/articles/abbott-partners-bigfoot-biomedical-to-expand-in-diabetics-2017-07-14 | nan | nan | Illinois-based global medical device company Abbott LaboratoriesABT partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.
Leveraged on Abbott's FreeStyle Libre glucose sensing technology, the collaboration will result in innovation and marketing of insulin delivery systems.
The alliance will help the companies develop patient-friendly insulin delivery systems with no calibration glucose sensor. Per management, an important trial on the combined technological systems is projected to initiate in 2018 at clinical research sites across the U.S.
Abbott has been moving steadily toward development in its diabetics segment. Recently, the company announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. This will further stimulate growth in the Diabetes Care sales segment, which was up 20.2% in first-quarter 2017 on continued consumer acceptance of FreeStyle Libre internationally.
We expect Freestyle Libre to further contribute to Abbott's top line as along with the Canadian development, the French Health Ministry recently approved national reimbursement for the device.
Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to value $30.25 billion by 2021 witnessing a CAGR of 5.93%. Moreover, the insulin delivery devices market is expected to see a CAGR of 5.59% to roughly $14.22 billion in 2019.
Thus, considering the market potential and Abbott's current developments in the diabetes care segment, this collaboration seems to be a lucrative and strategically aligned one.
We believe an ageing population, unhealthy lifestyle and rising awareness and expenditure in healthcare will continue to drive growth in the diabetes market. However, this market is dominated by many well established players, Johnson & Johnson JNJ being the most prominent one. In this space, Johnson & Johnson also has a tie-up with U.S.-based Animas Corporation to successfully develop and innovate insulin delivery systems.
Moreover, Abbott has been gaining investor confidence on consistent positive results. Over the past three months, the company's share price has outperformed the Zacks categorized Medical - Instruments sub-industry. The stock has gained 12.7%, higher than the broader industry's gain of 11.0%. The company has also outperformed the 5.1% gain of the S&P 500 market over the same time frame.
Zacks Rank & Other Key Picks
Abbott currently has a Zacks Rank #2 (Buy). A few other top-ranked medical stocks are Edwards Lifesciences Corporation EW and ABIOMED, Inc. ABMD . Notably, Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while ABIOMED carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.22%. The stock has gained around 23.0% over the last three months.
ABIOMED has a long-term expected earnings growth rate of 32.5%. The stock has gained around 14.8% over the last three months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Illinois-based global medical device company Abbott LaboratoriesABT partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Per management, an important trial on the combined technological systems is projected to initiate in 2018 at clinical research sites across the U.S. Abbott has been moving steadily toward development in its diabetics segment. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market. Leveraged on Abbott's FreeStyle Libre glucose sensing technology, the collaboration will result in innovation and marketing of insulin delivery systems. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market. Leveraged on Abbott's FreeStyle Libre glucose sensing technology, the collaboration will result in innovation and marketing of insulin delivery systems. | Illinois-based global medical device company Abbott LaboratoriesABT partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Leveraged on Abbott's FreeStyle Libre glucose sensing technology, the collaboration will result in innovation and marketing of insulin delivery systems. |
33564.0 | 2017-07-12 00:00:00 UTC | Edwards Emerges Strong on FDA Nods, International Prospect | ABT | https://www.nasdaq.com/articles/edwards-emerges-strong-on-fda-nods-international-prospect-2017-07-12 | nan | nan | On Jul 11, we issued an updated research report on the leading molecular diagnostic company, Edwards Lifesciences CorporationEW . The stock currently flaunts a Zacks Rank #1 (Strong Buy).
Over the last one month, Edwards Lifesciences has been trading above the Zacks categorized Medical - Instruments industry. The stock has gained 2.7% in this period, higher than the broader industry's 0.3% increase. The company getting several FDA approvals of late also raises hope. This includes SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve.
Edwards Lifesciences Corporation Price and Consensus
Edwards Lifesciences Corporation Price and Consensus | Edwards Lifesciences Corporation Quote
We are encouraged by the company's long-term growth strategies and recent progress in its technology pipeline. As far as transcatheter heart valve (THV) goes, Edwards Lifesciences expects to maintain its leadership position in the global Transcatheter Aortic Valve Replacement (TAVR) market through increased focus on expanding patient access, actively leveraging current valve platforms for additional indications, developing next-generation valve platforms as well as maintaining relationships with clinicians, payers and regulators.
During the last reported first-quarter 2017, management raised the lower end of the 2017 revenue guidance to indicate that this bullish trend will continue in the upcoming quarters.
Edwards Lifesciences' focus on building its pipeline to strengthen its foothold across all operating businesses may augur well for the company on the road ahead. In the first quarter of 2017, the company received an FDA clearance for its HemoSphere advanced monitoring platform. It has also witnessed growth across the emerging portfolio of mitral and tricuspid repair therapies, thanks to the positive feedback received during the reported quarter.
This apart, we are optimistic to note that management is striving to reinforce its hold in Asia, especially in Japan. The company is also looking forward to its launch of INSPIRIS RESILIA aortic valve by the end of 2017 in Japan.
On the flip side, foreign exchange headwinds continue to come across as a major dampener for the company's international businesses. Besides, a competitive landscape in the overseas market also weighs on Edwards Lifesciences' prospects. The U.S. government's significant reforms to overhaul the health care system bear potential to affect the company's financial position.
Other Key Picks
Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Abbott Laboratories ABT and Align Technology, Inc. ALGN . While Mesa Laboratories sports a Zacks Rank #1(Strong Buy), Abbott and Align Technology carry a Zacks Rank #2(Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Mesa Laboratories delivered a positive earnings surprise of 2.84% over the last four quarters. The stock has added roughly 11.6% over the last three months.
Abbott Laboratories has an expected long-term adjusted earnings growth of 10.84%. The stock has added around 12.8% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has surged nearly 32.8% over the last three months.
Accelerate Diagnostics has a long-term expected earnings growth rate of 30.0%. The stock has added roughly 10.1% over the last three months.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Abbott Laboratories ABT and Align Technology, Inc. ALGN . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. During the last reported first-quarter 2017, management raised the lower end of the 2017 revenue guidance to indicate that this bullish trend will continue in the upcoming quarters. | Other Key Picks Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Abbott Laboratories ABT and Align Technology, Inc. ALGN . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Edwards Lifesciences Corporation Price and Consensus Edwards Lifesciences Corporation Price and Consensus | Edwards Lifesciences Corporation Quote We are encouraged by the company's long-term growth strategies and recent progress in its technology pipeline. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Abbott Laboratories ABT and Align Technology, Inc. ALGN . Edwards Lifesciences Corporation Price and Consensus Edwards Lifesciences Corporation Price and Consensus | Edwards Lifesciences Corporation Quote We are encouraged by the company's long-term growth strategies and recent progress in its technology pipeline. | Other Key Picks Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Abbott Laboratories ABT and Align Technology, Inc. ALGN . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Over the last one month, Edwards Lifesciences has been trading above the Zacks categorized Medical - Instruments industry. |
33565.0 | 2017-07-12 00:00:00 UTC | LabCorp Diagnostics Strong on Novant Health Deal Extension | ABT | https://www.nasdaq.com/articles/labcorp-diagnostics-strong-on-novant-health-deal-extension-2017-07-12 | nan | nan | Laboratory Corporation of America HoldingsLH , also referred to as LabCorp, has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012. However, the financial terms of this multi-year agreement extension have been kept under wraps.
The Technical Services Agreement makes the company's diagnostics business - LabCorp Diagnostics - the laboratory management services provider for all Novant Health acute care facilities. Thus, we expect this agreement to expand LabCorp's reach.
LabCorp's highly sophisticated and exclusive services like IT and data analytics and high-end testing platforms provide a holistic and enriching range of laboratory and diagnostics solutions. In addition to these services, LabCorp acts as the primary reference laboratory for Novant Health and Novant Health Medical Group.
Interestingly, LabCorp's Diagnostics arm is its prime revenue generating business which accounted for around 71% of the company's total revenues in the first quarter of fiscal 2017. The latest development is expected to help the company to strengthen its position in this space.
Notably, the company has been riding high on this segment, courtesy of its continuous efforts to stimulate growth organically as well as through acquisitions and partnerships. In this regard, LabCorp recently teamed up with Walgreens Boots Alliance, Inc. WBA to set up specimen collection service stations at various Walgreens stores across the U.S.
The company also expanded its reach by closing the acquisition of Mount Sinai Health System Clinical Outreach Laboratories in May 2017. Post-acquisition, LabCorp's highly differentiated portfolio will be used by Mount Sinai's existing customers.
Per a report from MarketsandMarkets , the Vitro Diagnostics market is expected to witness a CAGR of 5.5% in the 2016-2021 period, while the Diagnostics Imaging Market is projected to see a CAGR of 6.6% over the same time frame. Thus, LabCorp's continuous efforts to grow in this niche market seem to be perfectly aligned and justified.
Management showed confidence in the Diagnostics segment by revising the Guidance for fiscal 2017 favorably. The projected revenue growth at this segment was increased by 50 basis points to 5.0-7.0% over 2016 net revenue of $6.59 billion. Moreover, in May 2017, company expanded its VistaSeq Hereditary Cancer portfolio through the addition of ten new test panels with focus on the risk of specific hereditary cancer syndromes.
Over the last three months, LabCorp has been lagging the broader Medical Instruments market, gaining 6.6% as compared to the industry's 11.6%. However, the company's strong fundamentals make us believe that this phase is only momentary. Also, we expect the latest development to provide some momentum to the stock.
Zacks Rank & Key Picks
LabCorp currently carries a Zacks Rank #4 (Sell). A few better-ranked medical stocks are Edwards Lifesciences Corporation EW and Abbott Laboratories ABT . Notably, Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Abbott Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Edwards Lifesciences has an expected long-term adjusted earnings growth of 15.22%. The stock has added roughly 24.7% over the last three months.
Abbott Laboratories has an expected long-term adjusted earnings growth of 10.84%. The stock has added around 12.8% over the last three months.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Edwards Lifesciences Corporation EW and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Laboratory Corporation of America HoldingsLH , also referred to as LabCorp, has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Edwards Lifesciences Corporation EW and Abbott Laboratories ABT . The Technical Services Agreement makes the company's diagnostics business - LabCorp Diagnostics - the laboratory management services provider for all Novant Health acute care facilities. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Edwards Lifesciences Corporation EW and Abbott Laboratories ABT . The Technical Services Agreement makes the company's diagnostics business - LabCorp Diagnostics - the laboratory management services provider for all Novant Health acute care facilities. | A few better-ranked medical stocks are Edwards Lifesciences Corporation EW and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. The Technical Services Agreement makes the company's diagnostics business - LabCorp Diagnostics - the laboratory management services provider for all Novant Health acute care facilities. |
33566.0 | 2017-07-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2017 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-july-12-2017-2017-07-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on July 12, 2017. A cash dividend payment of $0.265 per share is scheduled to be paid on August 15, 2017. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that ABT has paid the same dividend. At the current stock price of $48.23, the dividend yield is 2.2%.
The previous trading day's last sale of ABT was $48.23, representing a -2.74% decrease from the 52 week high of $49.59 and a 29.03% increase over the 52 week low of $37.38.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.96. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 11.94%, compared to an industry average of 7.6%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
SPDR S&P Health Care Equipment ( XHE )
First Trust VL Dividend ( FVD )
First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ).
The top-performing ETF of this group is IHI with an increase of 13.84% over the last 100 days. It also has the highest percent weighting of ABT at 8.83%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 11.94%, compared to an industry average of 7.6%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | ABT's current earnings per share, an indicator of a company's profitability, is $.96. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on July 12, 2017. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ). | ABT's current earnings per share, an indicator of a company's profitability, is $.96. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on July 12, 2017. |
33567.0 | 2017-07-10 00:00:00 UTC | Notable ETF Inflow Detected - ITOT, PM, ABT, USB | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-itot-pm-abt-usb-2017-07-10 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $46.8 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 174,000,000 to 174,850,000). Among the largest underlying components of ITOT, in trading today Philip Morris International Inc (Symbol: PM) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and US Bancorp (Symbol: USB) is lower by about 0.5%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average:
Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.24 as the 52 week high point - that compares with a last trade of $55.42. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ITOT, in trading today Philip Morris International Inc (Symbol: PM) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and US Bancorp (Symbol: USB) is lower by about 0.5%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.24 as the 52 week high point - that compares with a last trade of $55.42. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of ITOT, in trading today Philip Morris International Inc (Symbol: PM) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and US Bancorp (Symbol: USB) is lower by about 0.5%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.24 as the 52 week high point - that compares with a last trade of $55.42. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ITOT, in trading today Philip Morris International Inc (Symbol: PM) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and US Bancorp (Symbol: USB) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $46.8 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 174,000,000 to 174,850,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.24 as the 52 week high point - that compares with a last trade of $55.42. | Among the largest underlying components of ITOT, in trading today Philip Morris International Inc (Symbol: PM) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and US Bancorp (Symbol: USB) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $46.8 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 174,000,000 to 174,850,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.24 as the 52 week high point - that compares with a last trade of $55.42. |
33568.0 | 2017-07-10 00:00:00 UTC | Investors Look for Gains as Abbott Labs Set to Acquire Alere | ABT | https://www.nasdaq.com/articles/investors-look-for-gains-as-abbott-labs-set-to-acquire-alere-2017-07-10 | nan | nan | Abbott LaboratoriesABT provided some good news for investors as the much-contentious merger of the company with Alere is a step closer to completion. On majority of Alere shareholders' recent approval in favor of the merger, the deal is now expected to close by the end of third-quarter 2017. However, it is still subject to satisfaction of the customary closing conditions, including applicable regulatory approvals.
This news follows the announcement of an amendment of the original merger agreement in April. Per the amended terms of the agreement, Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from the earlier deal of $56 per common share in cash upon the transaction's completion. This results in an expected, new equity value of approximately $5.3 billion, lower that the originally estimated equity value of almost $5.8 billion.
With this amendment, both the companies agreed to dismiss their respective lawsuits that they were engaged in on issues regarding the pending merger. Significantly, the original contract was made on Feb 1 2016.
Our take
Abbott had earlier stated that with the successful completion of this transaction, its total diagnostics sales should exceed $7 billion. The company also expects to emerge a lead player in the $5.5 billion point-of-care diagnostic segment with this consolidation.
The acquisition would enable Abbott gain an access to new channels and geographies, including entry into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing. It will also add Alere's complementary portfolio of diagnostic products, comprising tests for infections such as HIV, tuberculosis, malaria and dengue. Notably, Alere develops simple, rapid tests, including Alere i, the molecular test for flu and strep, to deliver reports in less than 15 minutes.
Hence, the combined business will offer several options of tests in a broad array. For instance, infectious disease, molecular, cardiometabolic and toxicology testings. Plus, this union would definitely expand Abbott Labs' platforms to include benchtop and rapid strip tests. Although Alere has generated over half its total sales from the U.S. alone, the company has a growing presence in key international markets with a potential to strengthen the Abbott's business ahead in these territories.
Price Performance
Over the past three months,Abbott's share price has outperformed the Zacks categorized Medical - Instruments sub-industry. The stock has gained 11.2%, higher than the broader industry's gain of 9.8%.
Zacks Rank and Other Key Picks
Abbott currently carries a Zacks Rank #2 (Buy). Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Inogen, Inc. INGN and Align Technology, Inc. ALGN . Notably, Mesa Laboratories and Inogen sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four quarters. The stock has roughly gained 10.5% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has rallied around 23.8% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has surged nearly 30.5% over the last three months.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think. See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT provided some good news for investors as the much-contentious merger of the company with Alere is a step closer to completion. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition would enable Abbott gain an access to new channels and geographies, including entry into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT provided some good news for investors as the much-contentious merger of the company with Alere is a step closer to completion. Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Inogen, Inc. INGN and Align Technology, Inc. ALGN . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT provided some good news for investors as the much-contentious merger of the company with Alere is a step closer to completion. Notably, Alere develops simple, rapid tests, including Alere i, the molecular test for flu and strep, to deliver reports in less than 15 minutes. | Abbott LaboratoriesABT provided some good news for investors as the much-contentious merger of the company with Alere is a step closer to completion. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. This news follows the announcement of an amendment of the original merger agreement in April. |
33569.0 | 2017-07-10 00:00:00 UTC | Medtronic (MDT) Launches Resolute Onyx DES Device in Japan | ABT | https://www.nasdaq.com/articles/medtronic-mdt-launches-resolute-onyx-des-device-in-japan-2017-07-10 | nan | nan | Medtronic plcMDT , a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest-revenue-grossing Cardiovascular segment. Following the successful launch of its highly innovative and sophisticated Drug Eluting Stent (DES), Resolute Onyx in the U.S. in May 2017, Medtronic is now planning to start selling it in the high-growth Japan market from Jul 10, as per a Cardiovascular Business report released on Jul 7.
This is in line with the company's strategy to focus on research and development of high-end medical device products within its core business lines. Notably, the FDA-approved Resolute Onyx DES had also received CE mark in Europe in 2014.
Resolute Onyx DES is an upgraded version of Resolute Integrity DES which works on the Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST). Thus, Resolute Onyx DES provides enhanced visibility to surgeons, delivering superior clinical performance.
Interestingly, Medtronic's cardiovascular segment contributed 35.98% to total revenues in fourth-quarter fiscal 2017 banking on strong growth in Arrhythmia Management as well as transcatheter aortic valves and HeartWare International acquisition. Moreover, the company's latest development in Japan will help boost the company's performance in this segment.
Medtronic's strategy to gain traction in its Coronary and Structural Heart sub-segment seems to be aligned with data provided by Transparency Market Research. Per the report, the global coronary stents market is expected to see a CAGR of 6.6% from 2013 to 2019.
More specifically, the DES market within the Coronary stents market is expanding fast. It is estimated to witness a CAGR of 9.54% in the 2013-2019 period. The market is likely to expand 9% in the U.S., 10% in the Asia Pacific, and 3.1% in Europe as well as the Rest of the World
We believe the high incidence of atherosclerosis diseases due to unhealthy lifestyle, penetration by the DES providing companies in the untapped markets and increasing awareness among people will continue to stimulate the global acceptance of this technology. In the view of these encouraging factors, we believe that the company's Japanese launch plans for Resolute Onyx is strategic and will broaden its customer base in the densely populated Asia-Pacific market.
Though based in a highly fragmented Coronary Stents market, Medtronic faces strong competition from global leaders like Boston Scientific Corp. BSX , Abbott Laboratories ABT and others. Boston Scientific's PROMUS Element Plus Stent System and Abbott's XIENCE V and XIENCE nano Everolimus Eluting Coronary Stent System are worth a mention in this regard.
Medtronic has been performing better than the broader Medical Instruments market, gaining 18.2% as compared to the industry's 16.3% over the last six months. It also outperformed the 6.8% gain of the S&P 500 market over the same time frame.
Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A better-ranked medical stock is Inogen, Inc. INGN , with a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 23.5% over the last three months.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Though based in a highly fragmented Coronary Stents market, Medtronic faces strong competition from global leaders like Boston Scientific Corp. BSX , Abbott Laboratories ABT and others. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Medtronic plcMDT , a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest-revenue-grossing Cardiovascular segment. | Though based in a highly fragmented Coronary Stents market, Medtronic faces strong competition from global leaders like Boston Scientific Corp. BSX , Abbott Laboratories ABT and others. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Boston Scientific's PROMUS Element Plus Stent System and Abbott's XIENCE V and XIENCE nano Everolimus Eluting Coronary Stent System are worth a mention in this regard. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Though based in a highly fragmented Coronary Stents market, Medtronic faces strong competition from global leaders like Boston Scientific Corp. BSX , Abbott Laboratories ABT and others. Following the successful launch of its highly innovative and sophisticated Drug Eluting Stent (DES), Resolute Onyx in the U.S. in May 2017, Medtronic is now planning to start selling it in the high-growth Japan market from Jul 10, as per a Cardiovascular Business report released on Jul 7. | Though based in a highly fragmented Coronary Stents market, Medtronic faces strong competition from global leaders like Boston Scientific Corp. BSX , Abbott Laboratories ABT and others. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Per the report, the global coronary stents market is expected to see a CAGR of 6.6% from 2013 to 2019. |
33570.0 | 2017-07-08 00:00:00 UTC | 3 Top Stocks that Are Cash Cows | ABT | https://www.nasdaq.com/articles/3-top-stocks-are-cash-cows-2017-07-08 | nan | nan | You've probably heard the expression "cash cow," but what does it really mean? The metaphor comes from the dairy industry, where a farmer buys a cow and then receives a steady supply of milk for years to come. In the business world, the equivalent is a company that consistently generates solid cash flow.
Stocks with strong free cash flow (the amount of cash remaining after capital expenditures) often make great investment choices. They're more likely to pay out dividends and to keep those dividends coming. The companies also have more flexibility in reinvesting in their businesses to remain competitive.
Three top stocks that are definitely cash cows are Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , Apple (NASDAQ: AAPL) , and Johnson & Johnson (NYSE: JNJ) . Here's how they make their big moola (sorry -- the pun was too hard to resist).
Alphabet
Alphabet's free cash flow over the last 12 months totaled almost $28 billion. This great cash flow helped Google report cash, cash equivalents, and marketable securities of $92.4 billion at the end of the first quarter.
How does Alphabet generate its enormous cash flow? Nearly all of it (99%) comes from Google, with a small portion stemming from what the company calls its "other bets," which include Nest home automation and its Verily life sciences division. Within Google, advertising revenue on its search engine and YouTube social media site account for roughly 87% of revenue.
What's particularly great for Alphabet is that its free cash flow continues to grow. Sooner or later, the company will need to do something with the big cash stockpile that it has accumulated. Most likely, Alphabet will make strategic acquisitions, buy back more shares, and/or initiate a dividend. Any of these will reward investors, making Alphabet one of the most attractive cash cow stocks on the market.
Apple
Apple generated free cash flow over the last 12 months of nearly $53 billion. Thanks to this strong cash flow, Apple claims a massive cash stockpile totaling $67.1 billion (including cash, cash equivalents, and marketable securities). The company's cash flow also enables it to pay a dividend with a current yield of 1.76%.
While Apple makes money from many popular products and services, its iPhone sales generate 63% of total revenue. This could change in the future, though. One venture capital firm founder thinks that Apple could be developing augmented reality glasses that could be even bigger than the iPhone .
Also, Apple's iPhone sales are only growing by single-digit percentages. By comparison, revenue from the company's second-biggest moneymaker -- services, which includes digital content, AppleCare, Apple Pay, and licensing -- jumped 18% year over year in the first quarter of 2017. Although Apples faces some risks from competition, it seems likely that the company will remain a cash cow for years to come.
Johnson & Johnson
Johnson & Johnson's free cash flow over the last 12 months topped $16 billion. The healthcare giant reported cash, cash equivalents, and marketable securities of $39.3 billion at the end of March. J&J's dividend is one of the most solid in all of healthcare, with a current yield of 2.53% and a 54-year streak of dividend increases.
There isn't much in healthcare that J&J doesn't do. The company's top source of revenue is its pharmaceutical business, which generates around 46% of total sales. Its medical devices segment isn't too far behind, contributing more than 35% of total revenue. J&J's consumer business kicks in the rest of the company's sales.
The company has prioritized acquisitions as a key way of using its cash and cash flow. Earlier this year, J&J acquired Abbott Medical Optics from Abbott Laboratories , bolstering its medical devices business. More recently, the company completed its $30 billion acquisition of Swiss drugmaker Actelion. Although there have been quite a few questions about the price tag paid for Actelion, J&J seems poised to stay ranked as a top cash cow stock.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares) and Apple. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Apple, and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nearly all of it (99%) comes from Google, with a small portion stemming from what the company calls its "other bets," which include Nest home automation and its Verily life sciences division. Although there have been quite a few questions about the price tag paid for Actelion, J&J seems poised to stay ranked as a top cash cow stock. *Stock Advisor returns as of July 6, 2017 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. | This great cash flow helped Google report cash, cash equivalents, and marketable securities of $92.4 billion at the end of the first quarter. Thanks to this strong cash flow, Apple claims a massive cash stockpile totaling $67.1 billion (including cash, cash equivalents, and marketable securities). Johnson & Johnson Johnson & Johnson's free cash flow over the last 12 months topped $16 billion. | Three top stocks that are definitely cash cows are Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , Apple (NASDAQ: AAPL) , and Johnson & Johnson (NYSE: JNJ) . This great cash flow helped Google report cash, cash equivalents, and marketable securities of $92.4 billion at the end of the first quarter. Thanks to this strong cash flow, Apple claims a massive cash stockpile totaling $67.1 billion (including cash, cash equivalents, and marketable securities). | Any of these will reward investors, making Alphabet one of the most attractive cash cow stocks on the market. Apple Apple generated free cash flow over the last 12 months of nearly $53 billion. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Apple, and Johnson & Johnson. |
33571.0 | 2017-07-07 00:00:00 UTC | Health Care Sector Update for 07/07/2017: JNJ, PFE, ABT, MRK, AMGN, NVS, DXTR, CNAT, ADXS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07072017-jnj-pfe-abt-mrk-amgn-nvs-dxtr-cnat-adxs-2017-07-07 | nan | nan | Top Health Care stocks:
JNJ: +1.1%
PFE: +0.7%
ABT: flat
MRK: flat
AMGN: +0.7%
Health care shares were mostly higher in pre-market trade Friday.
Dextera Surgical ( DXTR ), the company developing and commercializing the Dextera MicroCutter 5/80 Stapler, said late Thursday it placed a temporary shipping hold on the MicroCutter 5/80 Stapler and reload cartridges in response to six reports that surgeons were unable to clamp the MicroCutter 5/80 Stapler after inserting a MicroCutter 30 Reload into the stapler prior to or during a surgical procedure. No adverse events or complications have been associated with these reports. DXTR shares were down 25.8%.
In other sector news,
(+) CNAT (+1.1%) Seals license deal with Novartis ( NVS ) and gets $7 million payment
ADXS (flat) CEO Daniel J. O'Connor steps down; Anthony Lombardo assumes role of interim CEO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Health care shares were mostly higher in pre-market trade Friday. Dextera Surgical ( DXTR ), the company developing and commercializing the Dextera MicroCutter 5/80 Stapler, said late Thursday it placed a temporary shipping hold on the MicroCutter 5/80 Stapler and reload cartridges in response to six reports that surgeons were unable to clamp the MicroCutter 5/80 Stapler after inserting a MicroCutter 30 Reload into the stapler prior to or during a surgical procedure. | ABT: flat MRK: flat Health care shares were mostly higher in pre-market trade Friday. In other sector news, (+) CNAT (+1.1%) Seals license deal with Novartis ( NVS ) and gets $7 million payment ADXS (flat) CEO Daniel J. O'Connor steps down; Anthony Lombardo assumes role of interim CEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat Health care shares were mostly higher in pre-market trade Friday. Dextera Surgical ( DXTR ), the company developing and commercializing the Dextera MicroCutter 5/80 Stapler, said late Thursday it placed a temporary shipping hold on the MicroCutter 5/80 Stapler and reload cartridges in response to six reports that surgeons were unable to clamp the MicroCutter 5/80 Stapler after inserting a MicroCutter 30 Reload into the stapler prior to or during a surgical procedure. | ABT: flat MRK: flat Health care shares were mostly higher in pre-market trade Friday. Dextera Surgical ( DXTR ), the company developing and commercializing the Dextera MicroCutter 5/80 Stapler, said late Thursday it placed a temporary shipping hold on the MicroCutter 5/80 Stapler and reload cartridges in response to six reports that surgeons were unable to clamp the MicroCutter 5/80 Stapler after inserting a MicroCutter 30 Reload into the stapler prior to or during a surgical procedure. |
33572.0 | 2017-07-07 00:00:00 UTC | Phibro Animal Health & Zydus Cadila Plan to Expand in India | ABT | https://www.nasdaq.com/articles/phibro-animal-health-zydus-cadila-plan-to-expand-in-india-2017-07-07 | nan | nan | Phibro Animal Health CorporationPAHC recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India. If the agreement comes to effect, Zydus Cadila will be licensing and constructing Phibro's advance poultry vaccines technologies to a manufacturing unit in India.
The companies' management seems to be upbeat about the plan as development of a manufacturing facility will result in the availability of highly innovative vaccines in India, eliminating the extra costs needed for imports. Along with increased gains, this plan is expected to strengthen the partnership between the companies which has been going strong for over 20 years.
The agreement will also be strategically aligned with Phibro's business expansion plans for its Animal Health segment. Notably, this part of Phirbo's business has been a major contributor to net sales (28.8% of total revenue in fiscal 2016).
In fact, within this space, the poultry processing and equipment market is growing in leaps and bounds. Going by Markets and Markets data, this market is projected to reach a worth of $3.83 billion by 2020, at a CAGR of 4.7% from 2015 to 2020.
Being one of the most densely populated nations, India should be able to capture a significant portion of this market. As per a report by the Market Research Reports Search Engine, the Indian Animal Health Care market is expected to see a healthy CAGR of 8.0% between 2016 and 2024, thereby reaching a value of whopping $1,179.4 million by the end of 2024. Also, according toglobal marketintelligence agency Mintel , India's processed meat and poultry market reached a value of INR11 billion in 2016. Being the second-fastest growing processed meat and poultry market, it has substantial potential.
In the view of the bullish trends in this niche market, we believe the collaboration with Zydus Cadila will boost Phibro's international growth and revenue expansion plans.
Notably, Phibro has been trading above the broader Medical Instruments market over the last three months, gaining 28.3% as compared to the industry's 10.3%. It has also outperformed the 3.5% gain of the S&P 500 market over the same time frame.
Zacks Rank & Other Key Picks
Phibro currently carries a Zacks Rank #2 (Buy). A few other top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Abbott Laboratories ABT . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Varian Medical and Abbott Laboratories carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 21.8% over the last three months.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock has gained around 13.6% over the last three months.
Abbott Laboratories has an expected long-term adjusted earnings growth of 10.84%. The stock has added roughly 9.4% over the last three months.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Phibro Animal Health CorporationPAHC recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India. | A few other top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Varian Medical and Abbott Laboratories carry a Zacks Rank #2. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Abbott Laboratories ABT . Phibro Animal Health CorporationPAHC recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India. | A few other top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Varian Medical and Abbott Laboratories carry a Zacks Rank #2. |
33573.0 | 2017-07-06 00:00:00 UTC | Exactech Boosts Knee System Portfolio, Launches New App | ABT | https://www.nasdaq.com/articles/exactech-boosts-knee-system-portfolio-launches-new-app-2017-07-06 | nan | nan | Exactech, Inc.EXAC took a step towards it's goal of providing an all-inclusive range of knee replacement systems with the launch of ExactechGPS TKA PLUS. This is an advanced software application that provides systematic computer guidance to orthopedic surgeons during total knee arthroplasty (TKA) procedures.
TKA PLUS software application is a supplementary feature to the existing ExactechGPS- a computer technology system for well guided, improvised and personalized joint replacement surgery. The software application is expected to provide the performing orthopedic surgeon with more precision and simplified intraoperative computer guidance to track the patient's implant alignment.
In this regard, we note that the ExactechGPS is a widely accepted product with users in 12 countries. Also, it has tended to more than a whopping 8500 cases in knee replacement. The latest application is expected to help the company widen its customer base in these regions.
The TKA PLUS software can be used in conjunction with Truliant Knee System for enhanced performance in total knee replacement. After the recent receipt of 510(k) clearance from the FDA, Truliant Knee system is a complete portfolio of implants and instrumentation that provides an enriching surgical experience in total knee replacement.
Following this pilot lauch, Exactech plans a complete commercial launch of TKA PLUS software application in 2018. This product development is in line with the company's objective to gain traction in the huge and untapped Total Knee Replacement market. As per data provided by Technavio, this market is expected to grow at an estimated CAGR of 3% by 2021.
Though, Exactech may benefit from the concentrated nature of the Total Knee Replacement market, it will have to face tough competition from a stronger player like Zimmer Biomet Holdings, INC. ZBH , which already provides the iASSIST knee Personalized Guidance System for knee replacement procedures. It is worth noting here that Exactech has been performing better than the broader Medical Instruments market , gaining 15.5% as compared to the industry's 9.8% over the last three months. It also outperformed the 2.6% gain of the S&P 500 market over the same time frame.
Zacks Rank and Key Picks
Exactech currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Inogen, INC. INGN and Abbott Laboratories ABT . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Abbott Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 24.1% over the last three months.
Abbott Laboratories has an expected long-term adjusted earnings growth of 10.84%. The stock has added roughly 11.8% over the last three months.
Today's Stocks from Zack's Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Exactech, Inc. (EXAC): Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Inogen, INC. INGN and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Exactech, Inc. (EXAC): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. This is an advanced software application that provides systematic computer guidance to orthopedic surgeons during total knee arthroplasty (TKA) procedures. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Exactech, Inc. (EXAC): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Inogen, INC. INGN and Abbott Laboratories ABT . This is an advanced software application that provides systematic computer guidance to orthopedic surgeons during total knee arthroplasty (TKA) procedures. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Exactech, Inc. (EXAC): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Inogen, INC. INGN and Abbott Laboratories ABT . The TKA PLUS software can be used in conjunction with Truliant Knee System for enhanced performance in total knee replacement. | A few better-ranked medical stocks are Inogen, INC. INGN and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Exactech, Inc. (EXAC): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. The TKA PLUS software can be used in conjunction with Truliant Knee System for enhanced performance in total knee replacement. |
33574.0 | 2017-07-06 00:00:00 UTC | Here's Why You Should Add Abbott Laboratories Right Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-add-abbott-laboratories-right-now-2017-07-06 | nan | nan | Illinois-based global medical device company Abbott LaboratoriesABT has been gaining investor confidence on consistent positive results.
Over the past three months, the company's share price has outperformed the Zacks categorized Medical - Instruments sub-industry. The stock has gained 11.8%, higher than the broader industry's gain of 10.1%. Abbott has also been performing better than the S&P 500 market over the same period. The stock has rallied 11.8%, compared to a mere 2.6% gain of the broader market.
For 2018, the company's estimate revision trend is positive. The stock has witnessed two upward revisions over the last 60 days with no downward movement. Accordingly, earnings estimates moved up 0.36% to $2.77 for the next fiscal.
For 2018, the company's estimate revision trend is also positive. The stock has witnessed two upward revisions over the last sixty days with no downward movement taking place. Accordingly, earnings estimate has moved up 0.36% to reach $2.77 for the next fiscal.
Based upon the promising estimates, solid past performance and a Zacks Rank #2 (Buy), the stock seems to be a lucrative pick for now. However, we would like to look into a few other factors to decide whether its a worthy pick for your portfolio?
A stellar first-quarter 2017 was a major market sentiment booster. Adjusted earnings in the quarter beat the Zacks Consensus Estimate by 11.6% and also improved 17.1% year over year.
The market is also upbeat about the company's receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System. This will provide a further impetus to the Diabetes Care sales segment, which was up 20.2% in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally.
We expect Freestyle Libre to further contribute to Abbott's top line in the coming quarters as apart from the Canadian development, the French Health Ministry recently granted national reimbursement for the device.
This apart, the market is looking forward to Abbott's recent CE Mark for Confirm Rx Insertable Cardiac Monitor. Post-approval, the product saw strong consumer acceptance with implants taking place in 10 countries across Europe. The company also announced CE Mark for its Tacticath Contact Force Ablation Catheter which seems to be another positive.
Continuing with its trend of extensive research and developing new products, the company launched two science-based nutrition drinks for better recovery from surgeries - Ensure Surgery Immunonutrition Shake and EnsurePre- Surgery Clear Nutrition Drink.
We are also bullish about the ongoing synergy achievements from Abbott's acquisition of St. Jude Medical on Jan 4. The comprehensive combined portfolio seems to be quite promising. Post-integration, the company has started generating positive outcome.
Meanwhile, investor sentiments seem to be positive with regard to the impending Alere buyout. It's worth noting here that the deal has been amended in favor of Abbott. Thus, the acquisition is expected to boost the company's performance in the Point of care diagnostics market.
Other Key Picks
A few top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Edwards Lifesciences Corporation EW . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Varian Medical and Edwards Lifesciences carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 24.4% over the last three months.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock has gained around 14.3% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.22%. The stock has gained around 26.6% over the last three months.
Today's Stocks from Zack's Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Illinois-based global medical device company Abbott LaboratoriesABT has been gaining investor confidence on consistent positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. This will provide a further impetus to the Diabetes Care sales segment, which was up 20.2% in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT has been gaining investor confidence on consistent positive results. Other Key Picks A few top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Edwards Lifesciences Corporation EW . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT has been gaining investor confidence on consistent positive results. Based upon the promising estimates, solid past performance and a Zacks Rank #2 (Buy), the stock seems to be a lucrative pick for now. | Illinois-based global medical device company Abbott LaboratoriesABT has been gaining investor confidence on consistent positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. For 2018, the company's estimate revision trend is positive. |
33575.0 | 2017-07-06 00:00:00 UTC | Health Care Sector Update for 07/06/2017: JNJ, PFE, ABT, MRK, AMGN, EGLT, TNXP, NVS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07062017-jnj-pfe-abt-mrk-amgn-eglt-tnxp-nvs-2017-07-06 | nan | nan | Top Health Care stocks:
JNJ: +0.3%
PFE: -0.4%
ABT: -0.7%
MRK: +1%
AMGN: -0.6%
Health care shares were mostly lower in pre-market trade Thursday.
In health care stocks news, Egalet ( EGLT ) fell 28.4% after the company said late Wednesday it is planning to raise funds to market its drugs including morphine sulfate and nasal spray, through the sale of shares and warrants. The drugmaker said the offering is subject to market conditions, with underwriters granted to sell up to 15% additional shares and warrants of securities sold in the offering.
In other sector news,
(+) TNXP (+2.1%) Receives conditional OK of Tonmya as brand name for PTSD treatment
(-) NVS (-2.1%) Gets approval in Europe for label update for psoriasis treatment Cosentyx
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mostly lower in pre-market trade Thursday. In health care stocks news, Egalet ( EGLT ) fell 28.4% after the company said late Wednesday it is planning to raise funds to market its drugs including morphine sulfate and nasal spray, through the sale of shares and warrants. In other sector news, (+) TNXP (+2.1%) Receives conditional OK of Tonmya as brand name for PTSD treatment (-) NVS (-2.1%) Gets approval in Europe for label update for psoriasis treatment Cosentyx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) fell 28.4% after the company said late Wednesday it is planning to raise funds to market its drugs including morphine sulfate and nasal spray, through the sale of shares and warrants. In other sector news, (+) TNXP (+2.1%) Receives conditional OK of Tonmya as brand name for PTSD treatment (-) NVS (-2.1%) Gets approval in Europe for label update for psoriasis treatment Cosentyx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) fell 28.4% after the company said late Wednesday it is planning to raise funds to market its drugs including morphine sulfate and nasal spray, through the sale of shares and warrants. In other sector news, (+) TNXP (+2.1%) Receives conditional OK of Tonmya as brand name for PTSD treatment (-) NVS (-2.1%) Gets approval in Europe for label update for psoriasis treatment Cosentyx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. | Top Health Care stocks: The drugmaker said the offering is subject to market conditions, with underwriters granted to sell up to 15% additional shares and warrants of securities sold in the offering. In other sector news, (+) TNXP (+2.1%) Receives conditional OK of Tonmya as brand name for PTSD treatment (-) NVS (-2.1%) Gets approval in Europe for label update for psoriasis treatment Cosentyx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33576.0 | 2017-07-05 00:00:00 UTC | Abbott Freestyle Libre System Gets Health Canada License | ABT | https://www.nasdaq.com/articles/abbott-freestyle-libre-system-gets-health-canada-license-2017-07-05 | nan | nan | Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. The company recently announced the receipt of Health Canada license for its FreeStyle Libre Flash Glucose Monitoring System.
This is a new glucose sensing technology for diabetic Canadian adults who do not need finger sticks for calibration and can scan current glucose levels anywhere and anytime. This first-of-its-kind system is available in 30 countries outside the U.S. making glucose monitoring more convenient and easier.
The Freestyle Libre system reads glucose levels through a sensor that can be worn on the back of the upper arm hence eliminating the need for routine finger sticks. The scan shows real-time glucose results for a period of eight hours and the direction toward which the glucose level is headed. Also, the device provides the historical pattern of glucose levels over time by storing 90 days of data which further help doctors and patients better manage the disease.
Two published clinical trials reveal that people who scan more frequently can better control and maintain glucose levels. They are also most likely to spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). In this regard, we note that results from the IMPACT clinical trial demonstrated that diabetic patients using the FreeStyle Libre system spent 38% lesser time in hypoglycemia than people using with traditional self-monitoring of blood glucose systems (SMBG).
The Freestyle Libre system is expected to be available in Canada soon.
According to a report by Allied Market Research , the global continuous glucose monitoring systems market is expected to reach a worth of $6,238 million by 2022, at a CAGR of approximately 39.9% from 2016 to 2022. Considering the huge potential of the diabetes management space, we believe this latest development will work in favor of Abbott.
Over the past one year, Abbott has been trading above the Zacks categorized Medical - Products industry. The company has gained 19.3%, when compared to the 10.6% rise of the broader industry.
Recent Developments
Abbott recently announced that the French Health Ministry has approved national reimbursement across France for FreeStyle Libre. This will lend Type 1 and Type 2 diabetes patients of all age groups using insulin multiple times a day access to the FreeStyle Libre system.
Zacks Rank & Other Key Picks
Abbott currently carries a Zacks Rank #2 (Buy). Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Inogen, Inc. INGN and Align Technology, Inc. ALGN . Notably, Mesa Laboratories and Inogen sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% for the last four quarters. The stock has added roughly 15.5% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 25.4% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 29.8% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The Freestyle Libre system reads glucose levels through a sensor that can be worn on the back of the upper arm hence eliminating the need for routine finger sticks. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Inogen, Inc. INGN and Align Technology, Inc. ALGN . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. In this regard, we note that results from the IMPACT clinical trial demonstrated that diabetic patients using the FreeStyle Libre system spent 38% lesser time in hypoglycemia than people using with traditional self-monitoring of blood glucose systems (SMBG). | Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently announced the receipt of Health Canada license for its FreeStyle Libre Flash Glucose Monitoring System. |
33577.0 | 2017-07-05 00:00:00 UTC | Health Care Sector Update for 07/05/2017: JNJ, PFE, ABT, MRK, AMGN, MTBC, BGNE, EVHC | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07052017-jnj-pfe-abt-mrk-amgn-mtbc-bgne-evhc-2017-07-05 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: +0.1%
ABT: flat
MRK: +0.1%
AMGN: flat
Health care shares were mostly quiet in pre-market trade Wednesday.
In health care stocks news, Medical Transcription Billing ( MTBC ) rose 33.6% after it revealed its recent acquisition of a Washington-based revenue cycle management company's client accounts and related business assets, which it says is expected to be accretive to earnings during Q3. Financial terms of the deal were not disclosed.
In other sector news,
(+) BGNE (+3%) Starts urothelial cancer trial
EVHC (flat) Acquires Infinity Healthcare, a multi-specialty physician group practice with headquarters in Wisconsin
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat AMGN: flat Health care shares were mostly quiet in pre-market trade Wednesday. In health care stocks news, Medical Transcription Billing ( MTBC ) rose 33.6% after it revealed its recent acquisition of a Washington-based revenue cycle management company's client accounts and related business assets, which it says is expected to be accretive to earnings during Q3. | ABT: flat In health care stocks news, Medical Transcription Billing ( MTBC ) rose 33.6% after it revealed its recent acquisition of a Washington-based revenue cycle management company's client accounts and related business assets, which it says is expected to be accretive to earnings during Q3. In other sector news, (+) BGNE (+3%) Starts urothelial cancer trial EVHC (flat) Acquires Infinity Healthcare, a multi-specialty physician group practice with headquarters in Wisconsin The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In health care stocks news, Medical Transcription Billing ( MTBC ) rose 33.6% after it revealed its recent acquisition of a Washington-based revenue cycle management company's client accounts and related business assets, which it says is expected to be accretive to earnings during Q3. Financial terms of the deal were not disclosed. | ABT: flat Top Health Care stocks: JNJ: flat Financial terms of the deal were not disclosed. |
33578.0 | 2017-07-03 00:00:00 UTC | Health Care Sector Update for 07/03/2017: JNJ, PFE, ABT, MRK, AMGN, OPXA, PTCT. KND | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07032017-jnj-pfe-abt-mrk-amgn-opxa-ptct-knd-2017-07-03 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: +0.3%
ABT: flat
MRK: -0.1%
AMGN: flat
Health care shares were mostly quiet in pre-market trade Monday.
In health care stocks news, Opexa Therapeutics ( OPXA ) rose 10% after the company said in a regulatory filing Monday it entered into an agreement and plan of merger and reorganization with Acer Therapeutics Inc., with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger. Under the merger agreement, each outstanding share of Acer common stock will be converted into the right to receive approximately one share of common stock of Opexa, which amount is subject to adjustment prior to closing of the merger upon the occurrence of specified events, including to account for any additional shares that Acer may issue before closing and for Opexa's net cash balance at closing. No fractional shares will be issued in connection with the merger and Opexa will pay cash in lieu of any such fractional shares.
In other sector news,
PTCT (flat) Reports favorable preliminary safety profile for spinal muscular atrophy drug in phase 2 trial
KND (flat) Divests nursing facility business
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In health care stocks news, Opexa Therapeutics ( OPXA ) rose 10% after the company said in a regulatory filing Monday it entered into an agreement and plan of merger and reorganization with Acer Therapeutics Inc., with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger. Under the merger agreement, each outstanding share of Acer common stock will be converted into the right to receive approximately one share of common stock of Opexa, which amount is subject to adjustment prior to closing of the merger upon the occurrence of specified events, including to account for any additional shares that Acer may issue before closing and for Opexa's net cash balance at closing. | ABT: flat AMGN: flat Health care shares were mostly quiet in pre-market trade Monday. In health care stocks news, Opexa Therapeutics ( OPXA ) rose 10% after the company said in a regulatory filing Monday it entered into an agreement and plan of merger and reorganization with Acer Therapeutics Inc., with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger. | ABT: flat In health care stocks news, Opexa Therapeutics ( OPXA ) rose 10% after the company said in a regulatory filing Monday it entered into an agreement and plan of merger and reorganization with Acer Therapeutics Inc., with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger. Under the merger agreement, each outstanding share of Acer common stock will be converted into the right to receive approximately one share of common stock of Opexa, which amount is subject to adjustment prior to closing of the merger upon the occurrence of specified events, including to account for any additional shares that Acer may issue before closing and for Opexa's net cash balance at closing. | ABT: flat Top Health Care stocks: JNJ: flat In health care stocks news, Opexa Therapeutics ( OPXA ) rose 10% after the company said in a regulatory filing Monday it entered into an agreement and plan of merger and reorganization with Acer Therapeutics Inc., with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger. |
33579.0 | 2017-06-30 00:00:00 UTC | Health Care Sector Update for 06/30/2017: JNJ, PFE, ABT, MRK, AMGN, SKLN, AMGN. CARA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06302017-jnj-pfe-abt-mrk-amgn-skln-amgn-cara-2017-06-30 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: +0.2%
ABT: -0.6%
MRK: flat
AMGN: +1.2%
Health care shares were mixed in pre-market trade Friday.
In health care stocks news, Skyline Medical ( SKLN ) rose 22.9% after the company said late Thursday it expects the full rollout of its Streamway system in Europe by early 2018. The Streamway system, a direct-to-drain fluid disposal system designed specifically for medical applications, has been granted a CE mark, making it available in 32 European countries. The company expects to record its first European sale by the end of the year.
In other sector news,
(+) AMGN (+0.4%) FDA approves supplemental Biologics License Application for Vectibix for patients with wild-type RAS metastatic colorectal cancer as first-line therapy.
(-) CARA (-27.7%) Says new pain reliever effective at higher dosage but shows no success at lower levels
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Skyline Medical ( SKLN ) rose 22.9% after the company said late Thursday it expects the full rollout of its Streamway system in Europe by early 2018. In other sector news, (+) AMGN (+0.4%) FDA approves supplemental Biologics License Application for Vectibix for patients with wild-type RAS metastatic colorectal cancer as first-line therapy. (-) CARA (-27.7%) Says new pain reliever effective at higher dosage but shows no success at lower levels The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Skyline Medical ( SKLN ) rose 22.9% after the company said late Thursday it expects the full rollout of its Streamway system in Europe by early 2018. (-) CARA (-27.7%) Says new pain reliever effective at higher dosage but shows no success at lower levels The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Skyline Medical ( SKLN ) rose 22.9% after the company said late Thursday it expects the full rollout of its Streamway system in Europe by early 2018. The Streamway system, a direct-to-drain fluid disposal system designed specifically for medical applications, has been granted a CE mark, making it available in 32 European countries. (-) CARA (-27.7%) Says new pain reliever effective at higher dosage but shows no success at lower levels The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: JNJ: flat In health care stocks news, Skyline Medical ( SKLN ) rose 22.9% after the company said late Thursday it expects the full rollout of its Streamway system in Europe by early 2018. In other sector news, (+) AMGN (+0.4%) FDA approves supplemental Biologics License Application for Vectibix for patients with wild-type RAS metastatic colorectal cancer as first-line therapy. |
33580.0 | 2017-06-29 00:00:00 UTC | 5 Underfollowed Stocks That Are Projected To Explode | ABT | https://www.nasdaq.com/articles/5-underfollowed-stocks-are-projected-explode-2017-06-29 | nan | nan | Not all stocks receive as much attention as they deserve. Zacks customers can utilize our Premium Screens to discover underfollowed stocks that are hidden throughout the market. Numerous analysts cover a multitude of stocks that are trading every day. However, some stocks do not receive as much analyst consideration as they might deserve.
Our Premium Screening tool has the ability search for stocks that lack trading volume and broker recommendations. This tool allows for customers to find investments that possess strong upside, but have been mostly neglected by the market. These stocks represent a few investments that could possibly turn out to be hidden gems.
Check out these underfollowed stocks to buy now:
1. Ciena CorporationCIEN
Ciena Corporation is a network specialist, focused on expanding the possibilities for its customers' networks while reducing their cost of ownership. Ciena has continued to build its product portfolio by expanding beyond its original optical networking expertise in order to grow its customer base. Additionally, Ciena's revenues are expected to surge due to increased demand for packet-optical transport and switching products, integrated network and service management software.
Over the past 60 days, Ciena's full-year EPS estimates increased by 9.56% to $1.49. Furthermore, the company posted a RoE of 18.60% and Current Cash Flow Growth of 17.33%. Both of these metrics compare favorably to the rest of the Fiber Optics industry. Also, Ciena Corporation currently has an EV/EBITDA of 13.18, which beats the industrial average of 23.11. Ciena Corporation presently sports a Zacks Rank #1 (Strong Buy).
2. CBOE Holdings, Inc.CBOE
CBOE Holdings operates as the holding company for Chicago Board Options Exchange, which is an options exchange which operates as an organized marketplace for the trade of listed options on equity securities. CBOE Holdings acquired Bats Global Markets a couple of months ago. This acquisition diversifies CBOE's product portfolio with the addition of European and U.S. equities, Global FX, and Global ETPs. Additionally, the company boasts an improving cash flow balance as they have lowered debt by $150 million and rewarded its shareholders by raising the quarterly dividend by 9% in July 2016.
CBOE Holdings posted Projected Sales Growth of 52.76% and Projected EPS Growth of 39.26%, both of which compare favorably to the industrial averages of 3.79% and 11.41%, respectively. Also, CBOE currently holds a beta rating of 0.53, which means that the stock is widely considered less volatile. The company also pays a steady 1.10% dividend to its shareholders. CBOE Holdings currently has a Zacks Rank #1 (Strong Buy).
3. Dave & Buster's Entertainment, Inc.PLAY
Dave & Buster's Entertainment Inc. owns and operates venues in North America that combine dining and entertainment. Dave & Buster's holds an "A" grade for Growth as the company has continued to develop in recent years. In fact, Dave & Buster's has been a model of consistency as they have defeated their earnings estimates in each of an incredible eleven straight operational quarters by an average of 54.74%. Also, the company expects to open twelve new locations during 2017 and maintain a 10% annual unit growth rate. Dave and Buster's is projected to outperform the restaurant industry, as 56% of the company's total revenues were collected from the amusement aspect of the company.
Dave & Buster's reported a Net Margin of 9.78% compared to an industry-wide average of 4.04%. In essence, the company is retaining a much larger profit per dollar than their industry peers. Further, the firm features a Cash Flow per Share of $4.26 compared to its competitors at $1.54, while the company's share price skyrocketed upward 45.84% over the past fiscal year. Overall, Dave & Buster's sports a Zacks Rank #1 (Strong Buy).
4. The Brink's CompanyBCO
The Brink's Company is a global leader in home security, supply chain management, and cash management services. The Brink's Company industry is located in the Top 17% of the Zacks Industry Rank. Further, Brink's reported a Cash/Price ratio of 63.64 and RoE of 31.50% compared to their competitors at 15.18 and 15.15%, respectively. Also, Brink's boasts a Sales/Assets ratio of 1.43, which beats their industry peers. This shows that Brink's is earning more revenue on their assets than their competitors.
The company posted Current Cash Flow Growth of 9.20%, which fares well among its industrial competitors. Brinks' share price has more than doubled in the past year with an increase of 139.87%. Now might be the perfect time to purchase shares of Brink's as it was recently promoted to a Zacks Rank #1 (Strong Buy).
5. Abbott LaboratoriesABT
Abbott Laboratories is a global healthcare company focused on improving life throughout the research and development of technologies. Abbott recently acquired St. Jude Medical which holds a strong position in areas such as atrial fibrillation, heart failure and chronic pain. These acquired strengths will complement Abbott's position in the coronary interventions and mitral valve disease markets. Abbott will now compete in almost every field of the cardiovascular market, which bodes well for its shareholders.
Additionally, Abbott believes in rewarding its shareholders with a respectable 2.19% dividend. The company posted a projected sales growth of 26.68% and P/E ratio of 19.70, both of which defeat their competitors' averages of 2.25% and 27.46, respectively. Finally, Abbott has represented a model of consistency, as they have beaten their earnings projections for the past twenty operational quarters dating back to 2012. Abbott Laboratories sports a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Ciena Corporation (CIEN): Free Stock Analysis Report
Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report
CBOE Holdings, Inc. (CBOE): Free Stock Analysis Report
Brink's Company (The) (BCO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT Abbott Laboratories is a global healthcare company focused on improving life throughout the research and development of technologies. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Ciena Corporation (CIEN): Free Stock Analysis Report Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report CBOE Holdings, Inc. (CBOE): Free Stock Analysis Report Brink's Company (The) (BCO): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, Ciena's revenues are expected to surge due to increased demand for packet-optical transport and switching products, integrated network and service management software. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Ciena Corporation (CIEN): Free Stock Analysis Report Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report CBOE Holdings, Inc. (CBOE): Free Stock Analysis Report Brink's Company (The) (BCO): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT Abbott Laboratories is a global healthcare company focused on improving life throughout the research and development of technologies. CBOE Holdings, Inc.CBOE CBOE Holdings operates as the holding company for Chicago Board Options Exchange, which is an options exchange which operates as an organized marketplace for the trade of listed options on equity securities. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Ciena Corporation (CIEN): Free Stock Analysis Report Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report CBOE Holdings, Inc. (CBOE): Free Stock Analysis Report Brink's Company (The) (BCO): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT Abbott Laboratories is a global healthcare company focused on improving life throughout the research and development of technologies. CBOE Holdings, Inc.CBOE CBOE Holdings operates as the holding company for Chicago Board Options Exchange, which is an options exchange which operates as an organized marketplace for the trade of listed options on equity securities. | Abbott LaboratoriesABT Abbott Laboratories is a global healthcare company focused on improving life throughout the research and development of technologies. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Ciena Corporation (CIEN): Free Stock Analysis Report Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report CBOE Holdings, Inc. (CBOE): Free Stock Analysis Report Brink's Company (The) (BCO): Free Stock Analysis Report To read this article on Zacks.com click here. Dave & Buster's holds an "A" grade for Growth as the company has continued to develop in recent years. |
33581.0 | 2017-06-29 00:00:00 UTC | What If St. Jude Medical Acquisition Doesn't Pan Out For Abbott? | ABT | https://www.nasdaq.com/articles/what-if-st-jude-medical-acquisition-doesnt-pan-out-abbott-2017-06-29 | nan | nan | Abbott Labs ( ABT ) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. St. Jude Medical does plug some gaps in Abbott's portfolio, and the cost synergies are likely to show up going forward. With the acquisition, which was closed earlier this year, the vascular business has become one of Abbott's largest segments. We currently forecast the vascular market to grow steadily and reach more than $25 billion by the end of our forecast period. At the same time, we expect Abbott to maintain around a 40% share in the market going forward, resulting in 3-4% annual growth in its vascular products revenue. While Abbott certainly has a size advantage, effectively integrating a new company is always a question mark. In Abbott's case, the risk is fairly significant because of the high debt load and significant competitive pressure in the market. So what happens if things don't pan out as expected? If price competition reduces our market forecast by 10%, and Abbott's share in the vascular market declines from 40% to 35%, there could be a nearly 10% downside to our price estimate for the company.
Our price estimate of $45 for Abbott Laboratories is slightly below the market.
The acquisition of St Jude Medical looked like a risky bet from the beginning. Earlier this year, credit ratings agency Fitch downgraded Abbott and St Jude Medial's IDRs to BBB. The agency stated that although St. Jude is a good strategic fit, the acquisition will put stress on Abbott's balance sheet for at least two years, thus increasing default risk. While BBB is still a fairly strong credit rating, the risks don't end there. The acquisition has also increased Abbott's exposure to the commoditized section of the cardiovascular medical device market. Johnson & Johnson's divestitures over the last couple of years suggest that the company is moving away from this business due to pricing pressure and a lack of growth. Additionally, Abbott's risk related to health care policy changes has increased as St. Jude is facing pressure from hospitals looking to cut costs.
Please let us know your views by commenting in the box below.
See More at Trefis|View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. The agency stated that although St. Jude is a good strategic fit, the acquisition will put stress on Abbott's balance sheet for at least two years, thus increasing default risk. Additionally, Abbott's risk related to health care policy changes has increased as St. Jude is facing pressure from hospitals looking to cut costs. | Abbott Labs ( ABT ) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. If price competition reduces our market forecast by 10%, and Abbott's share in the vascular market declines from 40% to 35%, there could be a nearly 10% downside to our price estimate for the company. Earlier this year, credit ratings agency Fitch downgraded Abbott and St Jude Medial's IDRs to BBB. | Abbott Labs ( ABT ) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. If price competition reduces our market forecast by 10%, and Abbott's share in the vascular market declines from 40% to 35%, there could be a nearly 10% downside to our price estimate for the company. The agency stated that although St. Jude is a good strategic fit, the acquisition will put stress on Abbott's balance sheet for at least two years, thus increasing default risk. | Abbott Labs ( ABT ) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. If price competition reduces our market forecast by 10%, and Abbott's share in the vascular market declines from 40% to 35%, there could be a nearly 10% downside to our price estimate for the company. Earlier this year, credit ratings agency Fitch downgraded Abbott and St Jude Medial's IDRs to BBB. |
33582.0 | 2017-06-28 00:00:00 UTC | Noteworthy ETF Inflows: FVD, ABT, PDCO, AWR | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-fvd-abt-pdco-awr-2017-06-28 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Value Line Dividend Index Fund (Symbol: FVD) where we have detected an approximate $139.2 million dollar inflow -- that's a 3.8% increase week over week in outstanding units (from 125,137,986 to 129,887,986). Among the largest underlying components of FVD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Patterson Companies Inc (Symbol: PDCO) is up about 1.2%, and American States Water Co (Symbol: AWR) is up by about 0.3%. For a complete list of holdings, visit the FVD Holdings page » The chart below shows the one year price performance of FVD, versus its 200 day moving average:
Looking at the chart above, FVD's low point in its 52 week range is $25.59 per share, with $29.95 as the 52 week high point - that compares with a last trade of $29.47. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of FVD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Patterson Companies Inc (Symbol: PDCO) is up about 1.2%, and American States Water Co (Symbol: AWR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Value Line Dividend Index Fund (Symbol: FVD) where we have detected an approximate $139.2 million dollar inflow -- that's a 3.8% increase week over week in outstanding units (from 125,137,986 to 129,887,986). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of FVD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Patterson Companies Inc (Symbol: PDCO) is up about 1.2%, and American States Water Co (Symbol: AWR) is up by about 0.3%. For a complete list of holdings, visit the FVD Holdings page » The chart below shows the one year price performance of FVD, versus its 200 day moving average: Looking at the chart above, FVD's low point in its 52 week range is $25.59 per share, with $29.95 as the 52 week high point - that compares with a last trade of $29.47. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of FVD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Patterson Companies Inc (Symbol: PDCO) is up about 1.2%, and American States Water Co (Symbol: AWR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Value Line Dividend Index Fund (Symbol: FVD) where we have detected an approximate $139.2 million dollar inflow -- that's a 3.8% increase week over week in outstanding units (from 125,137,986 to 129,887,986). For a complete list of holdings, visit the FVD Holdings page » The chart below shows the one year price performance of FVD, versus its 200 day moving average: Looking at the chart above, FVD's low point in its 52 week range is $25.59 per share, with $29.95 as the 52 week high point - that compares with a last trade of $29.47. | Among the largest underlying components of FVD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Patterson Companies Inc (Symbol: PDCO) is up about 1.2%, and American States Water Co (Symbol: AWR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Value Line Dividend Index Fund (Symbol: FVD) where we have detected an approximate $139.2 million dollar inflow -- that's a 3.8% increase week over week in outstanding units (from 125,137,986 to 129,887,986). For a complete list of holdings, visit the FVD Holdings page » The chart below shows the one year price performance of FVD, versus its 200 day moving average: Looking at the chart above, FVD's low point in its 52 week range is $25.59 per share, with $29.95 as the 52 week high point - that compares with a last trade of $29.47. |
33583.0 | 2017-06-28 00:00:00 UTC | Health Care Sector Update for 06/28/2017: JNJ, PFE, ABT, MRK, AMGN, GMRE, BLUE, FOLD | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06282017-jnj-pfe-abt-mrk-amgn-gmre-blue-fold-2017-06-28 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: +0.1%
ABT: flat
MRK: -0.1%
AMGN: -0.2%
Health care shares were mixed in pre-market trade Wednesday.
In health care stocks news, Global Medical REIT ( GMRE ) was down 10% after it said late Tuesday that it will sell 3.5 million shares in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase an additional 525,000 shares of common stock to cover over-allotments, if any. Global Medical REIT will use the net proceeds from this offering to repay $25.0 million of the outstanding indebtedness under its revolving credit facility and to fund acquisitions or for other general corporate purposes.
The company also provided an update on its previously announced Cardiologists of Lubbock acquisition. On June 5, the company said that it entered into a purchase contract to purchase a 27,280 square-foot cardiac clinic in Lubbock, Texas and that the company was going to enter into a new, 12-year, triple-net lease with the Lubbock Heart Hospital. Rent payments under such lease were expected to be guaranteed by Surgery Partners, Inc., which manages the Cardiac Clinic through a joint venture agreement. Since the announcement of the acquisition of the Cardiac Clinic, Surgery Partners has informed that company that, due to legal restrictions on the percentage of lease payments it may guarantee, it was only going to be guaranteeing approximately 52% of the rent payments, a figure which represents Surgery Partners' percentage ownership of the Cardiac Clinic prior to its sale to the company.
In other sector news,
(-) BLUE (-0.4%) Prices offering of 3.8 million shares at 1.8% discount
FOLD (flat) Files Japanese new drug application for Migalastat for Fabry disease
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat In health care stocks news, Global Medical REIT ( GMRE ) was down 10% after it said late Tuesday that it will sell 3.5 million shares in an underwritten public offering. Global Medical REIT will use the net proceeds from this offering to repay $25.0 million of the outstanding indebtedness under its revolving credit facility and to fund acquisitions or for other general corporate purposes. | ABT: flat In health care stocks news, Global Medical REIT ( GMRE ) was down 10% after it said late Tuesday that it will sell 3.5 million shares in an underwritten public offering. Rent payments under such lease were expected to be guaranteed by Surgery Partners, Inc., which manages the Cardiac Clinic through a joint venture agreement. | ABT: flat On June 5, the company said that it entered into a purchase contract to purchase a 27,280 square-foot cardiac clinic in Lubbock, Texas and that the company was going to enter into a new, 12-year, triple-net lease with the Lubbock Heart Hospital. Since the announcement of the acquisition of the Cardiac Clinic, Surgery Partners has informed that company that, due to legal restrictions on the percentage of lease payments it may guarantee, it was only going to be guaranteeing approximately 52% of the rent payments, a figure which represents Surgery Partners' percentage ownership of the Cardiac Clinic prior to its sale to the company. | ABT: flat In health care stocks news, Global Medical REIT ( GMRE ) was down 10% after it said late Tuesday that it will sell 3.5 million shares in an underwritten public offering. On June 5, the company said that it entered into a purchase contract to purchase a 27,280 square-foot cardiac clinic in Lubbock, Texas and that the company was going to enter into a new, 12-year, triple-net lease with the Lubbock Heart Hospital. |
33584.0 | 2017-06-26 00:00:00 UTC | How We Earn $5,300 In Dividends From A $10,000 Investment (VZ, PSX, GILD) | ABT | https://www.nasdaq.com/articles/how-we-earn-%245300-in-dividends-from-a-%2410000-investment-vz-psx-gild-2017-06-26 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It's the most lucrative investing strategy I've ever found. It won't happen overnight, but I'm convinced anyone can earn a significant amount of money with this strategy.
Let me explain…
Consider your typical income portfolio. It holds a position in a few dividend payers and maybe a fund or two. You get paid occasional dividends, that's for sure. But because you only hold a few positions that pay quarterly dividends, the income you receive is inconsistent.
That's where my Daily Paycheck strategy is different. (If you're a regular reader of StreetAuthority , then you know I've shared the details of my Daily Paycheck Retirement Plan before.)
The goal: To build a high and steady stream of income. Using the plan, my followers and I are creating a portfolio that can pay us more than 30 dividend checks a month. At the same time, I'm generating an average yield of 5.3%… and that's when interest rates - which fuel the yields on most "normal" income investments - have been at their lowest in history.
There's a major caveat, though. And it's one that will cause most investors to never take the first step to start their own Daily Paycheck portfolio. Most investors don't have the most important characteristic that allows you to earn the greatest amount of wealth with this strategy: patience.
Take a $10,000 investment. In a portfolio like mine that earns an average yield of 5.3%, that amount would earn $530 in dividend income during the year. I wouldn't sneeze at $530, but it's just a fraction of what you could earn if you simply let your portfolio pay you year after year.
7 Monthly Dividend Stocks to Pay Your Bills
The table below shows exactly what I mean. It shows how much you'd earn… if you have patience. As you can see, even modest amounts can generate substantial dividends.
I want to make something clear… this isn't a "get-rich-quick" scheme. It's simple math. You aren't going to invest a few thousand dollars and be buying expensive sports cars or going on exotic vacations anytime soon. This doesn't work overnight.
But I think that's part of what makes this style of investing so powerful… You don't have to be an investing genius to use this strategy. Anyone can do it. All it takes is discipline.
The key is finding stocks that will pay you consistent dividends… and having the patience to let them grow your wealth over the long-term.
But this is just the tip of the iceberg. Truth be told, there's a way to turbocharge the math here - and it's what my subscribers do each month over at my premium newsletter, The Daily Paycheck . We've been building our own model portfolio for years, earning more than $106,000 in total dividends so far. And after starting out with $200,000 portfolio, we've managed to grow our portfolio to a total value of $348,789 at last count. To learn more about how you can do the same, see my latest report here .
In the meantime, I'm happy to share with you some of my favorite recommendations from The Daily Paycheck .
Until now, only my paid subscribers have seen these picks…
A monthly dividend payer, the Tekla Healthcare Opportunities Fund (NYSE: THQ ) is a relatively young closed-end fund with a juicy 7.7% current yield. The fund holds a collection of biotechs - such as Celgene Corporation (NASDAQ: CELG ) and Gilead Sciences, Inc. (NASDAQ: GILD ) - large pharmaceuticals - such as Abbot Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) - and other health care companies, such as UnitedHealth Group Inc (NYSE: UNH ). Best of all, it's selling at a better than 7% discount to its net asset value (NAV) despite delivering a better than 14% total return over the past 12 months.
One of Warren Buffett's favorites (the famed investor holds 15.6% of all the shares outstanding), Phillips 66 (NYSE: PSX ) is also an incredible dividend payer, having grown its dividends from 20 cents per share five years ago to the current 63 cents per share. This works out to a current yield of 3.2% - and I also expect more dividend increases as the year progresses.
Verizon Communication Inc.'s (NYSE: VZ ) 5% yield is one of the strongest among S&P 500 companies. And this communications giant generates enough business to ensure its dividend is covered.
10 Best Dividend Stocks for the Market's 10 Sectors
These are the types of returns we want every StreetAuthority reader to experience, which is why we're offering a special deal for new Daily Paycheck subscribers. For a limited time you'll be able to join us for only $99 for a full year as our way of saying "thanks" for your loyal readership. Don't miss out on this special offer!
More From InvestorPlace
The 7 Best REITs to Buy Right Now
The Top 10 S&P 500 Dividend Stocks to Buy Now
10 Dividend Aristocrats That Are Ready to Rally
The post How We Earn $5,300 In Dividends From A $10,000 Investment (VZ, PSX, GILD) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The fund holds a collection of biotechs - such as Celgene Corporation (NASDAQ: CELG ) and Gilead Sciences, Inc. (NASDAQ: GILD ) - large pharmaceuticals - such as Abbot Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) - and other health care companies, such as UnitedHealth Group Inc (NYSE: UNH ). Most investors don't have the most important characteristic that allows you to earn the greatest amount of wealth with this strategy: patience. You aren't going to invest a few thousand dollars and be buying expensive sports cars or going on exotic vacations anytime soon. | The fund holds a collection of biotechs - such as Celgene Corporation (NASDAQ: CELG ) and Gilead Sciences, Inc. (NASDAQ: GILD ) - large pharmaceuticals - such as Abbot Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) - and other health care companies, such as UnitedHealth Group Inc (NYSE: UNH ). In a portfolio like mine that earns an average yield of 5.3%, that amount would earn $530 in dividend income during the year. One of Warren Buffett's favorites (the famed investor holds 15.6% of all the shares outstanding), Phillips 66 (NYSE: PSX ) is also an incredible dividend payer, having grown its dividends from 20 cents per share five years ago to the current 63 cents per share. | The fund holds a collection of biotechs - such as Celgene Corporation (NASDAQ: CELG ) and Gilead Sciences, Inc. (NASDAQ: GILD ) - large pharmaceuticals - such as Abbot Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) - and other health care companies, such as UnitedHealth Group Inc (NYSE: UNH ). In a portfolio like mine that earns an average yield of 5.3%, that amount would earn $530 in dividend income during the year. One of Warren Buffett's favorites (the famed investor holds 15.6% of all the shares outstanding), Phillips 66 (NYSE: PSX ) is also an incredible dividend payer, having grown its dividends from 20 cents per share five years ago to the current 63 cents per share. | The fund holds a collection of biotechs - such as Celgene Corporation (NASDAQ: CELG ) and Gilead Sciences, Inc. (NASDAQ: GILD ) - large pharmaceuticals - such as Abbot Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) - and other health care companies, such as UnitedHealth Group Inc (NYSE: UNH ). InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's the most lucrative investing strategy I've ever found. We've been building our own model portfolio for years, earning more than $106,000 in total dividends so far. |
33585.0 | 2017-06-26 00:00:00 UTC | How to Find Cheap Stocks With 5%+ Dividends | ABT | https://www.nasdaq.com/articles/how-to-find-cheap-stocks-with-5-dividends-2017-06-26 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too.
I'll also reveal a blue chip stock that's delivering both strong price gains and rising dividends. It will have you pocketing a nice 5%+ yield in short order.
The Dividend-Growth Signal Most People Miss
If you've been buying dividend stocks for a while, you probably know about the payout ratio.
It's a sacred cow for many folks; you calculate it by dividing the total amount of dividends paid by the company's last 12 months of net income.
If it comes out in the neighborhood of, say, 50% or less, you've got a safe dividend that's likely to grow. As you get climb closer to 100%, the noose around the payout gets tighter.
Simple, right?
Problem is, earnings are an accounting creation. They often have little relation to the actual cash the firm is making!
Earnings can be easily manipulated to overstate cash flow generation. But they can, at times, understate it too.
Take Pfizer Inc. (NYSE: PFE ), a drug stock I analyzed a few months ago . If you went by its net income-based payout ratio of 101%, you'd want to stay well away.
By that measure, the pharma giant is paying out more in dividends than it's earning-a disaster in the making!
Not so fast. Because you really need to look at the free cash flow payout ratio here.
Free cash what?
7 Monthly Dividend Stocks to Pay Your Bills
We don't have to get too deep in the weeds, but suffice it to say, free cash flow (FCF) tells you how much cash a company is generating once it's paid the cost of maintaining and growing its business.
You calculate it by subtracting capital expenditures from a company's cash flow from operating activities (both figures are available under the "Financials" tab on Yahoo Finance).
And when you look at Pfizer's dividends as a percentage of FCF, the picture looks a lot brighter:
At 54%, Pfizer's FCF payout ratio is right in my "safe" zone; it's a stock with plenty of dividend-growth juice left. The company's cash-flow generating power was indeed understated by its earnings numbers.
Now I know what you're probably thinking here: "I thought this article was supposed to help me find cheap 5% yielders, and Pfizer pays just 3.7%. What gives?"
That brings me to the next thing many dividend hounds ignore.
Beyond the Dividend Yield
When it comes to dividends, many people simply dial up a stock in Yahoo Finance or Google Finance, check out its current yield and leave it at that.
To be sure, current yield is important, but it's just a snapshot in time. We need to focus on future yields.
To show you what I mean, let's look at Pfizer again. Over the past five years, its yield has stayed in a tight range, from around 2.9% to, very briefly, just north of 3.9%.
That won't get your average income fan's pulse racing.
But what current yields don't tell you is that management has hiked the quarterly payout by 45% in that time, and the stock's price has jumped at roughly the same pace.
And because you calculate yield by dividing the yearly dividend by the current share price, the current yield has gone nowhere.
But roll back the curtain and you'll see the impact of that payout growth on your yield on investment -and it's shocking. Instead of 3.7%, you'd now be pocketing a nice 5.6% on your money if you'd bought PFE back in 2012.
This phenomenon is hardly unique to Pfizer. You've probably noticed that the yield on most of your favorite Dividend Aristocrats rarely changes meaningfully.
The good news is we can use that to our advantage, because it's shining a light on something almost everyone overlooks: the direct connection between a rising payout and a rising share price.
There's no clearer example of that than Pfizer, whose share price and dividend have marched upward in lockstep over the past five years, with each one up nearly 50%!
That's no coincidence, and it tells us that if we buy stocks with sterling dividend histories and safe FCF payout ratios, we'll give ourselves a great shot at serious price gains too, especially if we hold on for the long haul.
Even better if we can buy cheap, and with Pfizer, we can: the stock trades at just 15.2 times trailing-twelve-month FCF, well below rivals Johnson & Johnson (NYSE: JNJ ) at 22.9 and Abbott Laboratories (NYSE: ABT ) at 27.6.
10 Best Dividend Stocks for the Market's 10 Sectors
Here's How We'll Double Our MoneyandCollect 8.6% Income
A 50% gain in 5 years is nice, but we can do a lot better if we zero in on stocks with the same strengths as Pfizer but double the dividend growth.
I'm talking about companies handing their shareholders 15% to 20% payout hikes every single year, so your income stream will quickly expand by 100% or more. And as I just showed you with Pfizer, the share price will beforcedto follow suit!
I'm pounding the table on 7 such companies now, and I've put all 7 in a NEW special report-"The 7 Best Dividend Growth Stocks With 100%+ Upside"-YOURS FREE .
Here are just a few of the stocks you'll discover in this breakthrough FREE report:
The water company that's turning every $1 in sales into $10 in free cash flow. This one could easily give shareholders a nice raise today-and its next dividend hike will be BIG.
The self-storage operator that's hiked its dividend TWICE in the past year . At this rate, it will double its payout in 4 or 5 years, turning our 4.3% yield into a reliable 8.6% income stream!
The 800% dividend grower: This ignored company has boosted its payout eightfold in just four years, and it's just getting started! Plus, management is jumping on the stock's absurdly cheap valuation, carefully using share buybacks to set us up for even bigger gains.
PLUS 4 more stocks with surefire 100% dividend growth ahead.
I'm ready to show you all 7 of these standout companies now. All you have to do is click here to get my full dividend-growth strategy and your own copy of this eye-opening special report .
More From InvestorPlace
The 7 Best REITs to Buy Right Now
The Top 10 S&P 500 Dividend Stocks to Buy Now
10 Dividend Aristocrats That Are Ready to Rally
The post How to Find Cheap Stocks With 5%+ Dividends appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Even better if we can buy cheap, and with Pfizer, we can: the stock trades at just 15.2 times trailing-twelve-month FCF, well below rivals Johnson & Johnson (NYSE: JNJ ) at 22.9 and Abbott Laboratories (NYSE: ABT ) at 27.6. You calculate it by subtracting capital expenditures from a company's cash flow from operating activities (both figures are available under the "Financials" tab on Yahoo Finance). But what current yields don't tell you is that management has hiked the quarterly payout by 45% in that time, and the stock's price has jumped at roughly the same pace. | Even better if we can buy cheap, and with Pfizer, we can: the stock trades at just 15.2 times trailing-twelve-month FCF, well below rivals Johnson & Johnson (NYSE: JNJ ) at 22.9 and Abbott Laboratories (NYSE: ABT ) at 27.6. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too. 7 Monthly Dividend Stocks to Pay Your Bills We don't have to get too deep in the weeds, but suffice it to say, free cash flow (FCF) tells you how much cash a company is generating once it's paid the cost of maintaining and growing its business. | Even better if we can buy cheap, and with Pfizer, we can: the stock trades at just 15.2 times trailing-twelve-month FCF, well below rivals Johnson & Johnson (NYSE: JNJ ) at 22.9 and Abbott Laboratories (NYSE: ABT ) at 27.6. Beyond the Dividend Yield When it comes to dividends, many people simply dial up a stock in Yahoo Finance or Google Finance, check out its current yield and leave it at that. 10 Best Dividend Stocks for the Market's 10 Sectors Here's How We'll Double Our MoneyandCollect 8.6% Income A 50% gain in 5 years is nice, but we can do a lot better if we zero in on stocks with the same strengths as Pfizer but double the dividend growth. | Even better if we can buy cheap, and with Pfizer, we can: the stock trades at just 15.2 times trailing-twelve-month FCF, well below rivals Johnson & Johnson (NYSE: JNJ ) at 22.9 and Abbott Laboratories (NYSE: ABT ) at 27.6. To show you what I mean, let's look at Pfizer again. And because you calculate yield by dividing the yearly dividend by the current share price, the current yield has gone nowhere. |
33586.0 | 2017-06-26 00:00:00 UTC | How to Find Cheap Stocks With 5%+ Dividends | ABT | https://www.nasdaq.com/articles/how-find-cheap-stocks-5-dividends-2017-06-26-0 | nan | nan | By Brett Owens
Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too.
I'll also reveal a blue chip stock that's delivering both strong price gains and rising dividends. It will have you pocketing a nice 5%+ yield in short order.
So let's get going, starting with...
The Dividend-Growth Signal Most People Miss
If you've been buying dividend stocks for a while, you probably know about the payout ratio.
It's a sacred cow for many folks; you calcu | By Brett Owens Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too. I'll also reveal a blue chip stock that's delivering both strong price gains and rising dividends. The Dividend-Growth Signal Most People Miss If you've been buying dividend stocks for a while, you probably know about the payout ratio. | By Brett Owens Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too. I'll also reveal a blue chip stock that's delivering both strong price gains and rising dividends. The Dividend-Growth Signal Most People Miss If you've been buying dividend stocks for a while, you probably know about the payout ratio. | By Brett Owens Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too. It will have you pocketing a nice 5%+ yield in short order. It's a sacred cow for many folks; you calcu | By Brett Owens Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too. I'll also reveal a blue chip stock that's delivering both strong price gains and rising dividends. It will have you pocketing a nice 5%+ yield in short order. |
33587.0 | 2017-06-26 00:00:00 UTC | Health Care Sector Update for 06/26/2017: JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06262017-jnj-pfe-abt-mrk-amgn-2017-06-26 | nan | nan | Top Health Care stocks:
JNJ: +0.5%
PFE: +0.5%
ABT: -0.2%
MRK: +0.02%
AMGN: +0.5%
Health care shares were mainly firmer in pre-market trade Monday.
In health care stocks news, Conatus Pharmaceuticals ( CNAT ) was up 2% after it said the U.S. Food and Drug Administration has granted orphan drug designation to its IDN-7314 to treat primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. IDN-7314 is an orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, the company said. The drug has been evaluated in mouse studies.
In other sector news,
(+) TGTX (+3.4%) Reports positive results from phase 2 study of TG-1101 to treat MS
(-) BMY (-0.7%) Says follow-up data from its phase 3 Eloquent-2 study showed Empliciti plus lenalidomide/dexamethasone (Ld) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma, compared to Ld alone
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mainly firmer in pre-market trade Monday. In health care stocks news, Conatus Pharmaceuticals ( CNAT ) was up 2% after it said the U.S. Food and Drug Administration has granted orphan drug designation to its IDN-7314 to treat primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. In other sector news, (+) TGTX (+3.4%) Reports positive results from phase 2 study of TG-1101 to treat MS (-) BMY (-0.7%) Says follow-up data from its phase 3 Eloquent-2 study showed Empliciti plus lenalidomide/dexamethasone (Ld) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma, compared to Ld alone The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Conatus Pharmaceuticals ( CNAT ) was up 2% after it said the U.S. Food and Drug Administration has granted orphan drug designation to its IDN-7314 to treat primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. In other sector news, (+) TGTX (+3.4%) Reports positive results from phase 2 study of TG-1101 to treat MS (-) BMY (-0.7%) Says follow-up data from its phase 3 Eloquent-2 study showed Empliciti plus lenalidomide/dexamethasone (Ld) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma, compared to Ld alone The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Conatus Pharmaceuticals ( CNAT ) was up 2% after it said the U.S. Food and Drug Administration has granted orphan drug designation to its IDN-7314 to treat primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. In other sector news, (+) TGTX (+3.4%) Reports positive results from phase 2 study of TG-1101 to treat MS (-) BMY (-0.7%) Says follow-up data from its phase 3 Eloquent-2 study showed Empliciti plus lenalidomide/dexamethasone (Ld) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma, compared to Ld alone The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited. | Top Health Care stocks: In health care stocks news, Conatus Pharmaceuticals ( CNAT ) was up 2% after it said the U.S. Food and Drug Administration has granted orphan drug designation to its IDN-7314 to treat primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. In other sector news, (+) TGTX (+3.4%) Reports positive results from phase 2 study of TG-1101 to treat MS (-) BMY (-0.7%) Says follow-up data from its phase 3 Eloquent-2 study showed Empliciti plus lenalidomide/dexamethasone (Ld) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma, compared to Ld alone The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33588.0 | 2017-06-23 00:00:00 UTC | Health Care Sector Update for 06/23/2017: JNJ, PFE, ABT, MRK, AMGN, CARA, BLCM, NVS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06232017-jnj-pfe-abt-mrk-amgn-cara-blcm-nvs-2017-06-23 | nan | nan | Top Health Care stocks:
JNJ: +0.1%
PFE: +1.3%
ABT: +0.1%
MRK: flat
AMGN: -0.2%
Health care shares were mainly higher in pre-market trade Friday .
In health care stocks news, Cara Therapeutics ( CARA ) was up 8.2% after it said the U.S. Food and Drug Administration has granted breakthrough therapy designation to I.V. CR845 for the treatment of moderate-to-severe uremic pruritus in chronic kidney disease patients undergoing hemodialysis. The designation allows for the expedited review of the drug.
In other sector news,
(+) BLCM (+7.3%) Unveils 'encouraging' data on BPX-501 in pediatric leukemias
(-) NVS (-1%) Gets European approval for Kisqali as first-line breast cancer treatment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care shares were mainly higher in pre-market trade Friday . CR845 for the treatment of moderate-to-severe uremic pruritus in chronic kidney disease patients undergoing hemodialysis. In other sector news, (+) BLCM (+7.3%) Unveils 'encouraging' data on BPX-501 in pediatric leukemias (-) NVS (-1%) Gets European approval for Kisqali as first-line breast cancer treatment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: Health care shares were mainly higher in pre-market trade Friday . In health care stocks news, Cara Therapeutics ( CARA ) was up 8.2% after it said the U.S. Food and Drug Administration has granted breakthrough therapy designation to I.V. | MRK: flat In health care stocks news, Cara Therapeutics ( CARA ) was up 8.2% after it said the U.S. Food and Drug Administration has granted breakthrough therapy designation to I.V. In other sector news, (+) BLCM (+7.3%) Unveils 'encouraging' data on BPX-501 in pediatric leukemias (-) NVS (-1%) Gets European approval for Kisqali as first-line breast cancer treatment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: MRK: flat In health care stocks news, Cara Therapeutics ( CARA ) was up 8.2% after it said the U.S. Food and Drug Administration has granted breakthrough therapy designation to I.V. |
33589.0 | 2017-06-21 00:00:00 UTC | YieldBoost ABT To 5.6% Using Options | ABT | https://www.nasdaq.com/articles/yieldboost-abt-56-using-options-2017-06-21 | nan | nan | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the January 2019 covered call at the $52.50 strike and collect the premium based on the $2.59 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.6% annualized rate in the scenario where the stock is not called away. Any upside above $52.50 would be lost if the stock rises there and is called away, but ABT shares would have to advance 8.2% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 13.6% return from this trading level, in addition to any dividends collected before the stock was called.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.2% annualized dividend yield.
Below is a chart showing ABT's trailing twelve month trading history, with the $52.50 strike highlighted in red:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 covered call at the $52.50 strike gives good reward for the risk of having given away the upside beyond $52.50. ( Do most options expire worthless? This and six other common options myths debunked ). We calculate the trailing twelve month volatility for Abbott Laboratories (considering the last 252 trading day closing values as well as today's price of $48.34) to be 18%. For other call options contract ideas at the various different available expirations, visit the ABT Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Wednesday, the put volume among S&P 500 components was 591,949 contracts, with call volume at 1.11M, for a put:call ratio of 0.53 so far for the day. Compared to the long-term median put:call ratio of .65, that represents very high call volume relative to puts; in other words, buyers are preferring calls in options trading so far today. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a chart showing ABT's trailing twelve month trading history, with the $52.50 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 covered call at the $52.50 strike gives good reward for the risk of having given away the upside beyond $52.50. Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the January 2019 covered call at the $52.50 strike and collect the premium based on the $2.59 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.6% annualized rate in the scenario where the stock is not called away. Any upside above $52.50 would be lost if the stock rises there and is called away, but ABT shares would have to advance 8.2% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 13.6% return from this trading level, in addition to any dividends collected before the stock was called. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the January 2019 covered call at the $52.50 strike and collect the premium based on the $2.59 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.6% annualized rate in the scenario where the stock is not called away. Any upside above $52.50 would be lost if the stock rises there and is called away, but ABT shares would have to advance 8.2% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 13.6% return from this trading level, in addition to any dividends collected before the stock was called. Below is a chart showing ABT's trailing twelve month trading history, with the $52.50 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 covered call at the $52.50 strike gives good reward for the risk of having given away the upside beyond $52.50. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the January 2019 covered call at the $52.50 strike and collect the premium based on the $2.59 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.6% annualized rate in the scenario where the stock is not called away. Any upside above $52.50 would be lost if the stock rises there and is called away, but ABT shares would have to advance 8.2% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 13.6% return from this trading level, in addition to any dividends collected before the stock was called. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.2% annualized dividend yield. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the January 2019 covered call at the $52.50 strike and collect the premium based on the $2.59 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.6% annualized rate in the scenario where the stock is not called away. Below is a chart showing ABT's trailing twelve month trading history, with the $52.50 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 covered call at the $52.50 strike gives good reward for the risk of having given away the upside beyond $52.50. For other call options contract ideas at the various different available expirations, visit the ABT Stock Options page of StockOptionsChannel.com. |
33590.0 | 2017-06-21 00:00:00 UTC | Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago | ABT | https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-johnson-johnson-nantkwest-delek-us-holdings-abbot-labs-and | nan | nan | For Immediate Release
Chicago, IL - June 21, 2017 - Stocks in this week's article include Johnson & Johnson (NYSE: JNJ - Free Report ), NantKwest (NASDAQ: NK - Free Report ), Delek US Holdings (NYSE: DK - Free Report ), Abbot Labs (NYSE: ABT - Free Report ) and Winnebago (NYSE: WGO - Free Report ).
Screen of the Week of Zacks Investment Research by Kevin Matras:
How to Uncover Institutional Buying
One of the best ways to find stocks on the move that are grabbing the attention of investors is to screen for stocks with increasing volume.
This is because increased volume shows investor interest. As more investors buy the stock, the stock's price should go higher.
But the individual investor, while important to the market, doesn't really have the firepower to affect volume the way that big institutional investors do.
And very few things can move a stock more than institutional buying.
Why is that?
For one, institutions have the ability of buying tens of millions of dollars worth of a stock and even hundreds of millions of dollars. And because their purchases are often so large, it typically takes weeks, if not months, for an institutional investor to build a position.
Given this commitment, considering it will also take several weeks or months to get out, you can be sure that these institutional investors have done plenty of homework to feel good about the fundamental prospects of the company.
This does not mean you can ignore your own analysis or the stock market as a whole. But screening for stocks with rising volume (along with prices of course) can put some fantastic stocks on your radar screen.
What Kind of Volume Increase to Look For
I prefer to search for at least two weeks of increasing volume along with rising prices. And in my testing I have found that 3 weeks performs even better.
One week volume spikes, however, will not get thru, as oftentimes those can be driven by one day events. Instead, it's the successive volume increase that shows true buying demand, giving this set-up its value.
The volume increase also doesn't have to be huge. We're not talking about a several hundred percent increase. In fact, often those massive increases prove to be turning points.
What we're looking for are noticeable increases, like 10%, 20% or 50% increases, etc. But nothing outrageous, like a 10 fold increase. Remember, the last thing an institutional investor wants to do is call too much attention while he or she is in the midst of building a position. But if you know what to look for, you can see all of this happening in plain sight. And get in for the ride as they flesh out the rest of their position.
Screen Parameters
• Current Price greater than Price from 1 Week Ago
• Price from 1 Week Ago greater than Price from 2 Weeks Ago
• Price from 2 Week Ago greater than Price from 3 Weeks Ago
• Weekly Volume greater than Weekly Volume from 1 Week Ago
• Weekly Volume from 1 Wk Ago greater than Weekly Volume from 2 Wks Ago
• Weekly Volume from 2 Wks Ago greater than Weekly Volume from 3 Wks Ago
• Zacks Rank less than or equal to 3
• Price greater than or equal to $5
• Average 20-day Volume greater than or equal to 100,000 shares
The most important elements to this screen are the price and volume items (especially the volume). The Zacks Rank also helps to make sure that their earnings estimates are on the rise. The price item, however, is a personal preference as I generally don't buy stocks under $5. But it should also be noted that many institutions won't either. But if you're looking for lower priced stocks, you can of course remove this item. And lastly, the average volume item ensures there's enough trade activity on a daily basis to get in and out of the market easily.
Stocks
Here are 5 stocks that passed this week's screen:
(NYSE: JNJ - Free Report ) Johnson & Johnson
(NASDAQ: NK - Free Report ) NantKwest
(NYSE: DK - Free Report ) Delek US Holdings
(NYSE: ABT - Free Report ) Abbot Labs
(NYSE: WGO - Free Report ) Winnebago
All of these stocks look good fundamentally. But their successive increases in weekly volume suggest institutional buying, and warrant an even closer look.
Get the rest of the stocks on this list and start screening for weekly volume increases to uncover institutional buying on your own. It's easy to do.
Click here to sign up for a free trial to the Research Wizard today.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks' portfolios and strategies are available at:https://www.zacks.com/performance.
Zacks Restaurant Recommendations: In addition to dining at these special places, you can feast on their stock shares. A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector. Download it free »
Sign up now for your free trial today and start picking better stocks immediately. And with the backtesting feature, you can test your ideas to see how you can improve your trading in both up markets and down markets. Don't wait for the market to get better before you decide to do better. Start learning how to be a better trader today: https://at.zacks.com/?id=111
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use. Each week, Zacks Profit from the Pros free email newsletter shares a new screening strategy. Learn more about it here https://at.zacks.com/?id=112
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros .
Get the full Report on JNJ - FREE
Get the full Report on NK - FREE
Get the full Report on DK - FREE
Get the full Report on ABT - FREE
Get the full Report on WGO - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/performance
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer .
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
NantKwest, Inc. (NK): Free Stock Analysis Report
Delek US Holdings, Inc. (DK): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Winnebago Industries, Inc. (WGO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - June 21, 2017 - Stocks in this week's article include Johnson & Johnson (NYSE: JNJ - Free Report ), NantKwest (NASDAQ: NK - Free Report ), Delek US Holdings (NYSE: DK - Free Report ), Abbot Labs (NYSE: ABT - Free Report ) and Winnebago (NYSE: WGO - Free Report ). Stocks Here are 5 stocks that passed this week's screen: (NYSE: JNJ - Free Report ) Johnson & Johnson (NASDAQ: NK - Free Report ) NantKwest (NYSE: DK - Free Report ) Delek US Holdings (NYSE: ABT - Free Report ) Abbot Labs (NYSE: WGO - Free Report ) Winnebago All of these stocks look good fundamentally. Get the full Report on JNJ - FREE Get the full Report on NK - FREE Get the full Report on DK - FREE Get the full Report on ABT - FREE Get the full Report on WGO - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | For Immediate Release Chicago, IL - June 21, 2017 - Stocks in this week's article include Johnson & Johnson (NYSE: JNJ - Free Report ), NantKwest (NASDAQ: NK - Free Report ), Delek US Holdings (NYSE: DK - Free Report ), Abbot Labs (NYSE: ABT - Free Report ) and Winnebago (NYSE: WGO - Free Report ). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks Here are 5 stocks that passed this week's screen: (NYSE: JNJ - Free Report ) Johnson & Johnson (NASDAQ: NK - Free Report ) NantKwest (NYSE: DK - Free Report ) Delek US Holdings (NYSE: ABT - Free Report ) Abbot Labs (NYSE: WGO - Free Report ) Winnebago All of these stocks look good fundamentally. | Stocks Here are 5 stocks that passed this week's screen: (NYSE: JNJ - Free Report ) Johnson & Johnson (NASDAQ: NK - Free Report ) NantKwest (NYSE: DK - Free Report ) Delek US Holdings (NYSE: ABT - Free Report ) Abbot Labs (NYSE: WGO - Free Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - June 21, 2017 - Stocks in this week's article include Johnson & Johnson (NYSE: JNJ - Free Report ), NantKwest (NASDAQ: NK - Free Report ), Delek US Holdings (NYSE: DK - Free Report ), Abbot Labs (NYSE: ABT - Free Report ) and Winnebago (NYSE: WGO - Free Report ). | For Immediate Release Chicago, IL - June 21, 2017 - Stocks in this week's article include Johnson & Johnson (NYSE: JNJ - Free Report ), NantKwest (NASDAQ: NK - Free Report ), Delek US Holdings (NYSE: DK - Free Report ), Abbot Labs (NYSE: ABT - Free Report ) and Winnebago (NYSE: WGO - Free Report ). Stocks Here are 5 stocks that passed this week's screen: (NYSE: JNJ - Free Report ) Johnson & Johnson (NASDAQ: NK - Free Report ) NantKwest (NYSE: DK - Free Report ) Delek US Holdings (NYSE: ABT - Free Report ) Abbot Labs (NYSE: WGO - Free Report ) Winnebago All of these stocks look good fundamentally. Get the full Report on JNJ - FREE Get the full Report on NK - FREE Get the full Report on DK - FREE Get the full Report on ABT - FREE Get the full Report on WGO - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
33591.0 | 2017-06-21 00:00:00 UTC | Health Care Sector Update for 06/21/2017: JNJ, PFE, ABT, MRK, AMGN, RXII, PSTI, CARA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06212017-jnj-pfe-abt-mrk-amgn-rxii-psti-cara-2017-06-21 | nan | nan | Top Health Care stocks:
JNJ: -0.2%
PFE: flat
ABT: flat
MRK: +0.1%
AMGN: +0.9%
Health care shares were mixed in pre-market trade Wednesday.
In health care stocks news, RXI Pharmaceuticals ( RXII ) rose 15% after the company said it completed enrollment in its phase 1/2 study RXI-109-1501. This multi-center, multi-dose, dose escalation trial is being conducted in patients with advanced neovascular or 'wet' age-related macular degeneration where retinal scarring can result in continued vision loss. RXI-109 is a self-delivering RNAi compound developed to target connective tissue growth factor, a key regulator of scar formation.
In other sector news,
(+) PSTI (+2.3%) Terminates $30 million investment with Innovative Medical Management due to new Chinese policy
(-) CARA (-4.8%) Phase 3 Trial of I.V. CR845 in postoperative pain to continue following interim assessment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat In health care stocks news, RXI Pharmaceuticals ( RXII ) rose 15% after the company said it completed enrollment in its phase 1/2 study RXI-109-1501. This multi-center, multi-dose, dose escalation trial is being conducted in patients with advanced neovascular or 'wet' age-related macular degeneration where retinal scarring can result in continued vision loss. | PFE: flat ABT: flat In health care stocks news, RXI Pharmaceuticals ( RXII ) rose 15% after the company said it completed enrollment in its phase 1/2 study RXI-109-1501. CR845 in postoperative pain to continue following interim assessment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat In health care stocks news, RXI Pharmaceuticals ( RXII ) rose 15% after the company said it completed enrollment in its phase 1/2 study RXI-109-1501. CR845 in postoperative pain to continue following interim assessment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFE: flat ABT: flat Top Health Care stocks: This multi-center, multi-dose, dose escalation trial is being conducted in patients with advanced neovascular or 'wet' age-related macular degeneration where retinal scarring can result in continued vision loss. |
33592.0 | 2017-06-20 00:00:00 UTC | Health Care Sector Update for 06/20/2017: JNJ, PFE, ABT, MRK, AMGN, LPCN, PRXL, MD | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06202017-jnj-pfe-abt-mrk-amgn-lpcn-prxl-md-2017-06-20 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: -1%
Health care shares were mostly lower in pre-market trade Tuesday.
In health care stocks news, Lipocine ( LPCN ) rose 30.1% after it reported late Monday that both the Dosing Validation and the Dosing Flexibility studies evaluating efficacy and tolerability of LPCN 1021 successfully met Food and Drug Administration primary efficacy guidelines. LPCN 1021 is an oral testosterone product candidate for testosterone replacement therapy ( TRT ) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. In the DV study, 81% of the subjects achieved average testosterone levels within the normal range with a lower bound confidence interval of 72% . The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. The results from these studies confirm the validity of a fixed dose approach without the need for dose titration to orally administering LPCN 1021.
In other sector news,
(+) PRXL (+4.3%) Confirms deal to be bought for $88.10/share cash by Pamplona Capital
MD (flat) Buys maternal-fetal medicine practice in Tennessee
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat In health care stocks news, Lipocine ( LPCN ) rose 30.1% after it reported late Monday that both the Dosing Validation and the Dosing Flexibility studies evaluating efficacy and tolerability of LPCN 1021 successfully met Food and Drug Administration primary efficacy guidelines. In the DV study, 81% of the subjects achieved average testosterone levels within the normal range with a lower bound confidence interval of 72% . | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat In the DV study, 81% of the subjects achieved average testosterone levels within the normal range with a lower bound confidence interval of 72% . The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat In health care stocks news, Lipocine ( LPCN ) rose 30.1% after it reported late Monday that both the Dosing Validation and the Dosing Flexibility studies evaluating efficacy and tolerability of LPCN 1021 successfully met Food and Drug Administration primary efficacy guidelines. The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat Health care shares were mostly lower in pre-market trade Tuesday. The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. |
33593.0 | 2017-06-20 00:00:00 UTC | How to Uncover Institutional Buying | ABT | https://www.nasdaq.com/articles/how-uncover-institutional-buying-2017-06-20 | nan | nan | One of the best ways to find stocks on the move that are grabbing the attention of investors is to screen for stocks with increasing volume.
This is because increased volume shows investor interest. As more investors buy the stock, the stock's price should go higher.
But the individual investor, while important to the market, doesn't really have the firepower to affect volume the way that big institutional investors do.
And very few things can move a stock more than institutional buying.
Why is that?
For one, institutions have the ability of buying tens of millions of dollars worth of a stock and even hundreds of millions of dollars. And because their purchases are often so large, it typically takes weeks, if not months, for an institutional investor to build a position.
Given this commitment, considering it will also take several weeks or months to get out, you can be sure that these institutional investors have done plenty of homework to feel good about the fundamental prospects of the company.
This does not mean you can ignore your own analysis or the stock market as a whole. But screening for stocks with rising volume (along with prices of course) can put some fantastic stocks on your radar screen.
What Kind of Volume Increase to Look For
I prefer to search for at least two weeks of increasing volume along with rising prices. And in my testing I have found that 3 weeks performs even better.
One week volume spikes, however, will not get thru, as oftentimes those can be driven by one day events. Instead, it's the successive volume increase that shows true buying demand, giving this set-up its value.
The volume increase also doesn't have to be huge. We're not talking about a several hundred percent increase. In fact, often those massive increases prove to be turning points.
What we're looking for are noticeable increases, like 10%, 20% or 50% increases, etc. But nothing outrageous, like a 10 fold increase. Remember, the last thing an institutional investor wants to do is call too much attention while he or she is in the midst of building a position. But if you know what to look for, you can see all of this happening in plain sight. And get in for the ride as they flesh out the rest of their position.
Screen Parameters
• Current Price greater than Price from 1 Week Ago
• Price from 1 Week Ago greater than Price from 2 Weeks Ago
• Price from 2 Week Ago greater than Price from 3 Weeks Ago
• Weekly Volume greater than Weekly Volume from 1 Week Ago
• Weekly Volume from 1 Wk Ago greater than Weekly Volume from 2 Wks Ago
• Weekly Volume from 2 Wks Ago greater than Weekly Volume from 3 Wks Ago
• Zacks Rank less than or equal to 3
• Price greater than or equal to $5
• Average 20-day Volume greater than or equal to 100,000 shares
The most important elements to this screen are the price and volume items (especially the volume). The Zacks Rank also helps to make sure that their earnings estimates are on the rise. The price item, however, is a personal preference as I generally don't buy stocks under $5. But it should also be noted that many institutions won't either. But if you're looking for lower priced stocks, you can of course remove this item. And lastly, the average volume item ensures there's enough trade activity on a daily basis to get in and out of the market easily.
Stocks
Here are 5 stocks that passed this week's screen:
( JNJ - Research Report ) Johnson & Johnson
( NK - Research Report ) NantKwest
( DK - Research Report ) Delek US Holdings
( ABT - Research Report ) Abbot Labs
( WGO - Research Report ) Winnebago
All of these stocks look good fundamentally. But their successive increases in weekly volume suggest institutional buying, and warrant an even closer look.
Get the rest of the stocks on this list and start screening for weekly volume increases to uncover institutional buying on your own. It's easy to do.
Click here to sign up for a free trial to the Research Wizard today.
Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks' portfolios and strategies are available at: https://www.zacks.com/performance .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Winnebago Industries, Inc. (WGO): Free Stock Analysis Report
NantKwest, Inc. (NK): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Delek US Holdings, Inc. (DK): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks Here are 5 stocks that passed this week's screen: ( JNJ - Research Report ) Johnson & Johnson ( NK - Research Report ) NantKwest ( DK - Research Report ) Delek US Holdings ( ABT - Research Report ) Abbot Labs ( WGO - Research Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Given this commitment, considering it will also take several weeks or months to get out, you can be sure that these institutional investors have done plenty of homework to feel good about the fundamental prospects of the company. | Stocks Here are 5 stocks that passed this week's screen: ( JNJ - Research Report ) Johnson & Johnson ( NK - Research Report ) NantKwest ( DK - Research Report ) Delek US Holdings ( ABT - Research Report ) Abbot Labs ( WGO - Research Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Screen Parameters • Current Price greater than Price from 1 Week Ago • Price from 1 Week Ago greater than Price from 2 Weeks Ago • Price from 2 Week Ago greater than Price from 3 Weeks Ago • Weekly Volume greater than Weekly Volume from 1 Week Ago • Weekly Volume from 1 Wk Ago greater than Weekly Volume from 2 Wks Ago • Weekly Volume from 2 Wks Ago greater than Weekly Volume from 3 Wks Ago • Zacks Rank less than or equal to 3 • Price greater than or equal to $5 • Average 20-day Volume greater than or equal to 100,000 shares The most important elements to this screen are the price and volume items (especially the volume). | Stocks Here are 5 stocks that passed this week's screen: ( JNJ - Research Report ) Johnson & Johnson ( NK - Research Report ) NantKwest ( DK - Research Report ) Delek US Holdings ( ABT - Research Report ) Abbot Labs ( WGO - Research Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Screen Parameters • Current Price greater than Price from 1 Week Ago • Price from 1 Week Ago greater than Price from 2 Weeks Ago • Price from 2 Week Ago greater than Price from 3 Weeks Ago • Weekly Volume greater than Weekly Volume from 1 Week Ago • Weekly Volume from 1 Wk Ago greater than Weekly Volume from 2 Wks Ago • Weekly Volume from 2 Wks Ago greater than Weekly Volume from 3 Wks Ago • Zacks Rank less than or equal to 3 • Price greater than or equal to $5 • Average 20-day Volume greater than or equal to 100,000 shares The most important elements to this screen are the price and volume items (especially the volume). | Stocks Here are 5 stocks that passed this week's screen: ( JNJ - Research Report ) Johnson & Johnson ( NK - Research Report ) NantKwest ( DK - Research Report ) Delek US Holdings ( ABT - Research Report ) Abbot Labs ( WGO - Research Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. As more investors buy the stock, the stock's price should go higher. |
33594.0 | 2017-06-20 00:00:00 UTC | Health Care Sector Update for 06/20/2017: JNJ, PFE, ABT, MRK, AMGN, EGLT, NVIV, VAR | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06202017-jnj-pfe-abt-mrk-amgn-eglt-nviv-var-2017-06-20 | nan | nan | Top Health Care stocks:
JNJ: +0.4%
PFE: +1.3%
ABT: +0.8%
MRK: +1.7%
AMGN: +2.1%
Health care shares were higher in mid-day trade Tuesday.
In health care stocks news, Egalet ( EGLT ) was down 16.8% after the company said it received a complete response letter ( CRL ) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement of Oxaydo (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths. The FDA has requested more information regarding the effect of food on Oxaydo 15 mg and the intranasal abuse-deterrent properties of Oxaydo 10 mg and 15 mg. Egalet said it will work with the FDA to determine the path forward.
In other sector news,
(+) NVIV (6.3%) Enrolls new patient in Inspire study evaluating neuro-spinal scaffold
(-) VAR (-0.1%) Installs proton therapy device in Danish center
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) was down 16.8% after the company said it received a complete response letter ( CRL ) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement of Oxaydo (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths. The FDA has requested more information regarding the effect of food on Oxaydo 15 mg and the intranasal abuse-deterrent properties of Oxaydo 10 mg and 15 mg. Egalet said it will work with the FDA to determine the path forward. In other sector news, (+) NVIV (6.3%) Enrolls new patient in Inspire study evaluating neuro-spinal scaffold (-) VAR (-0.1%) Installs proton therapy device in Danish center The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) was down 16.8% after the company said it received a complete response letter ( CRL ) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement of Oxaydo (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths. In other sector news, (+) NVIV (6.3%) Enrolls new patient in Inspire study evaluating neuro-spinal scaffold (-) VAR (-0.1%) Installs proton therapy device in Danish center The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Egalet ( EGLT ) was down 16.8% after the company said it received a complete response letter ( CRL ) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement of Oxaydo (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths. The FDA has requested more information regarding the effect of food on Oxaydo 15 mg and the intranasal abuse-deterrent properties of Oxaydo 10 mg and 15 mg. Egalet said it will work with the FDA to determine the path forward. In other sector news, (+) NVIV (6.3%) Enrolls new patient in Inspire study evaluating neuro-spinal scaffold (-) VAR (-0.1%) Installs proton therapy device in Danish center The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: In health care stocks news, Egalet ( EGLT ) was down 16.8% after the company said it received a complete response letter ( CRL ) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement of Oxaydo (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths. In other sector news, (+) NVIV (6.3%) Enrolls new patient in Inspire study evaluating neuro-spinal scaffold (-) VAR (-0.1%) Installs proton therapy device in Danish center The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33595.0 | 2017-06-20 00:00:00 UTC | VHT, LLY, ABT, DHR: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/vht-lly-abt-dhr-large-inflows-detected-etf-2017-06-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $65.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 44,174,359 to 44,624,359). Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.7%, and Danaher Corp (Symbol: DHR) is higher by about 0.4%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average:
Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $147.35 as the 52 week high point - that compares with a last trade of $147.30. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.7%, and Danaher Corp (Symbol: DHR) is higher by about 0.4%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $147.35 as the 52 week high point - that compares with a last trade of $147.30. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.7%, and Danaher Corp (Symbol: DHR) is higher by about 0.4%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $147.35 as the 52 week high point - that compares with a last trade of $147.30. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.7%, and Danaher Corp (Symbol: DHR) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $65.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 44,174,359 to 44,624,359). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $147.35 as the 52 week high point - that compares with a last trade of $147.30. | Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.7%, and Danaher Corp (Symbol: DHR) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $65.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 44,174,359 to 44,624,359). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $147.35 as the 52 week high point - that compares with a last trade of $147.30. |
33596.0 | 2017-06-19 00:00:00 UTC | Health Care Sector Update for 06/19/2017: JNJ, PFE, ABT, MRK, AMGN, VRX, MACK, MDT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06192017-jnj-pfe-abt-mrk-amgn-vrx-mack-mdt-2017-06-19 | nan | nan | Top Health Care stocks:
JNJ: +0.2%
PFE: +0.3%
ABT: +0.6%
MRK: flat
AMGN: +0.4%
Health care shares were mostly firmer in pre-market trade Monday.
In health care stocks news, Valeant Pharmaceuticals International ( VRX ) gained 4.7% after the company said that its board elected John Paulson to serve as a director, effective June 14. With the addition of Paulson, Valeant has a total of 11 members on its board, 10 of whom are independent. Paulson is the president of Paulson & Co., Inc.
In other sector news,
(+) MACK (+4.3%) Enrolls last patient in Carrie study of MM-141 for metastatic pancreatic cancer
(-) MDT (-0.1%) Reports technology in cardiac implants reduces irregular heartbeats
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Valeant Pharmaceuticals International ( VRX ) gained 4.7% after the company said that its board elected John Paulson to serve as a director, effective June 14. With the addition of Paulson, Valeant has a total of 11 members on its board, 10 of whom are independent. In other sector news, (+) MACK (+4.3%) Enrolls last patient in Carrie study of MM-141 for metastatic pancreatic cancer (-) MDT (-0.1%) Reports technology in cardiac implants reduces irregular heartbeats The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Valeant Pharmaceuticals International ( VRX ) gained 4.7% after the company said that its board elected John Paulson to serve as a director, effective June 14. In other sector news, (+) MACK (+4.3%) Enrolls last patient in Carrie study of MM-141 for metastatic pancreatic cancer (-) MDT (-0.1%) Reports technology in cardiac implants reduces irregular heartbeats The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat In health care stocks news, Valeant Pharmaceuticals International ( VRX ) gained 4.7% after the company said that its board elected John Paulson to serve as a director, effective June 14. In other sector news, (+) MACK (+4.3%) Enrolls last patient in Carrie study of MM-141 for metastatic pancreatic cancer (-) MDT (-0.1%) Reports technology in cardiac implants reduces irregular heartbeats The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: MRK: flat In health care stocks news, Valeant Pharmaceuticals International ( VRX ) gained 4.7% after the company said that its board elected John Paulson to serve as a director, effective June 14. |
33597.0 | 2017-06-16 00:00:00 UTC | Health Care Sector Update for 06/16/2017: JNJ, PFE, ABT, MRK, AMGN, GSK, PFE, LLY | ABT | https://www.nasdaq.com/articles/health-care-sector-update-06162017-jnj-pfe-abt-mrk-amgn-gsk-pfe-lly-2017-06-16 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health care shares were inactive in pre-market trade Friday.
In health care stocks news, GlaxoSmithKline ( GSK ) was up 0.7% after it said results from a ten-year continuation study showed its Benlysta plus standard of care prolonged control of disease activity in patients with active systemic lupus erythematosus. The study demonstrated the percentage of treatment response to belimumab increased over time, with an overall response of 65.1% at year 10, the company said. Patients were able to decrease their corticosteroid dose over time from baseline to year 10. Of patients receiving more than 7.5 mg/day baseline prednisone, 32.6% decreased their dose to less than or equal to 7.5 mg/day by year 10. A total of 9.5% of patients receiving baseline prednisone less than or equal to 7.5 mg/day had a dose increase to more than 7.5 mg/day.
In other sector news,
PFE (flat) Xeljanz arthritis drug shows similar response rate to AbbVie's Humira
LLY (flat) Says long term data show rheumatoid arthritis drug lowers tate of joint damage progression
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In health care stocks news, GlaxoSmithKline ( GSK ) was up 0.7% after it said results from a ten-year continuation study showed its Benlysta plus standard of care prolonged control of disease activity in patients with active systemic lupus erythematosus. A total of 9.5% of patients receiving baseline prednisone less than or equal to 7.5 mg/day had a dose increase to more than 7.5 mg/day. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In health care stocks news, GlaxoSmithKline ( GSK ) was up 0.7% after it said results from a ten-year continuation study showed its Benlysta plus standard of care prolonged control of disease activity in patients with active systemic lupus erythematosus. In other sector news, PFE (flat) Xeljanz arthritis drug shows similar response rate to AbbVie's Humira LLY (flat) Says long term data show rheumatoid arthritis drug lowers tate of joint damage progression The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In other sector news, PFE (flat) Xeljanz arthritis drug shows similar response rate to AbbVie's Humira LLY (flat) Says long term data show rheumatoid arthritis drug lowers tate of joint damage progression The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited. | Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. Patients were able to decrease their corticosteroid dose over time from baseline to year 10. In other sector news, PFE (flat) Xeljanz arthritis drug shows similar response rate to AbbVie's Humira LLY (flat) Says long term data show rheumatoid arthritis drug lowers tate of joint damage progression The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33598.0 | 2017-06-16 00:00:00 UTC | 2 Solid Medical Device Stocks to Scoop Up Right Away | ABT | https://www.nasdaq.com/articles/2-solid-medical-device-stocks-to-scoop-up-right-away-2017-06-16 | nan | nan | The current scenario pertaining to the U.S. medical device sector is pretty blurred. While the players within the sector are eagerly waiting for the Senate to pass the final Obamacare Reform Bill in July, several recent comments by the Republicans are raising doubts over the consequences.
Some Republicans are thinking of retaining a few of the medical device taxes that were supposed to be abolished earlier. Another group of senators intend to retain all the taxes but reduce the proportion of those. According to a Breitbart report, they believe that a slower phase out of Obamacare taxes will generate enough revenues for a more generous health care bill.
So far, companies in the medical device sector were hopeful about the promised cancellation of major healthcare taxes (the Cadillac tax and the 2.3% MedTech tax) related to Obamacare under Trump's American Health Care Act (AHCA). Unquestionably, the latest political remarks have landed the MedTech space to more uncertain territories.
In spite of what the future may unfold, we would suggest investors to pick medical device stocks which are fundamentally strong at present. These stocks will make valuable additions to an investment portfolio in the wake of widespread volatility in the medical device market.
Top Two Picks
We have taken the help of the Zacks Stock Screener to select favorable stocks. To shortlist the stocks from the vast universe of the medical device sector, we have picked the ones that carry a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Baxter International Inc.BAX : Headquartered in Deerfield, IL, Baxter International is a global medical technology company. The company offers renal and hospital products such as kidney dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter International recently received guidance from the U.S. FDA clarifying the regulatory pathway for its home peritoneal dialysis (PD) solution system to improve patient access to home dialysis.
In the past one year, Baxter International has outperformed the Zacks categorized Medical - Products industry. The company represented a solid return of 30.3%, comparing favorably with the industry's return of roughly 13%. Meanwhile, the estimate revision trend for the current year remained favorable with nine estimates moving north in the last two months, compared to no movement in the opposite direction. As a result, current year estimates increased roughly 5% to $2.27 over the same time frame.
Of late, Baxter International has accelerated its pace of acquisitions and strategic collaborations that enhance its product portfolio, thereby opening up significant long-term opportunities. We are also upbeat about the company's recently signed definitive agreement to acquire Claris Injectables. Recurring revenue stream, expanding product portfolio, impressive product pipeline and strong presence in the international markets are other key positives.
Abbott LaboratoriesABT : This IL-based medical device major discovers, develops, manufactures and sells a diversified line of health care products. The company has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products. The company also launched science-based nutrition drinks for better recovery from surgeries.
Taking a glance at its share price performance, Abbott has been trading above the broader Medical products industry over the last one year. The company has so far gained 28.7%, compared to 13.2% of the industry. Additionally its current year estimate revision is favorable. Over the last two months, there have been five upward revisions compared to no downward revision. As a result, the current year magnitude has inched up 0.8% to $2.47 per share.
Overall, we believe that the company stands to benefit from the ongoing integration and synergy achievement of St. Jude Medical which was acquired at the start of 2017. We are also looking forward to the company's plans to focus on selling core therapeutic products in the emerging markets of India, Russia and Latin America.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT : This IL-based medical device major discovers, develops, manufactures and sells a diversified line of health care products. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. While the players within the sector are eagerly waiting for the Senate to pass the final Obamacare Reform Bill in July, several recent comments by the Republicans are raising doubts over the consequences. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT : This IL-based medical device major discovers, develops, manufactures and sells a diversified line of health care products. Download Report with 3 Top Tech Stocks >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT : This IL-based medical device major discovers, develops, manufactures and sells a diversified line of health care products. So far, companies in the medical device sector were hopeful about the promised cancellation of major healthcare taxes (the Cadillac tax and the 2.3% MedTech tax) related to Obamacare under Trump's American Health Care Act (AHCA). | Abbott LaboratoriesABT : This IL-based medical device major discovers, develops, manufactures and sells a diversified line of health care products. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. According to a Breitbart report, they believe that a slower phase out of Obamacare taxes will generate enough revenues for a more generous health care bill. |
33599.0 | 2017-06-15 00:00:00 UTC | The Zacks Analyst Blog Highlights: United Technologies, Abbott, Delta Air, Equity Residential and Ross Stores | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-united-technologies-abbott-delta-air-equity-residential | nan | nan | For Immediate Release
Chicago, IL - June 15, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), Delta Air (NYSE: DAL- Free Report ), Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Top Stock Reports for Thursday: UTX, ABT, DAL & More
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), and Delta Air (NYSE: DAL- Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all oftoday's research reports here >>>
Buy rated United Technologies shares have outperformed the Zacks Conglomerates sector as well as the S&P 500 index in the year-to-date period (the stock is up +9.5% vs. +3.1% gain for the sector) on the back of a revamped aerospace unit and improved growth outlook through strategic acquisition opportunities. While questions remain about the new administration's ability to ramp up defense spending, this favorable expectation is nevertheless a positive for the company. The improving outlook for the global economy is another macro tailwind for UTX. The company remains in excellent financial health and pays a stable dividend (currently yielding 2.2%), but value-oriented investors will likely have issues with the stock's current elevated valuation.
(You can read the full research report on United Technologies here >>> ) .
Abbott shares have outperformed the Zacks Medical sector in the year-to-date period (the stock is up +24.2% vs. +17.9% gain for the sector) on the back of greater appreciation for the company's strategic repositioning through acquisitions/divestitures. A case in point is the St. Jude Medical buyout that complements the company cardiovascular devices business. All in all, market participants like management's strategic focus on core therapeutic areas. On the flip side, the analyst identifies weakness in the nutrition business in China and sluggish growth in the Venezuelan market as areas of concern.
(You can read the full research report on Abbott here >>> ) .
DeltaAir Lines shares rallied +10.4% over the last three months, handily outperforming the Zacks Airline industry's +6.4% gain. However, the stock has underperformed fellow airline heavyweight, American Airlines, which have gained +17.4% in the same time frame. Delta, however, received encouraging news recently on the passenger unit revenue front. The metric registered 3.5% year over year growth in May. The company's decision to hike quarterly dividend is also reassuring. Moreover, the Zacks analyst likes Delta's employee-friendly approach as well as expansion and debt-reduction efforts. However, increasing costs are likely to once again hurt bottom-line growth in the second quarter of 2017.
(You can read the full research report on Delta here >>> ) .
Other noteworthy reports we are featuring today include Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on UTX - FREE
Get the full Report on ABT - FREE
Get the full Report on DAL - FREE
Get the full Report on EQR - FREE
Get the full Report on ROST - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Technologies Corporation (UTX): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Delta Air Lines, Inc. (DAL): Free Stock Analysis Report
Equity Residential (EQR): Free Stock Analysis Report
Ross Stores, Inc. (ROST): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), Delta Air (NYSE: DAL- Free Report ), Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ). Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for Thursday: UTX, ABT, DAL & More The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), and Delta Air (NYSE: DAL- Free Report ). | Stocks recently featured in the blog include United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), Delta Air (NYSE: DAL- Free Report ), Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ). Today's Research Daily features new research reports on 16 major stocks, including United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), and Delta Air (NYSE: DAL- Free Report ). Click to get this free report United Technologies Corporation (UTX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report Equity Residential (EQR): Free Stock Analysis Report Ross Stores, Inc. (ROST): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), Delta Air (NYSE: DAL- Free Report ), Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ). Get the full Report on UTX - FREE Get the full Report on ABT - FREE Get the full Report on DAL - FREE Get the full Report on EQR - FREE Get the full Report on ROST - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report United Technologies Corporation (UTX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report Equity Residential (EQR): Free Stock Analysis Report Ross Stores, Inc. (ROST): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), Delta Air (NYSE: DAL- Free Report ), Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ). Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for Thursday: UTX, ABT, DAL & More The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), and Delta Air (NYSE: DAL- Free Report ). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.